
<html lang="en"     class="pb-page"  data-request-id="7d90ded3-c011-437f-bf5d-7aa65004f052"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm201591k;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2012.55.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant" /></meta><meta name="dc.Creator" content="Shaohua  Chang" /></meta><meta name="dc.Creator" content="Lianwen  Zhang" /></meta><meta name="dc.Creator" content="Shilin  Xu" /></meta><meta name="dc.Creator" content="Jinfeng  Luo" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Zhang  Zhang" /></meta><meta name="dc.Creator" content="Tianfeng  Xu" /></meta><meta name="dc.Creator" content="Yingxue  Liu" /></meta><meta name="dc.Creator" content="Zhengchao  Tu" /></meta><meta name="dc.Creator" content="Yong  Xu" /></meta><meta name="dc.Creator" content="Xiaomei  Ren" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Duanqing  Pei" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="The EGFRT790M mutant contributes approximately 50% to clinically acquired resistance against gefitinib or erlotinib. However, almost all the single agent clinical trials of the second generation ir..." /></meta><meta name="Description" content="The EGFRT790M mutant contributes approximately 50% to clinically acquired resistance against gefitinib or erlotinib. However, almost all the single agent clinical trials of the second generation ir..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 1, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201591k" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201591k" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201591k" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201591k" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201591k" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0003.jpeg" /></meta><meta property="og:description" content="The EGFRT790M mutant contributes approximately 50% to clinically acquired resistance against gefitinib or erlotinib. However, almost all the single agent clinical trials of the second generation irreversible EGFR inhibitors appear inadequate to overcome the EGFRT790M-related resistance. We have designed and synthesized a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as novel EGFR inhibitors. The most potent compounds, 2q and 2s, inhibited the enzymatic activities of wild-type and mutated EGFRs, with IC50 values in subnanomolar ranges, including the T790M mutants. The kinase inhibitory efficiencies of the compounds were further validated by Western blot analysis of the activation of EGFR and downstream signaling in cancer cells harboring different mutants of EGFR. The compounds also strongly inhibited the proliferation of H1975 non small cell lung cancer cells bearing EGFRL858R/T790M, while being significantly less toxic to normal cells. Moreover, 2s displayed promising anticancer efficacy in a human NSCLC (H1975) xenograft nude mouse model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201591k"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201591k">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201591k&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201591k&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201591k&amp;href=/doi/10.1021/jm201591k" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2711-2723</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201570s" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm201620t" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine<sup>790</sup> → Methionine<sup>790</sup> Mutant</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shaohua++Chang">Shaohua Chang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lianwen++Zhang">Lianwen Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shilin++Xu">Shilin Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinfeng++Luo">Jinfeng Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhang++Zhang">Zhang Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tianfeng++Xu">Tianfeng Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingxue++Liu">Yingxue Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengchao++Tu">Zhengchao Tu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Xu">Yong Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaomei++Ren">Xiaomei Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Duanqing++Pei">Duanqing Pei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Key Laboratory of Regenerative Biology and Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">School of Life Science, University of Science and Technology of China, # 96 Jinzhai Road, Hefei 230026, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Graduate School of Chinese Academy of Sciences, # 19 Yuquan Road, Beijing 100049, China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">⊥</span> <span class="aff-text">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, # 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div><div class="corresp-info"><strong>*</strong>Tel: +86-20-32015276. Fax: +86-20-32015299. E-mail: <a href="/cdn-cgi/l/email-protection#6105080f063e0a0421060803094f00024f020f"><span class="__cf_email__" data-cfemail="8de9e4e3ead2e6e8cdeae4efe5a3eceea3eee3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201591k&amp;href=/doi/10.1021%2Fjm201591k" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2711–2723</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 16, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 November 2011</li><li><span class="item_label"><b>Published</b> online</span>1 March 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201591k" title="DOI URL">https://doi.org/10.1021/jm201591k</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2711%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShaohua%2BChang%252C%2BLianwen%2BZhang%252C%2BShilin%2BXu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D6%26contentID%3Djm201591k%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BConformationally%2BConstrained%2BInhibitors%2BTargeting%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BThreonine790%2B%25E2%2586%2592%2BMethionine790%2BMutant%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2723%26publicationDate%3DMarch%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201591k"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3916</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">68</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201591k" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shaohua&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Lianwen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Shilin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jinfeng&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Zhang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Tianfeng&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Yingxue&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Zhengchao&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Xiaomei&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Duanqing&quot;,&quot;last_name&quot;:&quot;Pei&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;2711-2723&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201591k&quot;},&quot;abstract&quot;:&quot;The EGFRT790M mutant contributes approximately 50% to clinically acquired resistance against gefitinib or erlotinib. However, almost all the single agent clinical trials of the second generation irreversible EGFR inhibitors appear inadequate to overcome the EGFRT790M-related resistance. We have designed and synthesized a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as novel EGFR inhibitors. The most potent compounds, 2q and 2s, inhibited the enzymatic activities of wild-type and mutated EGFRs, with IC50 values in subnanomolar ranges, including the T790M mutants. The kinase inhibitory efficiencies of the compounds were further validated by Western blot analysis of the activation of EGFR and downstream signaling in cancer cells harboring different mutants of EGFR. The compounds also strongly inhibited the proliferation of H1975 non small cell lung cancer cells bearing EGFRL858R/T790M, while being significantly less toxic to normal cells. Moreover, 2s displayed promising anticancer efficacy &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201591k&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201591k" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201591k&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201591k" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201591k&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201591k" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201591k&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201591k&amp;href=/doi/10.1021/jm201591k" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201591k" /></input><a href="/doi/pdf/10.1021/jm201591k" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26pmid%3D22339342%26genre%3Darticle%26aulast%3DChang%26date%3D2012%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BConformationally%2BConstrained%2BInhibitors%2BTargeting%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BThreonine790%2B%25E2%2586%2592%2BMethionine790%2BMutant%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jmcmar.2012.55.issue-6/production/jmcmar.2012.55.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The EGFR<sup>T790M</sup> mutant contributes approximately 50% to clinically acquired resistance against gefitinib or erlotinib. However, almost all the single agent clinical trials of the second generation irreversible EGFR inhibitors appear inadequate to overcome the EGFR<sup>T790M</sup>-related resistance. We have designed and synthesized a series of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as novel EGFR inhibitors. The most potent compounds, <b>2q</b> and <b>2s</b>, inhibited the enzymatic activities of wild-type and mutated EGFRs, with IC<sub>50</sub> values in subnanomolar ranges, including the T790M mutants. The kinase inhibitory efficiencies of the compounds were further validated by Western blot analysis of the activation of EGFR and downstream signaling in cancer cells harboring different mutants of EGFR. The compounds also strongly inhibited the proliferation of H1975 non small cell lung cancer cells bearing EGFR<sup>L858R/T790M</sup>, while being significantly less toxic to normal cells. Moreover, <b>2s</b> displayed promising anticancer efficacy in a human NSCLC (H1975) xenograft nude mouse model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span>#</span> Author Contributions</h4><p class="last">These authors contributed equally to this work.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases which play indispensable roles in cell proliferation, survival, adhesion, migration, and differentiation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Small molecular EGFR inhibitors, gefinitib and erlotinib, were approved by US Food and Drug Administration in 2002 and 2004, respectively, and have achieved significant clinical benefit for non small cell lung cancer (NSCLC) patients harboring activating EGFR mutations such as L858R or exon 19 deletions (del E746-A750), etc.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> Anti-EGFR antibodies cetuximab<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and panitumumab<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> have also become effective clinical therapies for different solid tumors associated with overexpressed EGFR. Despite the clear clinical benefits of gefinitib and erotinib, their efficacy is eventually diminished because of acquired point mutations in the kinase domain of EGFR as well as the upregulation of bypass signaling pathways.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Particularly, a single T790M point mutation (threonine<sup>790</sup> → methionine<sup>790</sup>) at the “gatekeeper” position in EGFR accounts for approximately 50% in clinically acquired resistant patients.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Different from the fact that T315I-mutated Abl introduces a steric impediment for imatinib binding,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> EGFR<sup>T790M</sup> only moderately affects the binding of gefinitib and erotinib. However, this mutation enhances the binding affinity for ATP with EGFR, which leads to higher concentrations of the competitive inhibitors being required for the kinase suppression.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">In order to overcome the T790M mutation related resistance, a number of irreversible ATP-competitive EGFR inhibitors<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> such as CI-1033,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> BIBW2992,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> HKI-272,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and PF00299804,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> etc., have been developed. The irreversible inhibitors contain a Michael addition receptor moiety which may form a covalent bind with the conserved cysteine residue present in the lip of the EGFR ATP binding site (Cys797) to achieve occupancy greater than that of the reversible inhibitors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The reaction of the Cys797 residue with irreversible inhibitors also potently prevents its sulfenylation-enhancing kinase activity.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, almost all the single agent clinical trials of the second generation irreversible EGFR inhibitors seemed to be disappointing.<a onclick="showRef(event, 'cit7b'); return false;" href="javascript:void(0);" class="ref cit7b">(7b)</a> For instance, HKI-272 (neratinib) has been demonstrated to show little activity against gefitinib-resistant NSCLC patients harboring EGFR mutations in a phase II trial, likely due to toxicity-related dose-limitation.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> PF00299804 also failed to show any responses in NSCLC patients with EGFR<sup>T790M</sup> mutants.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In a phase III clinical trial, BIBW2992 (afatinib) only displayed 7% response rate for NSCLC patients who progressed after ≥12 weeks of gefinitib or erlotinib treatment.<a onclick="showRef(event, 'cit7b ref19'); return false;" href="javascript:void(0);" class="ref cit7b ref19">(7b, 19)</a> The most promising results came from a phase Ib trial of a combination of BIBW2992 with cetuximab, which showed an approximate 40% objective response rate. However, the progression-free survival and overall survival results are unpredictable.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, the clinically acquired resistance against first-line EGFR inhibitors remains one of the major challenging unmet medical needs for NSCLC treatment. It is highly desirable to identify new molecules targeting EGFR<sup>T790M</sup> mutants.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Most recently, Gray et al. reported a novel series of substituted pyrimidines as irreversible EGFR inhibitors displaying good selectivity against EGFR<sup>T790M</sup> mutants over the wild type kinase.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> One of the most active and selective inhibitors, WZ4002 (<b>1</b>),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> potently inhibited the proliferation of the cancer cells or Ba/F3 cells harboring L858R, del E746-A750, and/or T790M mutated EGFR, while it was obviously less potent against the growth of wild type EGFR cells. Furthermore, the compound also displayed promising in vivo efficacy in gefitinib-resistant NSCLC models, which represented a new, promising strategy to overcome the acquired resistance for NSCLC patients. The clinical results of <b>1</b> or related candidates are eagerly awaited. In this paper, we report the structural design, synthesis, and biological evaluation of conformation-constrained 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as novel EGFR inhibitors which strongly suppressed the enzymatic activities of EGFR<sup>WT</sup>, EGFR<sup>L858R</sup>, EGFR<sup>T790M</sup>, EGFR<sup>L861Q</sup>, and EGFR<sup>L858R/T790M</sup>. The compounds also potently inhibited the proliferation of NSCLC cells bearing EGFR<sup>del E746-A750</sup> or EGFR<sup>L858R/T790M</sup> mutants. One of the most potent inhibitors, <b>2s</b>, displayed significant in vivo anticancer efficacy in a H1975 human NSCLC cancer xenograft mouse model, representing a new, promising lead compound with a different chemical scaffold for further development of EGFR inhibitors to overcome EGFR<sup>T790M</sup> mutation-induced clinical resistance to gefitinib and erotinib.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of conformation-constrained derivatives of <b>1</b> as new EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The designed compounds <b>2</b> were prepared by using ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (<b>3</b>) as the starting material (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Briefly, a direct nucleophilic coupling of compound <b>3</b> with <i>tert</i>-butyl 3-aminophenylcarbamate (<b>4</b>) almost quantitatively produced ethyl 4-(3-(<i>tert</i>-butoxycarbonyl)phenylamino)-2-(methylthio)pyrimidine-5-carboxylate (<b>5</b>) as a white solid. The reduction of compound <b>5</b> with lithium aluminum hydride yielded <i>tert</i>-butyl 3-(5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate (<b>6</b>) which was followed by selective oxidation to produce the aldehyde <b>7</b> in a good yield. A variety of diamine intermediates <b>8</b> could be prepared by a reductive amination of aldehyde <b>7</b> with different amines. With diamine compounds <b>8</b> in hand, the key intermediates <b>10</b> were readily synthesized by direct cyclization with triphosgene and followed by oxidation. Compound <b>10</b> coupled with different substituted anilines to produce precursor compounds <b>11</b> which were further deprotected with trifluoroacetic acid and reacted with acryloyl chloride to obtain the conformation-constrained EGFR inhibitors <b>2</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Conformation-Constrained Compounds <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last">Reagent and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), dimethylformamide (DMF), 60 °C, overnight, 97%; (b) lithium aluminum hydride (LAH, 2.0 equiv), THF, −40 °C to r.t., 57%; (c) MnO<sub>2</sub>, dichloromethane, r.t., overnight, 85%; (d) R<sup>2</sup>NH<sub>2</sub>, AcOH, NaBH<sub>4</sub>, MeOH, 0 °C to r.t., overnight; (e) triphosgene (0.34 equiv), Et<sub>3</sub>N (4.0 equiv), 0 °C to r.t., 2.0 h; (f) 3-chloroperbenzoic acid (<i>m</i>-CPBA, 3.0 equiv), dichloromethane, r.t., 3.0 h; (g) R<sup>1</sup>NH<sub>2</sub> (1.0 equiv), trifluoroacetic acid (1.0 equiv), 2-BuOH, 110 °C, sealed tube, 18.0 h, 30–60%; (h) trifluoroacetic acide, dichloromethane, r.t.; (i) acryloyl chloride (1.0 equiv), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 1.0 equiv), 0 °C to r.t.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Dicussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44322" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44322" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Taking <b>1</b> as the lead molecule, we designed a series of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new EGFR inhibitors using a combination of bioisosterism and conformational constraint strategies. The kinase inhibitory activities of the designed compounds were evaluated via a well established FRET-based Z′-Lyte assay<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> against different types of EGFR kinases, and the results are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Under the experimental conditions, compound <b>1</b> potently inhibited EGFR<sup>WT</sup>, EGFR<sup>T790M</sup>, EGFR<sup>L858R</sup>, EGFR<sup>L861Q</sup>, and EGFR<sup>L858R/T790M</sup> with IC<sub>50</sub> values of 6.18, 3.77, 5.37, 6.13, and 1.88 nM, respectively, which were similar to previously reported data.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">We were pleased to find that the conformation-constrained compound <b>2a</b> also strongly suppressed the enzymatic activities of all five types of EGFR kinases with potencies comparable to that of compound <b>1</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Taking compound <b>2a</b> as our new lead compound, we conducted further structure modification to explore the structure–activity relationships. The impact of the 1-(4-methylpiperazinyl) group in compound <b>2a</b> was first inspected by removal or replacement with other moieties. The results demonstrated that the 1-(4-methylpiperazinyl) group was important for the EGFR kinase inhibition. When the 1-(4-methylpiperazinyl) group was removed (<b>2g</b>) or replaced with dimethylamino (<b>2b</b>), 1-piperidinyl (<b>2c</b>), or <i>N</i>-morpholino (<b>2d</b>) moieties, the potencies against EGFR kinases decreased approximately 5–20 fold. For instance, the IC<sub>50</sub> values of compound <b>2a</b> against EGFR<sup>WT</sup>, EGFR<sup>T790M</sup>, EGFR<sup>L858R</sup>, EGFR<sup>L861Q</sup>, and EGFR<sup>L858R/T790M</sup> were 1.16, 6.56, 1.08, 1.21, and 3.14 nM, while the corresponding values for compound <b>2c</b> were decreased to 29.50, 95.71, 10.42, 15.40, and 36.43 nM, respectively. Further investigation also revealed that the potency loss of compound <b>2c</b> was partially restored by introducing a 4-dimethylamino group (<b>2b</b>) at the position of the original piperidinyl moiety. When the 1-(4-methylpiperazinyl) group was replaced with a 1-(4-methyl-1,4-diazepanyl) group, the resulting compound <b>2e</b> was almost equally potent to compound <b>2a</b>. However, when the substituted aniline in compound <b>2a</b> was replaced with a simple methylamino moiety (<b>2h</b>), the potencies against EGFR kinases were almost completely abolished.</div><div class="NLM_p">The impact of the R<sub>2</sub> methoxy group in <b>2a</b> was also investigated. Similar to the previous observation,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> removal of the R<sub>2</sub> methoxy group improved the potencies against all forms of the EGFR kinases 2- to 3-fold, but the resulting compound <b>2i</b> could lose the selectivity over JAK3 and the TEC-family kinase.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> When the methoxy group was moved from the 2′-position to the 3′-position (<b>2j</b>), the inhibitory potency against EGFR<sup>L858R/T790M</sup> was barely affected, although the potencies against EGFR<sup>WT</sup>, EGFR<sup>T790M</sup>, and EGFR<sup>L858R</sup> were improved 2–3 fold. When the 2′-methoxy group in <b>2a</b> was replaced with a slightly larger group such as an ethoxy (<b>2k</b>) or isopropoxy (<b>2l</b>) group, potencies were obviously decreased. Although the 2′-methyl analogue (<b>2m</b>) displayed  potencies similar to that of <b>2a</b>, the 2′-fluoro compound (<b>2n</b>) was totally inactive. The potency loss of <b>2n</b> might be due to a five-membered ring formation involving a hydrogen bond between the F atom and the NH moiety, which could alter the conformation of the molecule.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Enzymatic Inhibitory Activities of Compounds <b>2</b> against Different Types of EGFR<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">EGFR activity assays were performed using the FRET-based Z′-Lyte assay according to the manufacturer’s instructions. The compounds were incubated with the kinase reaction mixture for 1.5 h before measurement. The data were means from at least three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Binding constant values (<i>K</i><sub>d</sub>) were determined from Ambit KINOMEscan. The data were means from two independent experiments.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Reported data.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div></div><div></div></div><div class="NLM_p">The results also illustrated that the R<sub>3</sub> position in compound <b>2a</b> might be replaced with a larger hydrophobic group to improve the potency against EGFR kinase. When the R<sub>3</sub> methyl was replaced with an isopropyl (<b>2o</b>) or cyclopropyl (<b>2p</b>) group, the inhibitory activities against EGFR<sup>WT</sup>, EGFR<sup>L858R</sup>, and EGFR<sup>L861Q</sup> were obviously improved, with IC<sub>50</sub> values below 1 nM, but the suppressive functions against EGFR<sup>T790M</sup> and EGFR<sup>L858R/T790M</sup> were slightly decreased. The methyl group could also be replaced with large hydrophobic groups such as 2-naphthyl (<b>2r</b>), 4-biphenyl (<b>2t</b>), 4-phenoxyphenyl (<b>2u</b>), and 4-benzoxyphenyl (<b>2v</b>), etc., to maintain the strong inhibition against EGFR kinase. Interestingly, when the R<sub>3</sub> methyl in compound <b>2a</b> was replaced with a phenyl (<b>2q</b>) or benzyl (<b>2s</b>) group, the resulting compounds showed the best potencies. For instance, compound <b>2s</b> strongly bound to all the types of EGFR kinase and inhibited their enzymatic functions with <i>K</i><sub>d</sub> and IC<sub>50</sub> values both in subnanomolar ranges (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), which is obviously more potent than compound <b>1</b>. However, the binding affinities with EGFR were significantly decreased over 1000 fold (<i>K</i><sub>d</sub> values about 560–1500 nM) when the α,β-unsaturated acrylamide moieties were removed (<b>2w</b> and <b>2x</b>). Highly consistent with their binding affinity loss, <b>2w</b> and <b>2x</b> were almost totally inactive to inhibit the EGFR enzymatic activities (IC<sub>50</sub> values >1000 nM).</div><div class="NLM_p">Taking compounds <b>2q</b> and <b>2s</b> as examples, we further profiled the compounds against a panel of 451 kinases using the Ambit Kinome screening platform to investigate the selectivity of the new EGFR inhibitors (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The results suggested that both compounds displayed excellent selectivity on EGFR, and the specificity profile of compound <b>2s</b> was obviously greater than that of <b>2q</b>. In addition to EGFR, <b>2s</b> only exhibited obvious binding to BLK, BTK, ErbB-2, ErbB4, GAK, and TXK at a concentration of 100 nM, which was about 100 times its <i>K</i><sub>d</sub> values on EGFR, while compound <b>2q</b> also showed strong binding with BMX, FRK, JAK3, KIT<sup>V559D</sup>, LCK, MAP3K15, PDGFRβ, TEC, and TNK2 at the same time.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. KINOMEsacn tree spot maps illustrating the selectivity profiles for compounds <b>2q</b> and <b>2s</b> versus a panel of 451 kinase targets (including 392 wild-type kinases). The size of the red circle is proportional to the percent of DMSO control, where 0% and 35% of control equals 100% and 65% competition, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to further validate the activities of these new EGFR inhibitors, we examined the effects of representative compounds <b>2a</b>, <b>2q</b>, and <b>2s</b> on the activation of EGFR and the downstream signal in cancer cells harboring a different status of EGFR kinases, and the results are summarized in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Similar to that of compound <b>1</b>, inhibitors <b>2a</b>, <b>2q</b>, and <b>2s</b> dose-dependently inhibited the phosphorylation of EGFR in both H1975 NSCLC cells bearing EGFR<sup>L858R/T790M</sup> and HCC827 cells harboring EGFR<sup>del E746-A750</sup>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The protein levels of downstream p-Akt and p-Erk were also obviously decreased, while the total protein levels of EGFR, Akt, Erk, and GAPDH remained unchanged. Although gefitinib could potently induce the inhibition of EGFR activation and downstream signaling in HCC827 cells, it did not show an effect on the EGFR<sup>T790M</sup>-mutated H1975 cells. The effects of <b>2a</b>, <b>2q</b>, and <b>2s</b> on cells harboring wild type EGFR kinase (EGFR overexpressed A431<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> cells and A549<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> cells bearing <i>k-Ras</i> mutation) were also investigated. The results demonstrated that the compounds only moderately affected the activation of EGFR in the corresponding cells although they displayed strong inhibition against EGFR kinase under the in vitro screening assay (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>2a</b>, <b>2q</b>, and <b>2s</b> inhibit the activation of EGFR and downstream signaling in a dose-dependent manner. (A) Compounds <b>2a</b>, <b>2q</b>, <b>2s</b>, and <b>1</b> inhibit the activation of EGFR and downstream signaling in H1975 NSCLC cells harboring EGFR<sup>L858R/T790M</sup>, while gefitinib has no effects. (B) Compounds <b>2a</b>, <b>2q</b>, <b>2s</b>, <b>1</b>, and gefitinib inhibit the activation of EGFR and downstream signaling in HCC827 NSCLC cells harboring EGFR<sup>del E746-A750</sup>. The results are representative of experiments in triplicate. Gfb: gefitinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiproliferative effects of the new inhibitors were also investigated to monitor their potential antitumor activities (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Highly consistent with their strong kinase inhibition, the compounds displayed great antiproliferative effects on HCC827 and H1975 NSCLC cells harboring EGFR<sup>del E746-A750</sup> and EGFR<sup>L858R/T790M</sup>, respectively. Most of the compounds potently suppressed the growth of HCC827 cancer cells with IC<sub>50</sub> values in the low nanomolar ranges. Compounds <b>2o</b>, <b>2p</b>, <b>2q</b>, <b>2r</b>, and <b>2s</b> were equal in potency to that of gefitinib, CI-1033, and <b>1</b> for inhibiting the growth of HCC827 cancer cells, with IC<sub>50</sub> values of 3–9 nM. Moreover, several compounds also displayed strong antiproliferative effects on gefitinib-resistant H1975 cells bearing EGFR<sup>L858R/T790M</sup>. Compounds <b>2a</b>, <b>2i</b>, <b>2j</b>, <b>2o</b>, <b>2p</b>, <b>2r</b>, <b>2u</b>, and <b>2v</b> were almost equal in potency to that of CI-1033 and inhibitor <b>1</b>, while <b>2q</b> and <b>2s</b> displayed potencies 3–4 times greater than that of <b>1</b> against H1975 cancer cell growth. Further investigation also revealed that the compounds <b>2q</b> and <b>2s</b> potently induced G1 phase arrest and apoptosis in both HCC827 and H1975 NSCLC cells and inhibited the colony formation of H1975 cancer cells in dose-dependent manners (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>). Not surprisingly, the enzymatically inactive compounds <b>2n</b>, <b>2w</b>, and <b>2x</b> did not show obvious inhibition on the growth of HCC827 or H1975 cancer cells.</div><div class="NLM_p">Although the compounds also strongly inhibited the enzymatic activity of EGFR<sup>WT</sup>, they were obviously less potent to suppress the proliferation of A431 human epithelial carcinoma cells with overexpressed EGFR<sup>WT</sup>, which might be due to the complex genomic background and the strong binding of EGFR<sup>WT</sup> with ATP.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For instance, compound <b>2s</b> inhibited the enzymatic activities of EGFR<sup>WT</sup>, EGFR<sup>L858R</sup>, EGFR<sup>L861Q</sup>, and EGFR<sup>L858R/T790M</sup>, with IC<sub>50</sub> values of 0.29, 0.67, 0.38, 0.72, and 0.93 nM, respectively. It also potently inhibited the growth of HCC827 and H1975, with IC<sub>50</sub> values of 3 and 14 nM, but its activity on A431 cancer cells was approximate 10–50 times less potent (IC<sub>50</sub> value was about 170 nM). However, an irreversible clinical candidate CI-1033 displayed comparable potency to inhibit the growth of H1975 and A431 cancer cells. Similar to many other reversible and irreversible EGFR inhibitors, the compounds only showed moderate inhibitory activities against the growth of A549 NSCLC cells which possess EGFR<sup>WT</sup> and the <i>k-Ras</i> mutation-activating bypass MAPK signal pathway.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Our data have demonstrated that the new EGFR inhibitors also strongly inhibited EGFR<sup>WT</sup>. Because many tissues use wild-type EGFR for normal cellular processes, the potential for toxicity from irreversible EGFR inhibitors is a concern. Therefore, the growth inhibitory activities of the compounds against HL-7702 normal human liver cells which bear EGFR<sup>WT</sup> were also evaluated to monitor the potential toxic effects.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, only a few very potent EGFR inhibitors displayed moderate inhibitory activities against the growth of HL-7702 cells, indicating that the cytotoxic effects of these compounds were minimal. For instance, the highly potent inhibitors <b>2q</b> and <b>2s</b> inhibited the growth of HL-7702 cells with IC<sub>50</sub> values of 4.02 and 2.39 μM, respectively, which was approximately 200–1000 fold less potent than their activities against the HCC827 and H1975 NSCLC cells. The compounds also displayed moderate or minimal cytotoxicity on human HLF-1 cells (diploid human lung fibroblasts),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> which further suggested that the compounds might possess a high safety index (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activities of the Conformation-Constrained Inhibitors <b>2</b> against Cells Harboring a Different Status of EGFR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">HCC827 (Del E746_A750)</th><th class="colsep0 rowsep0" align="center">H1975 (L858R/T790M)</th><th class="colsep0 rowsep0" align="center">A431 (WT, overexpression)</th><th class="colsep0 rowsep0" align="center">A549 (WT, <i>k-Ras</i> mutation)</th><th class="colsep0 rowsep0" align="center">HL7702 (WT)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.048 ± 0.005</td><td class="colsep0 rowsep0" align="char" char="±">1.39 ± 0.28</td><td class="colsep0 rowsep0" align="char" char="±">5.31 ± 0.56</td><td class="colsep0 rowsep0" align="char" char="±">2.73 ± 0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.018 ± 0.007</td><td class="colsep0 rowsep0" align="char" char="±">0.047 ± 0.014</td><td class="colsep0 rowsep0" align="char" char="±">0.75 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">15.94 ± 1.64</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.74 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.54 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">5.62 ± 1.35</td><td class="colsep0 rowsep0" align="char" char="±">>20</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.170 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.61 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">5.06 ± 0.66</td><td class="colsep0 rowsep0" align="char" char="±">12.02 ± 1.21</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">10.46 ± 2.08</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.073 ± 0.008</td><td class="colsep0 rowsep0" align="char" char="±">0.72 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">2.15 ± 0.48</td><td class="colsep0 rowsep0" align="char" char="±">>20</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.53 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">1.39 ± 0.48</td><td class="colsep0 rowsep0" align="char" char="±">14.50 ± 1.76</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.044 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">6.90 ± 1.57</td><td class="colsep0 rowsep0" align="char" char="±">18.02 ± 0.51</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="char" char="±">6.92 ± 3.32</td><td class="colsep0 rowsep0" align="char" char="±">20.07 ± 1.65</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>20</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.014 ± 0.009</td><td class="colsep0 rowsep0" align="char" char="±">0.045 ± 0.017</td><td class="colsep0 rowsep0" align="char" char="±">0.55 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">11.35 ± 0.63</td><td class="colsep0 rowsep0" align="char" char="±">7.56 ± 1.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.041 ± 0.018</td><td class="colsep0 rowsep0" align="char" char="±">0.024 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.36 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">3.33 ± 0.71</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.014 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.103 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">1.08 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">10.35 ± 1.59</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2l</b></td><td class="colsep0 rowsep0" align="char" char="±">0.027 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.23 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">2.11 ± 0.66</td><td class="colsep0 rowsep0" align="char" char="±">11.67 ± 2.15</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2m</b></td><td class="colsep0 rowsep0" align="char" char="±">0.031 ± 0.015</td><td class="colsep0 rowsep0" align="char" char="±">0.20 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.99 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">11.92 ± 1.99</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2n</b></td><td class="colsep0 rowsep0" align="char" char="±">5.01 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">8.46 ± 1.26</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">11.13 ± 1.87</td><td class="colsep0 rowsep0" align="char" char="±">7.18 ± 2.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2o</b></td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.058 ± 0.014</td><td class="colsep0 rowsep0" align="char" char="±">0.82 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">8.42 ± 2.64</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2p</b></td><td class="colsep0 rowsep0" align="char" char="±">0.009 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.054 ± 0.020</td><td class="colsep0 rowsep0" align="char" char="±">0.81 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">17.90 ± 3.12</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2q</b></td><td class="colsep0 rowsep0" align="char" char="±">0.003 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.016 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.11 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">2.80 ± 1.35</td><td class="colsep0 rowsep0" align="char" char="±">4.02 ± 2.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2r</b></td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.030 ± 0.013</td><td class="colsep0 rowsep0" align="char" char="±">0.57 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">2.41 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">3.44 ± 1.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2s</b></td><td class="colsep0 rowsep0" align="char" char="±">0.003 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.014 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">2.66 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">2.39 ± 0.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2t</b></td><td class="colsep0 rowsep0" align="char" char="±">0.018 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.095 ± 0.008</td><td class="colsep0 rowsep0" align="char" char="±">1.21 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">2.27 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">3.69 ± 2.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2u</b></td><td class="colsep0 rowsep0" align="char" char="±">0.014 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.048 ± 0.019</td><td class="colsep0 rowsep0" align="char" char="±">1.20 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">1.77 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2v</b></td><td class="colsep0 rowsep0" align="char" char="±">0.023 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.033 ± 0.011</td><td class="colsep0 rowsep0" align="char" char="±">1.15 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">2.47 ± 0.60</td><td class="colsep0 rowsep0" align="char" char="±">2.79 ± 1.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2w</b></td><td class="colsep0 rowsep0" align="char" char="±">4.89 ± 1.02</td><td class="colsep0 rowsep0" align="char" char="±">>20</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">11.17 ± 2.17</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2x</b></td><td class="colsep0 rowsep0" align="char" char="±">6.79 ± 2.48</td><td class="colsep0 rowsep0" align="char" char="±">>20</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>30</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CI-1033</td><td class="colsep0 rowsep0" align="char" char="±">0.001 ± 0.0003</td><td class="colsep0 rowsep0" align="char" char="±">0.064 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">1.59 ± 0.58</td><td class="colsep0 rowsep0" align="char" char="±">2.30 ± 0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">0.008 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">9.02 ± 1.08</td><td class="colsep0 rowsep0" align="char" char="±">2.15 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">10.21 ± 2.43</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The antiproliferative activities of the compounds were evaluated using the MTS assay. The data were means from at least four independent experiments.</p></div></div></div><div class="NLM_p">Given its high potency and remarkable selectivity profile, compound <b>2s</b> was further evaluated for in vivo antitumor efficacy in an EGFR<sup>L858R/T790M</sup>-driven human NSCLC xenograft mouse model of H1975 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). SCID mice bearing established H1975 tumor xenografts were dosed orally with <b>2s</b> at 10 and 30 mg/kg daily (qd) over a 14-day period. Gefitinib (50 mg/kg, qd) was used as a reference drug to validate the resistant models. Both doses of <b>2s</b> were well tolerated, with no mortality or significant body weight loss (<5% relative to the vehicle matched controls) observed during the treatment. Dosing at 10 mg/kg/day of <b>2s</b> had little effect on the tumor growth compared with the control group. However, compound <b>2s</b> displayed significant in vivo antitumor efficacy (<i>p</i> < 0.05) and induced tumor stasis at 30 mg/kg/day, indicating that it might serve as a promising lead compound for further development of EGFR inhibitors to overcome EGFR<sup>T790M</sup> mutation-related clinical resistance to gefitinib or erotinib.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo antitumor effect of compound <b>2s</b> in a human NSCLC (H1975) xenograft nude mouse model. The H1975 model was resistant to gefitinib. Mice were monitored for signs of morbidity (behavior and body loss), and tumors were measured every other day. Statistical significance (<i>p</i> < 0.05) for antitumor efficacy, based upon tumor growth relative to the vehicle controls. Two animals died at day 10 and 12 in the vehicle control group, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, a series of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives have been designed and synthesized as novel EGFR inhibitors. The compounds potently inhibited the enzymatic activities of different mutants of EGFR as well as the wild type EGFR kinase. The most potent compounds <b>2q</b> and <b>2s</b> displayed good potencies, with IC<sub>50</sub> values in the high picomolar range against all types of EGFR kinase, including the clinical resistance-related EGFR<sup>T790M</sup> mutant. A further kinase profiling study also suggested that the compounds displayed remarkable selectivity on EGFR. The kinase inhibitory efficiencies of the compounds were further validated by Western blot analysis of the activation of EGFR and the downstream signaling in cancer cells harboring different mutants of EGFR. Furthermore, the compounds also strongly inhibited HCC827 and H1975 non small cell lung cancer cells bearing EGFR<sup>del E746-A750</sup> and EGFR<sup>L858R/T790M</sup>, respectively, with potencies better than that of <b>1</b> and CI-1033. The compounds only showed moderate or minimal cytotoxicity to normal HL-7702 and HLF-1 cells, indicating that they might possess a high safety index. Moreover, a further in vivo antitumor efficacy study demonstrated that compound <b>2s</b> significantly inhibited the tumor growth and induced tumor stasis in an EGFR<sup>L858R/T790M</sup>-driven human NSCLC xenograft mouse model of H1975 by orally dosing at 30 mg/kg/day. Our study provides a new lead compound with a different chemical scaffold for further development of EGFR inhibitors to overcome EGFR<sup>T790M</sup> mutation-related clinical resistance to gefitinib or erotinib. Further extensive pharmacokinetics and safety evaluation on <b>2s</b> are in progress and will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Chemistry</h3><div class="NLM_p">Reagents and solvents were obtained from commercial suppliers and used without further purification. Flash chromatography was performed using silica gel (300–400 mesh). All reactions were monitored by TLC, using silica gel plates with fluorescence F<sub>254</sub> and UV light visualization. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz and Bruker AV-500 spectrometer at 125 MHz, respectively. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to internal control (TMS). The low or high resolution of ESI-MS was recorded on an Agilent 1200 HPLC-MSD mass spectrometer or Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer, respectively. The purity of compounds was determined by reverse-phase high performance liquid chromatography (HPLC) analysis to be over 95% (>95%). HPLC instrument: Dionex Summit HPLC (Column: Diamonsil C18, 5.0 <b>μ</b>m, 4.6 × 250 mm (Dikma Technologies); detector: PDA-100 photodiode array; injector: ASI-100 autoinjector; pump: p-680A). Elution: MeOH in water; flow rate: 1.0 mL/min.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Ethyl 4-(3-(<i>tert</i>-Butoxycarbonylamino)phenylamino)-2-(methylthio)pyrimidine-5-carboxylate (<b>5</b>)</h4><div class="NLM_p last">To a solution of compound <b>4</b> (20.8 g, 100 mmol) in DMF (300 mL) were added potassium carbonate (27.6 g, 200 mmol) and compound <b>3</b> (23.3 g, 100 mmol). The reaction was heated to 80 °C and stirred overnight. After being cooled to room temperature, the reaction mixture was added to ice–water (1000 mL). The precipitate was filtered, and the filtered cake was rinsed with additional cool water and dried in a vacuum oven to give the title compound (38.8 g, 96% yield), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.37 (s, 1H), 8.76 (s, 1H), 7.90 (s, 1H), 7.34 (d, <i>J</i> = 8.0 Hz, 1H), 7.24 (t, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 8.0 Hz, 1H), 6.53 (s, 1H), 4.38 (q, <i>J</i> = 7.2, 14.4 Hz, 2H), 2.55 (s, 3H), 1.52 (s, 9H), 1.40 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> <i>tert</i>-Butyl 3-(5-(Hydroxymethyl)-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate (<b>6</b>)</h4><div class="NLM_p last">To a solution of compound <b>5</b> (20.2 g, 50 mmol) in THF (500 mL) was added 2.0 M lithium aluminum hydride solution in THF (50 mL, 100 mmol) at −40 °C. The reaction mixture was stirred until the temperature warmed to room temperature and was then treated with saturated NH<sub>4</sub>Cl solution (75 mL). After the mixture was stirred at room temperature for 30 min, the solid was filtered off. The filtrate was partitioned between dichloromethane (500 mL) and water (300 mL). The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by flash silica gel chromatography with dichloromethane/methanol (80/1 to 40/1, v/v) to yield the title product as a white solid (10.33 g, 57%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 1H), 7.86 (s, 1H), 7.80 (s, 1H), 7.36 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 7.22 (t, <i>J</i> = 8.0 Hz, 1H), 6.95 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 6.52 (s, 1H), 4.61 (s, 2H), 2.52 (s, 3H), 1.52 (s, 9H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> <i>tert</i>-Butyl 3-(5-Formyl-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate (<b>7</b>)</h4><div class="NLM_p last">To a solution of compound <b>6</b> (10.0 g, 27.6 mmol) in dichloromethane (300 mL) was added activated manganese(IV) oxide (24.0 g, 276 mmol) at room temperature, and the mixture was stirred overnight, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by flash silica gel chromatography with petroleum ether/ethyl acetate (5/1 to 3/1, v/v) to yield the title product as a white solid (8.36 g, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.61 (s, 1H), 9.77 (s, 1H), 8.43 (s, 1H), 7.98 (s, 1H), 7.36 (dd, <i>J</i> = 0.8, 8.0 Hz, 1H), 7.25–7.29 (m, 1H), 7.03 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 6.51 (s, 1H), 2.59 (s, 3H), 1.53 (s, 9H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> <i>tert</i>-Butyl 3-(5-((Methylamino)methyl)-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate (<b>8a</b>)</h4><div class="NLM_p last">To a solution of compound <b>7</b> (7.21 g, 20.0 mmol) in methanol (200 mL) were added sodium acetate (8.2 g, 100 mmol) and methanaminium chloride (6.75 g, 100 mmol) at room temperature, and the mixture was stirred for 1 h. NaBH<sub>4</sub> (1.51 g, 40.0 mmol) was added. The reaction mixture was partitioned between dichloromethane (200 mL) and saturated NaHCO<sub>3</sub> (100 mL), and then the water layer was extracted with dichloromethane (100 mL × 2). The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with dichloromethane/methanol (80/1 to 40/1, v/v) to give the title product as a white solid (5.25 g, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.12 (s, 1H), 7.89 (s, 1H), 7.78 (s, 1H), 7.35 (d, <i>J</i> = 8.8 Hz, 1H), 7.21 (t, <i>J</i> = 8.0 Hz, 1H), 6.97 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 6.50 (s, 1H), 3.74 (s, 2H), 3.55 (s, 3H), 2.44 (s, 3H), 1.52 (s, 9H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> <i>tert</i>-Butyl 3-(3-mMethyl-7-(methylthio)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenylcarbamate (<b>9a</b>)</h4><div class="NLM_p last">To a solution of compound <b>8a</b> (5.20 g, 13.8 mmol) in THF (140 mL) were added DIEA (8 mL, 55.2 mmol) and 0.2 M triphosgene (25 mL, 5.05 mmol) at 0 °C, and the mixture was stirred at room temperature for 1 h and then partitioned between dichloromethane (200 mL) and saturated NaHCO<sub>3</sub> (100 mL) solution. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with dichloromethane/methanol (60/1 to 30/1, v/v) to give the title product as a white solid (4.71 g, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (s, 1H), 7.44 (s, 1H), 7.34 (t, <i>J</i> = 8.0 Hz, 1H), 7.23 (d, <i>J</i> = 7.2 Hz, 1H), 6.90 (d, <i>J</i> = 8.0 Hz, 1H), 6.55 (s, 1H), 4.46 (s, 2H), 3.08 (s, 3H), 2.14 (s, 3H), 1.50 (s, 9H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> <i>tert</i>-Butyl 3-(3-Methyl-7-(methylsulfonyl)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenylcarbamate (<b>10a</b>)</h4><div class="NLM_p last">To a solution of compound <b>9a</b> (4.0 g, 10.0 mmol) in dichloromethane (100 mL) was added 85% <i>m</i>-chloroperbenzoic acid (6.1 g, 30.0 mmol) in batches at 0 °C. The reaction mixture was stirred for 3 h at room temperature. The reaction mixture was partitioned between dichloromethane (200 mL) and saturated NaHCO<sub>3</sub> (100 mL). The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting white solid (3.90 g, 90% yield) was recrystallized from a minimum amount of ethyl acetate, which was used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.45 (s, 1H), 7.58 (s, 1H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.15 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 6.89 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 6.67 (s, 1H), 4.62 (s, 2H), 3.11 (s, 3H), 2.98 (s, 3H), 1.48 (s, 9H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> <i>tert</i>-Butyl 3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenylcarbamate (<b>11a</b>)</h4><div class="NLM_p last">To a solution of compound <b>10a</b> (260 mg, 0.6 mmol) in butan-2-ol (2 mL) were added 2-methoxy-4-(4-methylpiperazin-1-yl)aniline (133 mg, 0.6 mmol) and trifluoroacetic acid (48 μL, 0.6 mmol). The reaction mixture was stirred for 18 h at 110 °C in a sealed tube. The reaction mixture was cooled to room temperature and partitioned between dichloromethane (30 mL) and saturated NaHCO<sub>3</sub> (10 mL), and the water layer was extracted with dichloromethane (10 mL × 2). The combined organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with dichloromethane/methanol (40/1 to 20/1, v/v) to give the title product as a yellow solid (151 mg, 44%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (s, 1H), 7.48 (d, <i>J</i> = 7.5 Hz, 1H), 7.44 (s, 1H), 7.41 (t, <i>J</i> = 8.0 Hz, 1H), 7.35 (s, 1H), 6.97 (d, <i>J</i> = 7.5 Hz, 1H), 6.63 (s, 1H), 6.42 (d, <i>J</i> = 2.0 Hz, 1H), 6.16 (d, <i>J</i> = 6.4 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.22 (m, 4H), 3.08 (s, 3H), 2.79 (m, 4H), 1.47 (s, 9H). LCMS (ESI): <i>m</i>/<i>z</i> 575.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 1-(3-Aminophenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2w</b>)</h4><div class="NLM_p last">To a solution of compound <b>11a</b> (143 mg, 0.25 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.2 mL, 2.7 mmol). The reaction mixture was stirred for 1 h at room temperature. The reaction mixture was cooled to room temperature and partitioned between dichloromethane (10 mL) and saturated NaHCO<sub>3</sub> (2 mL), and the water layer was extracted with dichloromethane (5 mL × 2). The combined organic layer was washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>, the solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with dichloromethane/methanol (40/1 to 20/1, v/v) to give the title product as a yellow solid (100 mg, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (s, 1H), 7.61 (s, 1H), 7.46 (s, 1H), 7.28 (t, <i>J</i> = 8.0 Hz, 2H), 6.78 (dd, <i>J</i> = 2.0, 8.0 Hz, 1H), 6.67 (d, <i>J</i> = 7.6 Hz, 1H), 6.61 (t, <i>J</i> = 2.0 Hz, 1H), 6.45 (d, <i>J</i> = 2.4 Hz, 1H), 6.21 (d, <i>J</i> = 7.6 Hz, 1H), 4.42 (s, 2H), 3.81 (s, 3H), 3.13 (t, <i>J</i> = 4.8 Hz, 4H), 3.09 (s, 3H), 2.64 (t, <i>J</i> = 4.8 Hz, 4H), 2.29 (s, 3H). LCMS (ESI): <i>m</i>/<i>z</i> 475.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2a</b>)</h4><div class="NLM_p">To a solution of compound <b>2x</b> (95 mg, 0.20 mmol) in dichloromethane (2 mL) were added diisopropyethylamine (40 μL, 0.20 mmol) and acryloyl chloride (16 μL, 0.20 mmol). The reaction mixture was stirred for 1 h at room temperature. The resulting crude product was purified by silica gel chromatography with dichloromethane/methanol (40/1 to 20/1, v/v) to give the title product as a yellow solid (90 mg, 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 8.11 (s, 1H), 7.81 (d, <i>J</i> = 7.6 Hz, 1H), 7.56 (s, 1H), 7.48 (s, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.27 (d, <i>J</i> = 8.4 Hz, 1H), 6.95 (d, <i>J</i> = 8.0 Hz, 1H), 6.51 (s, 1H), 6.44 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 6.02 (d, <i>J</i> = 8.0 Hz, 1H), 5.76 (d, <i>J</i> = 10.0 Hz, 1H), 4.46 (s, 2H), 3.76 (s, 3H), 2.99 (m, 4H), 2.96 (s, 3H), 2.50 (m, 4H), 2.22 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.12, 158.45, 157.23, 154.03, 152.54, 146.70, 139.52, 137.49, 131.76, 128.92, 126.92, 124.92, 120.79, 120.72, 118.24, 106.41, 101.15, 99.75, 55.61, 54.59, 48.72, 45.82, 45.70, 34.99. HRMS (ESI): exact mass calcd for C<sub>28</sub>H<sub>32</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 529.2670, found 529.2675.</div><div class="NLM_p last">The following compounds (<b>2b</b>–<b>x</b>) were prepared from compound <b>10</b> and the corresponding aniline by a method similar to that for <b>2a</b>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-(3-(7-(4-(Dimethylamino)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.28 (s, 1H), 8.09 (s, 1H), 7.79 (d, <i>J</i> = 8.8 Hz, 1H), 7.57 (s, 1H), 7.42 (t, <i>J</i> = 8.0 Hz, 2H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 6.95 (d, <i>J</i> = 8.0 Hz, 1H), 6.43 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.30 (d, <i>J</i> = 2.4 Hz, 1H), 6.25 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 5.87 (d, <i>J</i> = 7.6 Hz, 1H), 5.75 (dd, <i>J</i> = 2.0, 10.0 Hz, 1H), 4.45 (s, 2H), 3.76 (s, 3H), 2.96 (s, 3H), 2.78 (s, 6H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ163.12, 158.42, 157.20, 153.98, 152.58, 146.82, 139.51, 137.51, 131.76, 128.85, 126.91, 124.93, 120.70, 118.59, 118.16, 103.81, 100.82, 96.77, 55.48, 45.81, 40.58, 34.98. HRMS (ESI): exact mass calcd for C<sub>25</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 474.2248, found 474.2252.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(3-(7-(2-Methoxy-4-(piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.11 (s, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 7.56 (s, 1H), 7.47 (s, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.0 Hz, 1H), 6.95 (d, <i>J</i> = 8.0 Hz, 1H), 6.49 (d, <i>J</i> = 2.2 Hz, 1H), 6.43 (dd, <i>J</i> = 8.0, 16.0 Hz, 1H), 6.25 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 6.02 (d, <i>J</i> = 7.4 Hz, 1H), 5.76 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 4.46 (s, 2H), 3.75 (s, 3H), 2.96 (m, 7H), 1.59 (m, 4H), 1.49–1.504 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ163.57, 158.70, 157.68, 154.48, 153.00, 148.08, 139.99, 137.95, 132.20, 129.37, 127.36, 125.37, 121.15, 118.63, 107.50, 101.56, 100.87, 56.02, 50.90, 46.27, 35.44, 25.82, 24.30. HRMS (ESI): exact mass calcd for C<sub>28</sub>H<sub>31</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 514.2561, found 514.2565.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(3-(7-(2-Methoxy-4-morpholinophenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.12 (s, 1H), 7.81 (d, <i>J</i> = 6.8 Hz, 1H), 7.56 (s, 1H), 7.50 (s, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 10.0 Hz, 1H), 6.96 (d, <i>J</i> = 10.0 Hz, 1H), 6.52 (d, <i>J</i> = 2.0 Hz, 1H), 6.43 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.22–6.27 (m, 1H), 6.02 (d, <i>J</i> = 8.0 Hz, 1H), 5.74–5.77 (m, 1H), 4.46 (s, 2H), 3.76 (s, 3H), 3.71 (t, <i>J</i> = 4.4 Hz, 4H), 2.96 (m, 7H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.58, 158.68, 157.68, 154.49, 152.98, 147.23, 139.96, 137.95, 132.20, 129.38, 127.42, 125.39, 121.56, 121.19, 118.71, 106.61, 101.65, 100.02, 66.53, 56.09, 49.66, 46.27, 35.44. HRMS (ESI): exact mass calcd for C<sub>27</sub>H<sub>29</sub>N<sub>7</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 516.2354, found 516.2358.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(3-(7-(2-Methoxy-4-(4-methyl-1,4-diazepan-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>5e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.19 (s, 1H), 7.85 (s, 1H), 7.69–7.70 (m, 2H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 6.96–6.99 (m, 2H), 6.40–6.46 (m, 2H), 6.24 (dd, <i>J</i> = 1.6, 16.8 Hz, 1H), 5.75 (dd, <i>J</i> = 1.6, 10.0 Hz, 1H), 4.50 (s, 2H), 3.33 (m, 7H), 2.98 (s, 3H), 2.74 (t, <i>J</i> = 4.4 Hz, 4H), 2.49 (m, 2H), 2.24 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.11, 158.51, 157.21, 154.01, 152.63, 149.63, 139.54, 137.55, 131.77, 128.88, 126.93, 124.94, 120.69, 118.14, 117.40, 102.43, 100.64, 95.24, 57.14, 56.31, 55.45, 48.25, 47.90, 46.01, 45.84, 35.00, 26.93. HRMS (ESI): exact mass calcd for C<sub>29</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 543.2827, found 543.2832.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(3-(7-(4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>5f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 8.11 (s, 1H), 7.84 (d, <i>J</i> = 7.6 Hz, 1H), 7.55 (s, 1H), 7.48 (s, 1H), 7.42 (t, <i>J</i> = 8.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.4 Hz, 1H), 6.95 (d, <i>J</i> = 7.2 Hz, 1H), 6.51 (s, 1H), 6.45 (dd, <i>J</i> = 10.0, 17.2 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 6.04 (s, 1H), 5.76 (d, <i>J</i> = 9.6 Hz, 1H), 4.46 (s, 2H), 3.75 (s, 3H), 3.56 (d, <i>J</i> = 12.4 Hz, 2H), 3.35 (s, 3H), 2.87 (m, 1H), 2.49–2.56 (m, 2H), 2.34 (s, 6H), 1.86 (d, <i>J</i> = 10.4 Hz, 2H), 1.46–1.55 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ163.12, 158.24, 157.23, 154.04, 152.54, 146.93, 139.54, 137.50, 131.77, 128.91, 126.90, 124.92, 120.71, 120.65, 118.20, 106.98, 101.12, 100.32, 61.37, 55.59, 48.87, 45.83, 41.45, 34.99, 27.85. HRMS (ESI): exact mass calcd for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 557.2983, found 557.2989.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(3-(3-Methyl-2-oxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.41 (s, 1H), 8.18 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (s, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 7.27 (d, <i>J</i> = 8.0 Hz, 2H), 6.99 (d, <i>J</i> = 8.0 Hz, 1H), 6.93 (t, <i>J</i> = 7.6 Hz, 2H), 6.75 (t, <i>J</i> = 7.2 Hz, 1H), 6.42 (dd, <i>J</i> = 10.4, 16.8 Hz, 1H), 6.24(d, <i>J</i> = 16.8 Hz, 1H), 5.75 (d, <i>J</i> = 10.4 Hz, 1H), 4.48 (s, 2H), 2.97 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ163.14, 158.32, 157.17, 154.05, 152.52, 140.33, 139.59, 137.66, 131.70, 128.94, 127.93, 127.00, 125.06, 120.75, 120.67, 118.26, 118.05, 101.39, 45.87, 34.99. HRMS (ESI): exact mass calcd for C<sub>22</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 401.1721, found 401.1735.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-(3-Methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 8.01 (s, 1H), 7.61 (d, <i>J</i> = 8.0 Hz, 1H), 7.55 (s, 1H), 7.36 (t, <i>J</i> = 8.0 Hz, 1H), 6.91 (d, <i>J</i> = 7.6 Hz, 1H), 6.71 (s, 1H), 6.43 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 5.76 (d, <i>J</i> = 10.4 Hz, 1H), 4.37 (s, 2H), 2.93 (s, 3H), 2.59 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.11, 161.56, 157.11, 153.74, 152.93, 139.14, 137.44,131.75, 128.50, 126.92, 125.14, 120.87, 118.23, 45.68, 35.01. HRMS (ESI): exact mass calcd for C<sub>17</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 339.1564, found 339.1566.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(3-(3-Methyl-7-(4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 9.17 (s, 1H), 8.13 (s, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.56 (s, 1H), 7.44 (t, <i>J</i> = 8.0 Hz, 1H), 7.12 (d, <i>J</i> = 7.2 Hz, 2H), 6.96 (d, <i>J</i> = 7.6 Hz, 1H), 6.53 (d, <i>J</i> = 8.0 Hz, 2H), 6.43 (dd, <i>J</i> = 9.6, 16.4 Hz, 1H), 6.25 (d, <i>J</i> = 16.4 Hz, 1H), 5.76 (d, <i>J</i> = 10.0 Hz, 1H), 4.46 (s, 2H), 2.97 (s, 3H), 2.92 (s, 4H), 2.41 (s, 4H), 2.20 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.15, 158.41, 157.12, 154.03, 152.63, 145.53, 139.58, 137.68, 132.69, 131.75, 129.00, 126.99, 124.99, 120.79, 119.07, 118.22, 115.44, 100.58, 54.64, 48.83, 45.77, 35.01. HRMS (ESI): exact mass calcd for C<sub>27</sub>H<sub>30</sub>N<sub>8</sub>O<sub>22</sub> [M + H]<sup>+</sup>, 499.2564, found 499.2562.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(3-(7-(3-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.13 (s, 1H), 8.15 (s, 1H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.58 (s, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 1H), 6.91–6.97 (m, 2H), 6.86 (s, 1H), 6.39–6.46 (m, 2H), 6.24 (d, <i>J</i> = 16.8 Hz, 1H), 5.75 (d, <i>J</i> = 10.0 Hz, 1H), 4.46 (s, 2H), 3.58 (s, 3H), 2.96 (s, 3H), 2.79 (s, 4H), 2.39 (s, 4H), 2.19 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.11, 158.46, 157.14, 153.92, 152.64, 151.68, 139.55, 137.55, 135.51, 135.36, 131.74, 128.89, 126.93, 124.95, 120.74, 118.20, 117.34, 110.55, 103.72, 101.06, 55.20, 54.95, 50.18, 45.86, 45.82, 35.01. HRMS (ESI): exact mass calcd for C<sub>28</sub>H<sub>32</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 529.2670, found 529.2667.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(3-(7-(2-Ethoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.28 (s, 1H), 7.99 (s, 1H), 7.93 (d, <i>J</i> = 7.6 Hz, 1H), 7.48 (s, 1H), 7.40 (t, <i>J</i> = 8.0 Hz, 2H), 7.28 (s, 1H), 6.96 (d, <i>J</i> = 8.0 Hz, 1H), 6.38 (s, 1H), 6.34 (d, <i>J</i> = 16.4 Hz, 1H), 6.18 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.10 (d, <i>J</i> = 8.4 Hz, 1H), 5.65 (d, <i>J</i> = 10.4 Hz, 1H), 4.42 (s, 2H), 4.00 (q, <i>J</i> = 6.8, 13.6 Hz, 2H), 3.13 (s, 4H), 3. 06 (s, 3H), 2.70 (s, 4H), 2.44 (s, 3H), 1.39 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 163.39, 158.58, 157.56, 153.72, 147.44, 146.03, 139.35, 137.15, 131.54, 129.63, 127.12, 125.19, 122.57, 121.09, 119.70, 118.94, 108.52, 101.04, 100.11, 64.19, 54.78, 49.44, 46.96, 45.49, 35.62, 14.91. HRMS (ESI): exact mass calcd for C<sub>29</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 543.2827, found 543.2834.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-(7-(2-Isopropoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2l</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 7.96 (s, 1H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.49 (s, 1H), 7.37 (t, <i>J</i> = 8.0 Hz, 2H), 7.25 (s, 1H), 6.94 (d, <i>J</i> = 7.6 Hz, 1H), 6.41 (d, <i>J</i> = 2.0 Hz, 1H), 6.32 (d, <i>J</i> = 12.8 Hz, 1H), 6.14–6.18 (m, 1H), 6.08–6.11 (m, 1H), 5.62 (d, <i>J</i> = 10.0 Hz, 1H), 4.47–4.53 (m, 1H), 4.39 (s, 2H), 3.05 (t, <i>J</i> = 4.8 Hz, 4H), 3.03 (s, 3H), 2.56 (t, <i>J</i> = 4.6 Hz, 4H), 2.34 (s, 3H), 1.30 (d, <i>J</i> = 6.0 Hz, 6H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.39, 158.50, 157.46, 153.70, 146.39, 139.54, 136.95, 131.65, 129.61, 126.83, 124.95, 123.15, 121.02, 119.75, 118.92, 108.52, 102.48, 99.86, 71.26, 55.05, 49.80, 46.94, 45.99, 35.61, 22.19. HRMS (ESI): exact mass calcd for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 557.2987, found 557.2990.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(3-(3-Methyl-7-(2-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2m</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (s, 1H), 7.97 (s, 1H), 7.62 (d, <i>J</i> = 7.6 Hz, 1H), 7.45 (s, 1H), 7.27–7.33 (m, 2H), 6.91 (d, <i>J</i> = 8.0 Hz, 1H), 6.64 (s, 1H), 6.56 (s, 1H), 6.49 (d, <i>J</i> = 8.0 Hz, 1H), 6.33 (d, <i>J</i> = 16.8 Hz, 1H), 6.17 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 5.64 (d, <i>J</i> = 10.4 Hz, 1H), 4.44 (s, 2H), 3.14 (m, 4H), 3.10 (s, 3H), 2.65 (m, 4H), 2.41 (s, 3H), 2.14 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 163.47, 159.65, 157.61, 153.65, 147.23, 139.42, 136.82, 131.65, 129.92, 129.27, 126.80, 125.04, 121.15, 119.65, 118.22, 114.43, 100.52, 54.90, 49.17, 46.87, 45.69, 35.67, 18.38. HRMS (ESI): exact mass calcd for C<sub>28</sub>H<sub>32</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 513.2721, found 513.2719.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(3-(7-(2-Fluoro-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.19 (s, 1H), 7.86 (s, 1H), 7.69–7.70 (m, 2H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 6.96–6.99 (m, 2H), 6.40–6.47 (m, 2H), 6.24 (dd, <i>J</i> = 2.0, 17.2 Hz, 1H), 5.75 (dd, <i>J</i> = 2.0, 10.0 Hz, 1H), 4.50 (s, 2H), 2.98 (s, 3H), 2.74 (t, <i>J</i> = 4.4 Hz, 4H), 2.50 (m, 4H), 2.24 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.63, 158.28, 158.10, 157.76, 156.37, 154.66, 152.80, 142.47, 142.41, 140.00, 137.93, 132.14, 130.90, 129.41, 127.48, 125.45, 121.17, 118.80, 110.27, 110.10, 108.35, 108.17, 102.59, 55.42, 51.48, 46.28, 45.98, 35.45. HRMS (ESI): exact mass calcd for C<sub>27</sub>H<sub>29</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 517.2470, found 517.2473.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(3-(3-Isopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.14 (s, 1H), 7.80 (d, <i>J</i> = 6.8 Hz, 1H), 7.57 (s, 1H), 7.48 (s, 1H), 7.42 (t, <i>J</i> = 8.0 Hz, 1H), 7.29 (d, <i>J</i> = 7.6 Hz, 1H), 6.97 (d, <i>J</i> = 8.0 Hz, 1H), 6.52 (s, 1H), 6.43 (dd, <i>J</i> = 10.0, 17.2 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 6.04 (d, <i>J</i> = 9.2 Hz, 1H), 5.76 (d, <i>J</i> = 10.4 Hz, 1H), 4.52–4.55 (m, 1H), 4.37 (s, 2H), 3.76 (s, 3H), 3.04 (m, 4H), 2.57 (m, 4H), 2.32 (s, 3H), 1.19 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ163.11, 158.31, 157.12, 154.03, 152.13, 146.79, 139.44, 137.58, 131.75, 128.85, 126.91, 125.01, 120.80, 118.22, 106.43, 101.45, 99.75, 55.59, 54.63, 48.77, 45.74, 45.65, 37.28, 18.74. HRMS (ESI): exact mass calcd for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 557.2983, found 557.2985.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-(3-Cyclopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2p</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 8.12 (s, 1H), 7.81 (d, <i>J</i> = 7.6 Hz, 1H), 7.55 (s, 1H), 7.48 (s, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.27 (d, <i>J</i> = 7.6 Hz, 1H), 6.96 (d, <i>J</i> = 7.6 Hz, 1H), 6.50 (s, 1H), 6.43 (dd, <i>J</i> = 10.0, 17.2 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 6.03 (s, 1H), 5.76 (d, <i>J</i> = 10.0 Hz, 1H), 4.43 (s, 2H), 3.75 (s, 3H), 3.00 (m, 4H), 2.67 (m, 1H), 2.46 (m, 4H), 2.24 (s, 3H), 0.76 (d, <i>J</i> = 5.6 Hz, 2H), 0.68 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.11, 158.27, 157.11, 154.01, 153.89, 146.78, 139.49, 137.42, 131.74, 128.91, 126.92, 124.91, 120.77, 120.73, 118.28, 106.41, 101.87, 99.74, 55.59, 54.62, 48.76, 45.74, 44.50, 30.04, 6.86. HRMS (ESI): exact mass calcd for C<sub>30</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 555.2827, found 555.2821.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2q</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.17 (s, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 7.68 (s, 1H), 7.56 (s, 1H), 7.41–7.47 (m, 5H), 7.26–7.32 (m, 2H), 7.07 (d, <i>J</i> = 7.6 Hz, 1H), 6.52 (d, <i>J</i> = 2.0 Hz, 1H), 6.44 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.26 (dd, <i>J</i> = 1.6, 16.8 Hz, 1H), 6.05 (d, <i>J</i> = 7.2 Hz, 1H), 5.76 (d, <i>J</i> = 11.6 Hz, 1H), 4.87 (s, 2H), 3.77 (s, 3H), 3.01 (m, 4H), 2.43 (m, 4H), 2.22 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.14, 158.43, 157.20, 154.08, 152.17, 146.90, 142.39, 139.53, 137.28, 131.75, 128.97, 128.73, 126.96, 126.16, 125.60, 124.98, 120.79, 120.70, 118.44, 106.42, 101.82, 99.76, 55.61, 54.63, 48.75, 46.74, 45.75. HRMS (ESI): exact mass calcd for C<sub>33</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 591.2827, found 591.2823.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-(naphthalen-1-yl)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2r</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 8.21 (s, 1H), 7.93–7.97 (m, 4H), 7.83 (d, <i>J</i> = 8.4 Hz, 1H), 7.72 (s, 1H), 7.63 (dd, <i>J</i> = 2.0, 8.4 Hz, 1H), 7.59 (s, 1H), 7.50–7.57 (m, 2H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 7.33 (d, <i>J</i> = 8.8 Hz, 1H), 7.11 (d, <i>J</i> = 7.6 Hz, 1H), 6.53 (d, <i>J</i> = 2.0 Hz, 1H), 6.45 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.26 (dd, <i>J</i> = 1.6, 16.8 Hz, 1H), 6.06 (d, <i>J</i> = 8.0 Hz, 1H), 5.77 (dd, <i>J</i> = 1.6, 10.0 Hz, 1H), 5.01 (s, 2H), 3.78 (s, 3H), 3.01 (m, 4H), 2.44 (m, 4H), 2.22 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.15, 158.48, 157.18, 154.11, 152.35, 140.09, 139.54, 137.25, 133.06, 131.75, 131.09, 128.98, 127.95, 127.52, 127.46, 126.94, 126.38, 125.89, 124.99, 122.26, 120.81, 120.71, 118.49, 106.44, 101.91, 99.78, 55.62, 54.57, 48.68, 46.74, 45.65. HRMS (ESI): exact mass calcd for C<sub>37</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 641.2983, found 641.2985.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(3-(3-Benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2s</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.08 (s, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.60 (s, 1H), 7.49 (s, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 7.33–7.41 (m, 4H), 7.26–7.32 (m, 1H), 7.02 (d, <i>J</i> = 7.6 Hz, 1H), 6.50 (d, <i>J</i> = 2.4 Hz, 1H), 6.43 (dd, <i>J</i> = 10.0, 16.4 Hz, 1H), 6.25 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 6.03 (d, <i>J</i> = 6.8 Hz, 1H), 5.76 (dd, <i>J</i> = 2.0, 10.0 Hz, 1H), 4.64 (s, 2H), 4.40 (s, 2H), 3.75 (s, 3H), 2.99 (t, <i>J</i> = 4.8 Hz, 4H), 2.42 (t, <i>J</i> = 4.8 Hz, 4H), 2.21 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.14, 158.28, 157.08, 154.24, 152.61, 146.81, 139.51, 137.49, 136.68, 131.75, 128.96, 128.61, 127.75, 127.40, 126.94, 125.00, 120.77, 120.73, 118.35, 106.41, 101.00, 99.74, 55.61, 54.63, 50.52, 48.75, 45.75, 43.73. HRMS (ESI): exact mass calcd for C<sub>34</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 605.2983, found 605.2984.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(3-(3-(Biphenyl-4-yl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2t</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 8.19 (s, 1H), 7.83 (d, <i>J</i> = 7.6 Hz, 1H), 7.69–7.74 (m, 5H), 7.46–7.58 (m, 6H), 7.37 (t, <i>J</i> = 7.2 Hz, 1H), 7.32 (d, <i>J</i> = 8.8 Hz, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.52 (s, 1H), 6.45 (dd, <i>J</i> = 10.0, 16.4 Hz, 1H), 6.26 (d, <i>J</i> = 16.8 Hz, 1H), 6.06 (d, <i>J</i> = 6.8 Hz, 1H), 5.77 (d, <i>J</i> = 10.0 Hz, 1H), 4.92 (s, 2H), 3.77 (s, 3H), 3.01 (m, 4H), 2.43 (m, 4H), 2.22 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.14, 158.44, 157.17, 154.09, 152.15, 146.93, 141.69, 139.54, 139.43, 137.78, 137.27, 131.74, 128.97, 128.91, 127.41, 126.94, 126.88, 126.58, 125.83, 124.98, 120.80, 120.71, 118.46, 106.43, 101.81, 99.76, 55.61, 54.60, 48.71, 46.60, 45.70. HRMS (ESI): exact mass calcd for C<sub>39</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 667.3140, found 667.3146.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-(4-phenoxyphenyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2u</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.17 (s, 1H), 7.81 (d, <i>J</i> = 8.4 Hz, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.40–7.47 (m, 5H), 7.30 (d, <i>J</i> = 8.8 Hz, 1H), 7.16 (t, <i>J</i> = 7.6 Hz, 1H), 7.04–7.07 (m, 5H), 6.52 (d, <i>J</i> = 2.4 Hz, 1H), 6.44 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.25 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 6.04 (s, 1H), 5.76 (dd, <i>J</i> = 2.0, 10.0 Hz, 1H), 4.86 (s, 2H), 3.77 (s, 3H), 3.00 (t, <i>J</i> = 4.4 Hz, 4H), 2.43 (t, <i>J</i> = 4.4 Hz, 4H), 2.22 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.13, 158.40, 157.19, 156.49, 154.71, 154.07, 152.20, 146.90, 139.51, 137.69, 137.27, 131.74, 130.07, 128.95, 127.46, 126.94, 124.96, 123.61, 120.77, 120.70, 118.73, 118.61, 118.41, 106.41, 101.77, 99.75, 55.61, 54.62, 48.73, 47.01, 45.73. HRMS (ESI): exact mass calcd for C<sub>39</sub>H<sub>38</sub>N<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 683.3089, found 683.3095.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(3-(3-(4-(Benzyloxy)phenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>2v</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 8.15 (s, 1H), 7.81 (d, <i>J</i> = 8.4 Hz, 1H), 7.66 (s, 1H), 7.54 (s, 1H), 7.29–7.47 (m, 8H), 7.04–7.07 (m, 3H), 6.52 (d, <i>J</i> = 2.0 Hz, 1H), 6.44 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.25 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 6.05 (d, <i>J</i> = 8.0 Hz, 1H), 5.76 (dd, <i>J</i> = 2.0, 10.0 Hz, 1H), 5.13 (s, 2H), 4.81 (s, 2H), 3.77 (s, 3H), 3.00 (t, <i>J</i> = 4.4 Hz, 4H), 2.42 (t, <i>J</i> = 4.4 Hz, 4H), 2.22(s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.13, 158.37, 157.23, 156.52, 154.03, 152.21, 146.84, 139.51, 137.33, 136.97, 135.44, 131.74, 128.93, 128.39, 127.79, 127.63, 127.13, 126.93, 124.97, 120.78, 120.72, 118.37, 114.89, 106.42, 101.77, 99.75, 69.36, 55.61, 54.63, 48.75, 47.24, 45.75. HRMS (ESI): exact mass calcd for C<sub>40</sub>H<sub>40</sub>N<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 697.3245, found 697.3252.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)propionamide (<b>2x</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 1H), 8.10 (s, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (s, 1H), 7.46 (s, 1H), 7.39 (t, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 1H), 6.90 (d, <i>J</i> = 8.0 Hz, 1H), 6.51 (d, <i>J</i> = 2.4 Hz, 1H), 6.03 (d, <i>J</i> = 7.6 Hz, 1H), 4.45 (s, 2H), 3.76 (s, 3H), 3.01 (t, <i>J</i> = 4.4 Hz, 4H), 2.96 (s, 3H), 2.43 (t, <i>J</i> = 4.4 Hz, 4H), 2.30 (q, <i>J</i> = 7.2, 14.8 Hz, 2H), 2.22 (s, 3H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ171.97, 158.24, 157.26, 153.99, 152.54, 146.78, 139.89, 137.41, 128.76, 124.32, 120.79, 120.31, 117.87, 106.44, 101.13, 99.74, 55.61, 54.66, 48.79, 45.81, 45.75, 39.00, 29.55, 9.60. HRMS (ESI): exact mass calcd for C<sub>28</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 531.2827, found 531.2819.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Cell Lines and Reagents</h3><div class="NLM_p last">H1975 (NSCLC, EGFR<sup>L858R/T790M</sup>), HCC827 (NSCLC, EGFR <sup>del E746-A750</sup>), A431 (epidermoid carcinoma, EGFR overexpression), and A549 (NSCLC, EGFR wild type) cells were obtained from ATCC. The cells were maintained at 37 °C in a 5% CO<sub>2</sub> incubator in RPMI 1640 (Gibco, Invitrogen) containing 10% fetal bovine serum (Gibco, Invitrogen). HLF-1(diploid human lung fibroblasts) and HL-7702 (diploid human liver cell) were gifts from Prof<i>.</i> Duanqing Pei. The HLF-1 was maintained in Ham’s F12K medium (Gibco, Invitrogen) with 15% FBS. The HL-7702 was cultured in RPMI 1640 containing 10% FBS. The EGFR gene of every cell line was sequenced before use. Gefitinib was synthesized in our chemistry laboratory.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> In Vitro Enzymatic Activity Assay</h3><div class="NLM_p last">Wild type and different EGFR mutants (T790M, L858R, L861Q, L858R/T790M) and the Z′-Lyte Kinase Assay Kit were purchased from Invitrogen. Ten concentration gradients from 5.1 × 10<sup>–11</sup> to 1.0 × 10<sup>–6</sup> mol/L were set for all the tested compounds. The experiments were performed according to the instructions of the manufacturer.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Kinase Profiling Study and <i>K</i><sub>d</sub> Determination</h3><div class="NLM_p last">The kinase profiling study and <i>K</i><sub>d</sub> determination were conducted using the Ambit Kinome screening platform (<a href="http://www.kinomescan.com" class="extLink">www.kinomescan.com</a>). Kinases were produced displayed on T7 phage or by expression in HEK-293 cells and tagged with DNA. Binding reactions were performed at r.t. for 1 h, and the fraction of kinase not bound to test compound was determined by capture with an immobilized affinity ligand and quantitation by quantitative PCR. Each kinase was tested individually against each compound. <i>K</i><sub>d</sub> values were determined using 11 serial 3-fold dilutions and presented as mean values from experiments performed in duplicate.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Cell Proliferation and Growth Inhibition Assay</h3><div class="NLM_p last">Cell proliferation was assessed by MTS assay. The cells were exposed to treatment for 72 h, and the number of cells used per experiment for each cell line was adjusted to obtain an absorbance of 1.3 to 2.2 at 490 nm. Six concentrations (0.1 nM to 10 μM) were set for the compounds. At least six parallels of every concentration were used. All experiments were repeated at least four times. The data were calculated using GraphPad Prism version 4.0. The IC<sub>50</sub> were fitted using a nonlinear regression model with a sigmoidal dose–response.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Colony Formation Assay</h3><div class="NLM_p last">The H1975 cells were plated in 6-cm dishes with densities of 500 cells/dish. After 24-h growth, the cells were treated with compounds <b>2q</b> and <b>2s</b> under concentrations ranging from 0.1 to 10 nM. The medium with compounds were changed every 3 days. After 9-day incubation, plates were fixed with 4% formaldehyde, and 0.2% crystal violet was used for staining.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Antibodies and Western Blotting</h3><div class="NLM_p last">Cells were plated in 6-cm dishes. After 24-h growth, the cells were treated with the compounds under the indicated concentrations for 24 h. Cell lysates were collected with 1× lysis buffer (CST) and were briefly sonicated. Western blot analyses were conducted after separation by SDS/PAGE electrophoresis and transfer to PVDF membranes. Membranes were blocked in 5% bovine serum albumin/TBST and probed with the indicated antibodies, followed by a peroxidase-conjugated antimouse or rabbit secondary antibody. Blots were developed by enhanced chemiluminescence (Thermo). Anti-phospho Akt (Ser 173), anti-total Akt, anti-EGFR, anti-phospho specific EGFR (pY1068), anti-total ERK1/2, and anti-phospho ERK1/2 (pT202/pY204) antibodies were obtained from Cell Signaling Technology.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Flow Cytometry Assay</h3><div class="NLM_p">For the apoptosis assay, cells were plated in six-well plates overnight and were treated with the compounds under indicated concentrations for 48 h. Trypsin (0.25%) was used, and a single cell suspension was prepared according to the instructions of the manufacturer. Apoptosis was assessed using a PE-Annexin V Kit (BD Pharmingen). The samples were detected with a FACS Calibur flow cytometer (Becton Dickinson)</div><div class="NLM_p last">The cell cycle analysis was performed by using Cycletest Plus DNA Reagent Kit (BD Pharmingen). Cells seeded in six-well plates were serum-starved for 24 h to synchronize cells in the G0–G1 phase of the cell cycle. Then the cells were treated with <b>2q</b> and <b>2s</b> under the indicated concentrations for 24 h. The cells were lightly trypsinized, and samples were prepared according to the instructions of the manufacturer. Samples were analyzed on a FACS Calibur flow cytometer (Becton Dickinson), and data were analyzed using the Modfit software package.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Mouse Tumor Xenograft Efficacy Study</h3><div class="NLM_p last">The efficacy study was conducted in accordance with the guidelines for the Care and Use of Laboratory Animals in Guangzhou Institute of Biomedicine and Health (GIBH, CAS). Six week old SCID mice were inoculated subcutaneously with H1975 NSCLC cells (2 × 10<sup>6</sup>/mouse) in the right flank. Upon reaching an average tumor volume of 380–420 mm<sup>3</sup> (10–12 days post implantation), animals were randomized into treatment groups (<i>n</i> = 6 mice/group). Each group was dosed orally for 14 days with either vehicle only or with compound <b>2s</b> at 10 or 30 mg/kg or gefitinib at 50 mg/kg daily (qd). The doses were in a volume of 0.1 mL/20 g of the animal body weight. Tumor volumes were measured every other day using vernier calipers, and volumes were calculated using the following formula: tumor volume (mm<sup>3</sup>) = <i>W</i><sup>2</sup>(<i>L</i>/2), where <i>W</i> = width and <i>L</i> = length in mm.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49"><a href="/doi/suppl/10.1021/jm201591k">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR spectrum and purity determination for compounds <b>2a</b>–<b>x</b>, apoptosis, cell cycle arrest, and colony formation inhibition induced by compounds <b>2q</b> and <b>2s</b>, Western blot analysis on A549 and A431 cells, growth inhibition on HLF-1 cells. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201591k/suppl_file/jm201591k_si_001.pdf">jm201591k_si_001.pdf (3.63 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm201591k" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1074797e774f7b7550777972783e71733e737e"><span class="__cf_email__" data-cfemail="fa9e93949da5919fba9d939892d49b99d49994">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaohua Chang</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate School of
Chinese Academy of Sciences, # 19 Yuquan Road, Beijing
100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lianwen Zhang</span> - <span class="hlFld-Affiliation affiliation">Graduate School of
Chinese Academy of Sciences, # 19 Yuquan Road, Beijing
100049, China</span>; 
    <span class="hlFld-Affiliation affiliation">School of Life Science, University
of Science and Technology of China, # 96
Jinzhai Road, Hefei 230026, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shilin Xu</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate School of
Chinese Academy of Sciences, # 19 Yuquan Road, Beijing
100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinfeng Luo</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhang Zhang</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianfeng Xu</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate School of
Chinese Academy of Sciences, # 19 Yuquan Road, Beijing
100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingxue Liu</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengchao Tu</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Xu</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaomei Ren</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, # 555 Zu-Chong-Zhi Road, Zhangjiang
Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, # 555 Zu-Chong-Zhi Road, Zhangjiang
Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duanqing Pei</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory
of Regenerative
Biology and Institute of Chemical Biology, Guangzhou Institutes of
Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d402e3985-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank National Basic Research Program of China (# 2010CB529706, 2009CB940904), National Natural Science Foundation (# 21072192), Key Project on Innovative Drug of Guangdong Province (# 2011A080501013), Strategic Collaborative Project of Guangdong Province and Chinese Academy of Sciences, Key Project on Innovative Drug of Guangzhou City (grant # 2009Z1-E911, 2010J-E551), and the 100-talent program of Chinese Academy of Sciences (CAS) for their financial support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> Abbreviations Used</h2><tr><td class="NLM_term">T</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">methionine</p></td></tr><tr><td class="NLM_term">I</td><td class="NLM_def"><p class="first last">isoleucine</p></td></tr><tr><td class="NLM_term">L</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">R</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">E</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">Q</td><td class="NLM_def"><p class="first last">glutamine</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non small cell lung cancer</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine-triphosphate</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term"><i>m</i>-CPBA</td><td class="NLM_def"><p class="first last">3-chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i><i>N</i></i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>d</sub></td><td class="NLM_def"><p class="first last">binding constant</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">GAK</td><td class="NLM_def"><p class="first last">cyclin G associated kinase</p></td></tr><tr><td class="NLM_term">FRK</td><td class="NLM_def"><p class="first last">Fyn-related kinase</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase signaling pathway</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0ljuDmlATrpDJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ciaardiello., F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=18337605" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciaardiello.author=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiaardiello.%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0ljuDmlATrpDJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+erlotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0ljuDmlATrpDJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makhson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Braud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loos, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koralewski, P.</span><span> </span><span class="NLM_article-title">Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">671</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1200%2FJCO.2008.20.8397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=19114683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsVCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=663-671&author=C.+Bokemeyerauthor=I.+Bondarenkoauthor=A.+Makhsonauthor=J.+T.+Hartmannauthor=J.+Aparicioauthor=F.+de+Braudauthor=S.+Doneaauthor=H.+Ludwigauthor=G.+Schuchauthor=C.+Strohauthor=A.+H.+Loosauthor=A.+Zubelauthor=P.+Koralewski&title=Fluorouracil%2C+leucovorin%2C+and+oxaliplatin+with+and+without+cetuximab+in+the+first-line+treatment+of+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</span></div><div class="casAuthors">Bokemeyer, Carsten; Bondarenko, Igor; Makhson, Anatoly; Hartmann, Joerg T.; Aparicio, Jorge; de Braud, Filippo; Donea, Serban; Ludwig, Heinz; Schuch, Gunter; Stroh, Christopher; Loos, Anja H.; Zubel, Angela; Koralewski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-671</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer.  The influence of KRAS mutation status was investigated.  Patients received cetuximab (400 mg/m2 initial dose followed by 250 mg/m2/wk thereafter) plus FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, plus leucovorin 200 mg/m2 and fluorouracil as a 400 mg/m2 bolus followed by a 600 mg/m2 infusion during 22 h on days 1 and 2; n = 169) or FOLFOX-4 alone (n = 168).  Treatment was continued until disease progression or unacceptable toxicity.  KRAS mutation status was assessed in the subset of patients with assessable tumor samples (n = 233).  The confirmed ORR for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone (46% v 36%).  A statistically significant increase in the odds for a response with the addn. of cetuximab to FOLFOX-4 could not be established (odds ratio = 1.52; P = .064).  In patients with KRAS wild-type tumors, the addn. of cetuximab to FOLFOX-4 was assocd. with a clin. significant increased chance of response (ORR = 61% v 37%; odds ratio = 2.54; P = .011) and a lower risk of disease progression (hazard ratio = 0.57; P = .0163) compared with FOLFOX-4 alone.  Cetuximab plus FOLFOX-4 was generally well tolerated.  KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addn. of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRjIYcrL-IG7Vg90H21EOLACvtfcHk0lj93xG9wl7LOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsVCjsrk%253D&md5=d7ca7c68ee0a4c8e55e11a0fbfa0ada8</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.8397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.8397%26sid%3Dliteratum%253Aachs%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DMakhson%26aufirst%3DA.%26aulast%3DHartmann%26aufirst%3DJ.%2BT.%26aulast%3DAparicio%26aufirst%3DJ.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DDonea%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DH.%26aulast%3DSchuch%26aufirst%3DG.%26aulast%3DStroh%26aufirst%3DC.%26aulast%3DLoos%26aufirst%3DA.%2BH.%26aulast%3DZubel%26aufirst%3DA.%26aulast%3DKoralewski%26aufirst%3DP.%26atitle%3DFluorouracil%252C%2520leucovorin%252C%2520and%2520oxaliplatin%2520with%2520and%2520without%2520cetuximab%2520in%2520the%2520first-line%2520treatment%2520of%2520metastatic%2520colorectal%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D663%26epage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köhne, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaluski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makhson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Haens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintér, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodoky, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roh, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folprecht, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejpar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nippgen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rougier, P.</span><span> </span><span class="NLM_article-title">Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">360</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1056%2FNEJMoa0805019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=19339720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFGjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=1408-1417&author=E.+Van+Cutsemauthor=C.+H.+K%C3%B6hneauthor=E.+Hitreauthor=J.+Zaluskiauthor=C.+C.+R.+Changauthor=A.+Makhsonauthor=G.+D%E2%80%99Haensauthor=T.+Pint%C3%A9rauthor=R.+Limauthor=G.+Bodokyauthor=J.+K.+Rohauthor=G.+Folprechtauthor=P.+Ruffauthor=C.+Strohauthor=S.+Tejparauthor=M.+Schlichtingauthor=J.+Nippgenauthor=P.+Rougier&title=Cetuximab+and+chemotherapy+as+initial+treatment+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</span></div><div class="casAuthors">Van Cutsem, Eric; Kohne, Claus-Henning; Hitre, Erika; Zaluski, Jerzy; Chien, Chung-Rong Chang; Makhson, Anatoly; D'Haens, Geert; Pinter, Tamas; Lim, Robert; Bodoky, Gyorgy; Roh, Jae Kyung; Folprecht, Gunnar; Ruff, Paul; Stroh, Christopher; Tejpar, Sabine; Schlichting, Michael; Nippgen, Johannes; Rougier, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1408-1417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought assocns. between the mutation status of the KRAS gene in tumors and clin. response to cetuximab.  We randomly assigned patients with epidermal growth factor receptor-pos. colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.  The primary end point was progression-free survival.  A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone.  The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048).  There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31).  There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P = 0.44).  The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94); in favor of the cetuximab-FOLFIRI group.  The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P < 0.001), infusion-related reactions (in 2.5% vs. 0%, P < 0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008).  First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer.  The benefit of cetuximab was limited to patients with KRAS wild-type tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl8xKwg-xTfrVg90H21EOLACvtfcHk0lj93xG9wl7LOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFGjt7g%253D&md5=74bb78d1779d6b571930b10d632d273f</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0805019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0805019%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DK%25C3%25B6hne%26aufirst%3DC.%2BH.%26aulast%3DHitre%26aufirst%3DE.%26aulast%3DZaluski%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%2BR.%26aulast%3DMakhson%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DPint%25C3%25A9r%26aufirst%3DT.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DBodoky%26aufirst%3DG.%26aulast%3DRoh%26aufirst%3DJ.%2BK.%26aulast%3DFolprecht%26aufirst%3DG.%26aulast%3DRuff%26aufirst%3DP.%26aulast%3DStroh%26aufirst%3DC.%26aulast%3DTejpar%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DM.%26aulast%3DNippgen%26aufirst%3DJ.%26aulast%3DRougier%26aufirst%3DP.%26atitle%3DCetuximab%2520and%2520chemotherapy%2520as%2520initial%2520treatment%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D1408%26epage%3D1417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Giusti, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shastri, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA drug approval summary: panitumumab (Vectibix)</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=577-583&author=R.+M.+Giustiauthor=K.+A.+Shastriauthor=M.+H.+Cohenauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+panitumumab+%28Vectibix%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiusti%26aufirst%3DR.%2BM.%26aulast%3DShastri%26aufirst%3DK.%2BA.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520panitumumab%2520%2528Vectibix%2529%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D577%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pallis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briasoulis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitriiou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bafaloukos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, S.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1628</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.2174%2F092986711795471383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21428885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1613-1628&author=A.+Pallisauthor=E.+Briasoulisauthor=H.+Linardouauthor=C.+Papadimitriiouauthor=D.+Bafaloukosauthor=P.+Kosmidisauthor=S.+Murray&title=Mechanisms+of+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+patients+with+advanced+non-small-cell+lung+cancer%3A+clinical+and+molecular+considerations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations</span></div><div class="casAuthors">Pallis, A.; Briasoulis, E.; Linardou, H.; Papadimitriou, C.; Bafaloukos, D.; Kosmidis, P.; Murray, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1613-1628</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth factor receptor (EGFR) is anticipated to respond to small-mol. tyrosine kinase inhibitors (TKIs) of the EGFR tyrosine kinase.  There are, however, patients with EGFR mutated tumors who do not demonstrate tumor response.  The most widely accepted mechanism of "de novo" (inherent) resistance to these TKIs involves mutations of the KRAS gene.  KRAS is a downstream mediator of EGFR-induced cell signaling, such mutations appear to be mutually exclusive from EGFR mutations in lung cancer.  The first mol. modifier of resistance identified in patients who developed resistance (termed "acquired resistance") to TK inhibition was a new acquired somatic EGFR mutation (T790M).  Today there is an ever-growing series of mol. events that have recently come to the forefront to explain other instances of TKI resistance not attributable to T790M or KRAS.  These include a no. of mols. that interact with EGFR or form part of its downstream signaling pathway such as HER-2, IGFR-1, MET and B-RAF.  Considering that the majority of studies carried out to date with respect to the identification of resistant clones have not used highly sensitive techniques (e.g. allelic discrimination to identify somatic mutations), coupled with the relatively low no. of studies examg. multiple mol. markers and the accepted mol. heterogeneity of NSCLC raise question as to the existence of "acquired" vs. "de-novo" resistance.  By examg. the current knowledge base with respect to mechanisms of resistance to EGFR TKIs in NSCLC, we explore whether "acquired" resistance is "de-novo" resistance in disguise, and discuss the promises and limitations of mol. stratification with respect to strategies incorporating TKIs in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmcf_n5Pd9F7Vg90H21EOLACvtfcHk0li5QCH0W-EHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOiurw%253D&md5=5583d328dd5182c2b14ea1f921ec1f64</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.2174%2F092986711795471383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795471383%26sid%3Dliteratum%253Aachs%26aulast%3DPallis%26aufirst%3DA.%26aulast%3DBriasoulis%26aufirst%3DE.%26aulast%3DLinardou%26aufirst%3DH.%26aulast%3DPapadimitriiou%26aufirst%3DC.%26aulast%3DBafaloukos%26aufirst%3DD.%26aulast%3DKosmidis%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DS.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520clinical%2520and%2520molecular%2520considerations%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D1613%26epage%3D1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemieleck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5530</span><span class="NLM_x">–</span> <span class="NLM_lpage">5537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F1078-0432.CCR-10-2571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21775534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5530-5537&author=G.+R.+Oxnardauthor=M.+E.+Arcilaauthor=J.+Chemieleckauthor=M.+Ladanyauthor=V.+A.+Millerauthor=W.+Pao&title=New+strategies+in+overcoming+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Arcila, Maria E.; Chmielecki, Juliann; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5530-5537</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The management of non-small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal growth factor receptor (EGFR) are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKI).  In these patients, acquired resistance to EGFR-TKI develops after a median of 10 to 14 mo, at which time the current std. practice is to switch to conventional cytotoxic chemotherapy.  Several possible mechanisms for acquired resistance have been identified, the most common being the development of an EGFR T790M gatekeeper mutation in more than 50% of cases.  In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies.  Clin Cancer Res; 17(17); 5530-7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqYmPYYBThNLVg90H21EOLACvtfcHk0li5QCH0W-EHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN&md5=209a41173563ee3776e020c0dacdd465</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2571%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChemieleck%26aufirst%3DJ.%26aulast%3DLadany%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNew%2520strategies%2520in%2520overcoming%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5530%26epage%3D5537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pao, W</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi1, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=1-11&author=W+Paoauthor=V.+A.+Millerauthor=K.+A.+Politi1author=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti1%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0li5QCH0W-EHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke Ding, K.</span><span> </span><span class="NLM_article-title">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2146</span><span class="NLM_x">–</span> <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.2174%2F092986711795656135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21517764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2146-2157&author=X.+Luauthor=Q.+Caiauthor=K.+Ke+Ding&title=Recent+developments+in+the+third+generation+inhibitors+of+Bcr-Abl+for+overriding+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span></div><div class="casAuthors">Lu, X. Y.; Cai, Q.; Ding, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2146-2157</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by disrupting important contact interactions between the inhibitors and the enzyme.  To overcome this particular resistance, several different strategies have been explored and many mols. have been investigated as capable of potently inhibiting Bcr-Abl T315I.  Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the "hybrid-design" strategy for creating type-II class ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoM774pVEqrVg90H21EOLACvtfcHk0liIJ9qfDh_Upg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D&md5=23109d1eb81a48f93cdf9ffbb4728c7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F092986711795656135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795656135%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DKe%2BDing%26aufirst%3DK.%26atitle%3DRecent%2520developments%2520in%2520the%2520third%2520generation%2520inhibitors%2520of%2520Bcr-Abl%2520for%2520overriding%2520T315I%2520mutation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2146%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liIJ9qfDh_Upg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">Recent examples see: </p></div><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno[2,3-<i>d</i>]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.-H.+Wuauthor=M.+S.+Coumarauthor=C.-Y.+Chuauthor=W.-H.+Linauthor=Y.-R.+Chenauthor=C.-T.+Chenauthor=H.-Y.+Shiaoauthor=S.+Rafiauthor=S.-Y.+Wangauthor=H.+Hsuauthor=C.-H.+Chenauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=T.-W.+Lienauthor=M.-Y.+Fangauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=J.+T.-A+Hsuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+The+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DY.-R.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520The%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monica, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2038</span><span class="NLM_x">–</span> <span class="NLM_lpage">2050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901558p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2038-2050&author=C.+Carmiauthor=A.+Cavazzoniauthor=S.+Vezzosiauthor=F.+Bordiauthor=F.+Vacondioauthor=C.+Silvaauthor=S.+Rivaraauthor=A.+Lodolaauthor=R.+R.+Alfieriauthor=S.+L.+Monicaauthor=M.+Galettiauthor=A.+Ardizzoniauthor=P.+G.+Petroniniauthor=M.+Mor&title=Novel+irreversible+epidermal+growth+factor+receptor+inhibitors+by+chemical+modulation+of+the+cysteine-trap+portion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DVezzosi%26aufirst%3DS.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DMonica%26aufirst%3DS.%2BL.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DNovel%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520chemical%2520modulation%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2038%26epage%3D2050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0liBVVD6RFjgdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of A novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901146p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+A+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Fjm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520A%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6880%26epage%3D6888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leou, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.-T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=Y.-H.+Pengauthor=J.-S.+Leouauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.-K.+Chittimallaauthor=J.-S.+Songauthor=J.-T.+A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+Aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0ljWnIRaUVmwgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.-T.%2BA.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520Aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors%3A+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+Wangauthor=L.+M.+Greenbergerauthor=H.+Tsou&title=Synthesis+and+structure%E2%80%93activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles%3A+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles%253A%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">31192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-31192&author=J.+A.+Engelmanauthor=F.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+Pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DF.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520Pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D31192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+Application+to+the+design+of+selective+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lg7lA7AZxwZMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520Application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: An orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+An+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lg7lA7AZxwZMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520An%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+Results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0ljBFbvZ2Og58A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520Results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">7596</span><div class="note"><p class="first last"> (suppl; abstr)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=7596&author=A.+Campbellauthor=K.+L.+Reckampauthor=D.+R.+Camidgeauthor=G.+Giacconeauthor=S.+M.+Gadgeelauthor=F.+R.+Khuriauthor=J.+A.+Engelmanauthor=L.+J.+Denisauthor=J.+P.+O%E2%80%99Connellauthor=P.+A.+Janne&title=PF-00299804+%28PF299%29+patient+%28pt%29-reported+outcomes+%28PROs%29+and+efficacy+in+adenocarcinoma+%28adeno%29+and+nonadeno+non-small+cell+lung+cancer+%28NSCLC%29%3A+A+phase+%28P%29+II+trial+in+advanced+NSCLC+after+failure+of+chemotherapy+%28CT%29+and+erlotinib+%28E%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BP.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPF-00299804%2520%2528PF299%2529%2520patient%2520%2528pt%2529-reported%2520outcomes%2520%2528PROs%2529%2520and%2520efficacy%2520in%2520adenocarcinoma%2520%2528adeno%2529%2520and%2520nonadeno%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520A%2520phase%2520%2528P%2529%2520II%2520trial%2520in%2520advanced%2520NSCLC%2520after%2520failure%2520of%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520%2528E%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D7596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberdick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span> </span><span class="NLM_article-title">Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1–2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">LBA1</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=LBA1&author=C.+Yangauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+Chenauthor=K.+Parkauthor=S.+Kimauthor=T.+Chaoauthor=M.+Oberdickauthor=M+Shahidiauthor=V.+Miller&title=Phase+IIb%2FIII+double-blind+randomized+trial+of+BIBW+2992%2C+an+irreversible%2C+dual+inhibitor+of+EGFR+and+HER2+plus+best+supportive+care+%28BSC%29+versus+placebo+plus+BSC+in+patients+with+NSCLC+failing+1%E2%80%932+lines+of+chemotherapy+%28CT%29+and+erlotinib+or+gefitinib+%28LUX-+Lung1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChao%26aufirst%3DT.%26aulast%3DOberdick%26aufirst%3DM.%26aulast%3DShahidi%26aufirst%3DM%26aulast%3DMiller%26aufirst%3DV.%26atitle%3DPhase%2520IIb%252FIII%2520double-blind%2520randomized%2520trial%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%252C%2520dual%2520inhibitor%2520of%2520EGFR%2520and%2520HER2%2520plus%2520best%2520supportive%2520care%2520%2528BSC%2529%2520versus%2520placebo%2520plus%2520BSC%2520in%2520patients%2520with%2520NSCLC%2520failing%25201%25E2%2580%25932%2520lines%2520of%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520or%2520gefitinib%2520%2528LUX-%2520Lung1%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26spage%3DLBA1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">7525</span><div class="note"><p class="first last"> (suppl; abstr)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=7525&author=Y.+Y.+Janjigianauthor=H.+J.+Groenauthor=L.+Hornauthor=E.+F.+Smitauthor=Y.+Fuauthor=F.+Wangauthor=M.+Shahidiauthor=L.+J.+Denisauthor=W.+Paoauthor=V.+A.+Miller&title=Activity+and+tolerability+of+afatinib+%28BIBW+2992%29+and+cetuximab+in+NSCLC+patients+with+acquired+resistance+to+erlotinib+or+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DGroen%26aufirst%3DH.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DActivity%2520and%2520tolerability%2520of%2520afatinib%2520%2528BIBW%25202992%2529%2520and%2520cetuximab%2520in%2520NSCLC%2520patients%2520with%2520acquired%2520resistance%2520to%2520erlotinib%2520or%2520gefitinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D7525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yuanauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Lacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhSKyZhAacHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DLacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+Janneauthor=N.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lhSKyZhAacHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jare-Erijma, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jov, T. M.</span><span> </span><span class="NLM_article-title">FRET imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jare-Erijmaauthor=T.+M.+Jov&title=FRET+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJare-Erijma%26aufirst%3DE.%2BA.%26aulast%3DJov%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">The assay was performed based on the manufacturer’s instructions (Invitrogen).</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+assay+was+performed+based+on+the+manufacturer%E2%80%99s+instructions+%28Invitrogen%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Steiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joynes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadari, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span> </span><span class="NLM_article-title">Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1540</span><span class="NLM_x">–</span> <span class="NLM_lpage">1551</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F1078-0432.CCR-06-1887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=17332300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1540-1551&author=P.+Steinerauthor=C.+Joynesauthor=R.+Bassiauthor=S.+Wangauthor=J.+R.+Tonraauthor=Y.+R.+Hadariauthor=D.+J.+Hicklin&title=Tumor+growth+inhibition+with+cetuximab+and+chemotherapy+in+non-small+cell+lung+cancer+xenografts+expressing+wild-type+and+mutated+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor</span></div><div class="casAuthors">Steiner, Philipp; Joynes, Christopher; Bassi, Rajiv; Wang, Su; Tonra, James R.; Hadari, Yaron R.; Hicklin, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1540-1551</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor (EGFR) is a validated approach to treat cancer.  In non-small cell lung cancer (NSCLC), EGFR contains somatic mutations in 10% of patients, which correlates with increased response rates to small mol. inhibitors of EGFR.  We analyzed the effects of the monoclonal IgG1 antibody Erbitux (cetuximab) in NSCLC xenografts with wild-type (wt) or mutated EGFR.  NSCLC cell lines were grown s.c. in nude mice.  Dose-dependent efficacy was established for cetuximab.  To det. whether combination therapy produces tumor regressions, cetuximab was dosed at half-maximal efficacy with chemotherapy used at max. tolerated dose.  Cetuximab showed antitumor activity in wt (A549, NCI-H358, NCI-H292) and mutated [HCC-827 (delE746-A750), NCI-H1975 (L858R, T790M)] EGFR-expressing xenografts.  In the H292 model, cetuximab and docetaxel combination therapy was more potent to inhibit tumor growth than cetuximab or docetaxel alone.  Cisplatin augmented efficacy of cetuximab to produce 6 of 10 regressions, whereas 1 of 10 regressions was found with cetuximab and no regression was found with cisplatin.  Using H1975 xenografts, gemcitabine increased efficacy of cetuximab resulting in 12 of 12 regressions.  Docetaxel with cetuximab was more efficacious with seven of nine regressions compared with single treatments.  Cetuximab inhibited autophosphorylation of EGFR in both H292 and H1975 tumor lysates.  Exploring the underlying mechanism for combination effects in the H1975 xenograft model, docetaxel in combination with cetuximab added to the antiproliferative effects of cetuximab but was the main component in this drug combination to induce apoptosis.  Cetuximab showed antitumor activity in NSCLC models expressing wt and mutated EGFR.  Combination treatments increased the efficacy of cetuximab, which may be important for the management of patients with chemorefractory NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzO5QyA9_4rVg90H21EOLACvtfcHk0lijDmMSb0YR0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLw%253D&md5=8a39b5dd9916f184996fdeed9b381bb1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1887%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DP.%26aulast%3DJoynes%26aufirst%3DC.%26aulast%3DBassi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTonra%26aufirst%3DJ.%2BR.%26aulast%3DHadari%26aufirst%3DY.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DTumor%2520growth%2520inhibition%2520with%2520cetuximab%2520and%2520chemotherapy%2520in%2520non-small%2520cell%2520lung%2520cancer%2520xenografts%2520expressing%2520wild-type%2520and%2520mutated%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1540%26epage%3D1551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Libermann, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nusbaum, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lax, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soreq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Amplification, enhanced expression and possible rearrangement of egf receptor gene in primary human-brain tumors of glial origin</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=144-147&author=T.+A.+Libermannauthor=H.+R.+Nusbaumauthor=N.+Razonauthor=R.+Krisauthor=I.+Laxauthor=H.+Soreqauthor=N.+Whittleauthor=M.+D.+Waterfieldauthor=A.+Ullrichauthor=J.+Schlessinger&title=Amplification%2C+enhanced+expression+and+possible+rearrangement+of+egf+receptor+gene+in+primary+human-brain+tumors+of+glial+origin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLibermann%26aufirst%3DT.%2BA.%26aulast%3DNusbaum%26aufirst%3DH.%2BR.%26aulast%3DRazon%26aufirst%3DN.%26aulast%3DKris%26aufirst%3DR.%26aulast%3DLax%26aufirst%3DI.%26aulast%3DSoreq%26aufirst%3DH.%26aulast%3DWhittle%26aufirst%3DN.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DAmplification%252C%2520enhanced%2520expression%2520and%2520possible%2520rearrangement%2520of%2520egf%2520receptor%2520gene%2520in%2520primary%2520human-brain%2520tumors%2520of%2520glial%2520origin%26jtitle%3DNature%26date%3D1985%26volume%3D313%26spage%3D144%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchihashi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1185</span><span class="NLM_x">–</span> <span class="NLM_lpage">1194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1093%2Fjnci%2Fdji238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16106023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=1185-1194&author=T.+Mukoharaauthor=J.+A.+Engelmanauthor=N.+H.+Hannaauthor=B.+Y.+Yeapauthor=S.+Kobayashiauthor=N.+Lindemanauthor=B.+Halmosauthor=J.+Pearlbergauthor=Z.+Tsuchihashiauthor=L.+C.+Cantleyauthor=D.+G.+Tenenauthor=B.+E.+Johnsonauthor=P.+A.+Janne&title=Differential+effects+of+gefitinib+and+cetuximab+on+non-small-cell+lung+cancers+bearing+epidermal+growth+factor+receptor+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Effects of Gefitinib and Cetuximab on Non-small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations</span></div><div class="casAuthors">Mukohara, Toru; Engelman, Jeffrey A.; Hanna, Nasser H.; Yeap, Beow Y.; Kobayashi, Susumu; Lindeman, Neal; Halmos, Balazs; Pearlberg, Joseph; Tsuchihashi, Zenta; Cantley, Lewis C.; Tenen, Daniel G.; Johnson, Bruce E.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1185-1194</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Many patients with non-small-cell lung cancer (NSCLC) who achieve radiog. responses to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib have somatic mutations in the EGFR tyrosine kinase domain.  However, little is known about the efficacy of cetuximab, an antibody against the EGFR extracellular domain, in EGFR mutant NSCLC.  Methods: NSCLC cell lines carrying wild-type EGFR (A549, H441, and H1666) or mutant EGFR (H3255, DFCILU-011, PC-9, and HCC827) were treated with various dilns. of gefitinib or cetuximab relative to maximal achievable serum concn.  Cell growth was analyzed by the MTS assay, with differences between dose-response curves analyzed nonparametrically.  Apoptosis was analyzed by propidium iodide staining and immunoblotting for PARP.  Phosphorylation of EGFR and the downstream signaling components ERK1/2 and Akt were analyzed by immunoblotting.  Statistical tests were two-sided.  Results: Growth of NSCLC lines with wild-type EGFR was slightly (A549 and H441) or moderately (H1666) inhibited by gefitinib and cetuximab, and the effects of the two agents were similar.  Both agents also induced no (H441) or moderate (H1666) apoptosis in NSCLC cells with wild-type EGFR.  By contrast, gefitinib was statistically significantly more effective than cetuximab at inhibiting growth of EGFR mutant cells (H3255: P = .003, DFCILU-011: P = .011, and PC-9: P = .003), and gefitinib-treated EGFR mutant cells had higher levels of apoptosis than cetuximab-treated cells (mean fold increase in apoptosis by 1 μM of gefitinib and 10 μg/mL of cetuximab relative to control, H3255: 8.3 [95% confidence interval {CI} = 4.8 to 11.8] and 2.1 [95% CI = 2.0 to 2.2], resp., P = .025; DFCILU-011: 5.7 [95% CI = 5.1 to 6.3] and. 0.9 [95% CI = 0.3 to 1.5], resp., P < .001).  Gefitinib treatment decreased EGFR, ERK1/2, and Akt phosphorylation in EGFR mutant cell lines whereas cetuximab had relatively little effect.  Both gefitinib and cetuximab inhibited the growth of HCC827 cells, but gefitinib inhibited growth to a greater extent (P = .003).  Conclusions: EGFR mutations in NSCLC cells are assocd. with sensitivity to gefitinib but not to cetuximab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfmCDcRLe60rVg90H21EOLACvtfcHk0lijDmMSb0YR0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVaks7Y%253D&md5=60c96e3587183397139243b4dd3bdc84</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdji238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdji238%26sid%3Dliteratum%253Aachs%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DPearlberg%26aufirst%3DJ.%26aulast%3DTsuchihashi%26aufirst%3DZ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DDifferential%2520effects%2520of%2520gefitinib%2520and%2520cetuximab%2520on%2520non-small-cell%2520lung%2520cancers%2520bearing%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2005%26volume%3D97%26spage%3D1185%26epage%3D1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wei, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span> </span><span class="NLM_article-title">SeO2 induces apoptosis with down-regulation of Bcl-2 and up-regulation of P53 expression in both immortal human hepatic cell line and hepatoma cell line</span> <span class="citation_source-journal">Mutat. Res.: Genet. Toxicol. Environ. Mutagen</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">490</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2001&pages=113-121&author=Y.+M.+Weiauthor=X.+Z.+Caoauthor=Y.+X.+Ouauthor=J.+H.+Luauthor=C.+P.+Xingauthor=R.+L.+Zheng&title=SeO2+induces+apoptosis+with+down-regulation+of+Bcl-2+and+up-regulation+of+P53+expression+in+both+immortal+human+hepatic+cell+line+and+hepatoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DY.%2BM.%26aulast%3DCao%26aufirst%3DX.%2BZ.%26aulast%3DOu%26aufirst%3DY.%2BX.%26aulast%3DLu%26aufirst%3DJ.%2BH.%26aulast%3DXing%26aufirst%3DC.%2BP.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26atitle%3DSeO2%2520induces%2520apoptosis%2520with%2520down-regulation%2520of%2520Bcl-2%2520and%2520up-regulation%2520of%2520P53%2520expression%2520in%2520both%2520immortal%2520human%2520hepatic%2520cell%2520line%2520and%2520hepatoma%2520cell%2520line%26jtitle%3DMutat.%2520Res.%253A%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen%26date%3D2001%26volume%3D490%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Breul, K. H. B. S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hance, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, M. P R</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, R G.</span><span> </span><span class="NLM_article-title">Control of collagen production by human diploid lung fibroblasts</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">255</span><span class="NLM_x">, </span> <span class="NLM_fpage">5250</span><span class="NLM_x">–</span> <span class="NLM_lpage">5260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=7372635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADyaL3cXksVans7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1980&pages=5250-5260&author=K.+H.+B.+S.+D.+Breulauthor=A.+J.+Hanceauthor=M.+P+R+Schaferauthor=A+Bergauthor=R+G.+Crystal&title=Control+of+collagen+production+by+human+diploid+lung+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Control of collagen production by human diploid lung fibroblasts</span></div><div class="casAuthors">Breul, Sally D.; Bradley, Kathryn H.; Hance, Allan J.; Schafer, Millie P.; Berg, Richard A.; Crystal, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5250-60</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">To evaluate the control soft tissue fibroblasts have over collagen prodn., HFL-1, a diploid human lung cell strain, was studied during periods of rapid cell growth and relatively slow growth over 25 population doublings.  To minimize environmental influences, the extracellular milieu of the cells was kept const. throughout the study period.  Rates of collagen prodn. per cell unit time were quantitated by labeling HFL-1 with [14C]proline and measuring the prodn. of [14C]hydroxyproline after taking into consideration the sp. activity of [14C]proline within the free intracellular proline pool and the percent hydroxylation of proline residues in newly synthesized collagen.  Although the sp. activity of intracellular free proline and the percent hydroxylation of proline in collagen varied considerably depending on the growth rates of the cells, collagen prodn. by HFL-1 was const., even during periods of rapid cell growth.  Thus, under conditions of a stable environment, populations of soft tissue fibroblasts rigidly control their collagen prodn.  In cultures that maintained a const. doubling time, this stability was maintained over ≥25 population doublings, suggesting that on the av., collagen prodn. appears to be tightly controlled and dissocd. from the events and sequelae of cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyK2bRXCUwSrVg90H21EOLACvtfcHk0liPdGwdZDvSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXksVans7s%253D&md5=73ba43348807e2bdd8fe59b18af080ea</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBreul%26aufirst%3DK.%2BH.%2BB.%2BS.%2BD.%26aulast%3DHance%26aufirst%3DA.%2BJ.%26aulast%3DSchafer%26aufirst%3DM.%2BP%2BR%26aulast%3DBerg%26aufirst%3DA%26aulast%3DCrystal%26aufirst%3DR%2BG.%26atitle%3DControl%2520of%2520collagen%2520production%2520by%2520human%2520diploid%2520lung%2520fibroblasts%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1980%26volume%3D255%26spage%3D5250%26epage%3D5260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Toulany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodemann, H. P.</span><span> </span><span class="NLM_article-title">Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway</span> <span class="citation_source-journal">Radiother. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1016%2Fj.radonc.2005.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16024124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslChsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2005&pages=143-150&author=M.+Toulanyauthor=K.+Dittmannauthor=M.+Krugerauthor=M.+Baumannauthor=H.+P.+Rodemann&title=Radioresistance+of+K-Ras+mutated+human+tumor+cells+is+mediated+through+EGFR-dependent+activation+of+PI3K-AKT+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway</span></div><div class="casAuthors">Toulany, Mahmoud; Dittmann, Klaus; Krueger, Maren; Baumann, Michael; Rodemann, H. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-150</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the context of EGFR-targeting strategies we investigated autocrine/paracrine factors leading to in vitro radioresistance of K-Ras mutated tumor cells through activation of EGFR mediated signal transduction.  Ras mutated (Rasmt) and normal Ras (Raswt) presenting human tumor cell lines were used to analyze the potential of conditioned media (CM) of both cell types to mediate radioresistance and to activate EGFR-signaling cascades.  Therefore, clonogenic assays as well as SDS-PAGE combined with immunoblotting was performed.  Addnl., Ras-mutated cells were transfected with K-Ras-siRNA to investigate, how downregulation of mutated K-Ras affects secretion of EGFR-ligands, stimulation of EGFR-signaling and modulation of radiation response.  TGFα, Amphiregulin (ARG) and CM from Rasmt cells (Rasmt-CM) resulted in an increased clonogenic survival of irradiated Raswt cells.  Both, EGFR ligands as well as Rasmt-CM led to a strong phosphorylation of EGFR and activation of downstream pathways, i.e. PI3K-AKT.  However, neutralization of TGFα or ARG in Rasmt-CM led to a marked redn. of P-AKT.  Furthermore, Rasmt-CM from K-Ras-siRNA transfected Rasmt-cells markedly inhibited phosphorylation of AKT in Raswt cells and enhanced radiation sensitivity of A549 cells transfected with the siRNA.  The data suggest that constitutively upregulated autocrine/paracrine secretion of EGF receptor ligands, esp. ARG from K-Ras mutated cells, mediates radioresistance in Rasmt-cells through stimulation of EGFR-PI3K-AKT pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHKxuufeqS7Vg90H21EOLACvtfcHk0liPdGwdZDvSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslChsb4%253D&md5=5ddcac2c06906c05f1d3e265cdece924</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2005.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2005.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DDittmann%26aufirst%3DK.%26aulast%3DKruger%26aufirst%3DM.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DRodemann%26aufirst%3DH.%2BP.%26atitle%3DRadioresistance%2520of%2520K-Ras%2520mutated%2520human%2520tumor%2520cells%2520is%2520mediated%2520through%2520EGFR-dependent%2520activation%2520of%2520PI3K-AKT%2520pathway%26jtitle%3DRadiother.%2520Oncol.%26date%3D2005%26volume%3D76%26spage%3D143%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun., F</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&author=H.+G.+Choiauthor=P.+Renauthor=F+Adrianauthor=F+Sun.author=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF%26aulast%3DSun.%26aufirst%3DF%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5439%26epage%3D5448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Paulsen, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K. S.</span><span> </span><span class="NLM_article-title">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1038%2Fnchembio.736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=57-64&author=C.+E.+Paulsenauthor=T.+H.+Truongauthor=F.+J.+Garciaauthor=A.+Homannauthor=V.+Guptaauthor=S%2C+E.+Leonardauthor=K.+S.+Carroll&title=Peroxide-dependent+sulfenylation+of+the+EGFR+catalytic+site+enhances+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span></div><div class="casAuthors">Paulsen, Candice E.; Truong, Thu H.; Garcia, Francisco J.; Homann, Arne; Gupta, Vinayak; Leonard, Stephen E.; Carroll, Kate S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein sulfenylation is a post-translational modification of emerging importance in higher eukaryotes.  However, investigation of its diverse roles remains challenging, particularly within a native cellular environment.  Herein we report the development and application of DYn-2, a new chemoselective probe for detecting sulfenylated proteins in human cells.  These studies show that epidermal growth factor receptor (EGFR)-mediated signaling results in H2O2 prodn. and oxidn. of downstream proteins.  In addn., we demonstrate that DYn-2 has the ability to detect differences in sulfenylation rates within the cell, which are assocd. with differences in target protein localization.  We also show that the direct modification of epidermal growth factor receptor by H2O2 at a crit. active site cysteine (Cys797) enhances its tyrosine kinase activity.  Collectively, our findings reveal sulfenylation as a global signaling mechanism that is akin to phosphorylation and has regulatory implications for other receptor tyrosine kinases and irreversible inhibitors that target oxidant-sensitive cysteines in proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp30snMrGIfzLVg90H21EOLACvtfcHk0ljCi8qtmWggTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E&md5=44011c82266cf6a47922b1ba1038cc30</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.736%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DC.%2BE.%26aulast%3DTruong%26aufirst%3DT.%2BH.%26aulast%3DGarcia%26aufirst%3DF.%2BJ.%26aulast%3DHomann%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLeonard%26aufirst%3DS%252C%2BE.%26aulast%3DCarroll%26aufirst%3DK.%2BS.%26atitle%3DPeroxide-dependent%2520sulfenylation%2520of%2520the%2520EGFR%2520catalytic%2520site%2520enhances%2520kinase%2520activity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D57%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, Erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+Erlotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0ljCi8qtmWggTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520Erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 68 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2020,</strong> <em>124 </em>
                                    (28)
                                     , 5813-5824. <a href="https://doi.org/10.1021/acs.jpcb.0c03440" title="DOI URL">https://doi.org/10.1021/acs.jpcb.0c03440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.0c03440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.0c03440%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DMechanistic%252BStudy%252Bof%252BPotent%252BFluorinated%252BEGFR%252BKinase%252BInhibitors%252Bwith%252Ba%252BQuinazoline%252BScaffold%252Bagainst%252BL858R%25252FT790M%25252FC797S%252BResistance%252BMutation%25253A%252BUnveiling%252Bthe%252BFluorine%252BSubstituent%252BCooperativity%252BEffect%252Bon%252Bthe%252BInhibitory%252BActivity%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17042020%26date%3D16062020%26date%3D30062020%26volume%3D124%26issue%3D28%26spage%3D5813%26epage%3D5824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhen Wang, Yali Zhang, Daniel M. Pinkas, Alice E. Fox, Jinfeng Luo, Huocong Huang, Shengyang Cui, Qiuping Xiang, Tingting Xu, Qiuju Xun, Dongsheng Zhu, Zhengchao Tu, Xiaomei Ren, Rolf A. Brekken, Alex N. Bullock, Guang Liang, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xiaoyun Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7977-7990. <a href="https://doi.org/10.1021/acs.jmedchem.8b01045" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01045%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B3-%252528Imidazo%25255B1%25252C2-a%25255Dpyrazin-3-ylethynyl%252529-4-isopropyl-N-%2525283-%252528%2525284-methylpiperazin-1-yl%252529methyl%252529-5-%252528trifluoromethyl%252529phenyl%252529benzamide%252Bas%252Ba%252BDual%252BInhibitor%252Bof%252BDiscoidin%252BDomain%252BReceptors%252B1%252Band%252B2%26aulast%3DWang%26aufirst%3DZhen%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02072018%26date%3D20082018%26date%3D03082018%26volume%3D61%26issue%3D17%26spage%3D7977%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew T. Parsons, Michele Kubryk, Simon J. Hedley, Oliver R. Thiel, David Bauer, Matthew S. Potter-Racine, <span class="NLM_string-name hlFld-ContribAuthor">Zhenxin Lin</span>. </span><span class="cited-content_cbyCitation_article-title">An Improved Process for the Preparation of a Covalent Kinase Inhibitor through a C–N Bond-Forming SNAr Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (7)
                                     , 898-902. <a href="https://doi.org/10.1021/acs.oprd.8b00080" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00080%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DAn%252BImproved%252BProcess%252Bfor%252Bthe%252BPreparation%252Bof%252Ba%252BCovalent%252BKinase%252BInhibitor%252Bthrough%252Ba%252BC%2525E2%252580%252593N%252BBond-Forming%252BSNAr%252BReaction%26aulast%3DParsons%26aufirst%3DAndrew%2BT.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20032018%26date%3D12062018%26volume%3D22%26issue%3D7%26spage%3D898%26epage%3D902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongjia Hao, Jiankun Lyu, Rong Qu, Yi Tong, Deheng Sun, Fang Feng, Linjiang Tong, Tingyuan Yang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Yufang Xu, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Honglin Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5609-5622. <a href="https://doi.org/10.1021/acs.jmedchem.8b00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BPyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-diones%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04032018%26date%3D25062018%26date%3D15062018%26volume%3D61%26issue%3D13%26spage%3D5609%26epage%3D5622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiuju Xun, Zhang Zhang, Jinfeng Luo, Linjiang Tong, Minhao Huang, Zhen Wang, Jian Zou, Yingqiang Liu, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2353-2371. <a href="https://doi.org/10.1021/acs.jmedchem.7b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudy%252Bof%252B2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidines%252Bas%252BNew%252BColony%252BStimulating%252BFactor%252B1%252BReceptor%252B%252528CSF1R%252529%252BKinase%252BInhibitors%26aulast%3DXun%26aufirst%3DQiuju%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01112017%26date%3D13032018%26date%3D02032018%26volume%3D61%26issue%3D6%26spage%3D2353%26epage%3D2371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Xiao-E  Yan</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, and <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 2944-2962. <a href="https://doi.org/10.1021/acs.jmedchem.6b01907" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01907</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01907%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-1-%2525283-%2525284-Amino-3-%2525283-chloro-4-%252528pyridin-2-ylmethoxy%252529phenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529piperidin-1-yl%252529prop-2-en-1-one%252B%252528CHMFL-EGFR-202%252529%252Bas%252Ba%252BNovel%252BIrreversible%252BEGFR%252BMutant%252BKinase%252BInhibitor%252Bwith%252Ba%252BDistinct%252BBinding%252BMode%26aulast%3DWang%26aufirst%3DAoli%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D28122016%26date%3D22032017%26date%3D13042017%26date%3D10032017%26volume%3D60%26issue%3D7%26spage%3D2944%26epage%3D2962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (12)
                                     , 1050-1055. <a href="https://doi.org/10.1021/acsmedchemlett.6b00235" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitors%252BBearing%252Ba%252BN%25252C9-Diphenyl-9H-purin-2-amine%252BScaffold%26aulast%3DGe%26aufirst%3DYang%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11062016%26date%3D21092016%26date%3D27092016%26date%3D08122016%26date%3D21092016%26volume%3D7%26issue%3D12%26spage%3D1050%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Deheng  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Yuqiong  Xu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (15)
                                     , 7111-7124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00403" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructural%252BOptimization%252Bof%252BN5-Substituted%252B6%25252C7-Dioxo-6%25252C7-dihydropteridines%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26032016%26date%3D21072016%26date%3D11082016%26date%3D11072016%26volume%3D59%26issue%3D15%26spage%3D7111%26epage%3D7124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gérald  Lelais</span>, <span class="hlFld-ContribAuthor ">Robert  Epple</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Marsilje</span>, <span class="hlFld-ContribAuthor ">Yun O.  Long</span>, <span class="hlFld-ContribAuthor ">Matthew  McNeill</span>, <span class="hlFld-ContribAuthor ">Bei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenshuo  Lu</span>, <span class="hlFld-ContribAuthor ">Jaganmohan  Anumolu</span>, <span class="hlFld-ContribAuthor ">Sangamesh  Badiger</span>, <span class="hlFld-ContribAuthor ">Badry  Bursulaya</span>, <span class="hlFld-ContribAuthor ">Michael  DiDonato</span>, <span class="hlFld-ContribAuthor ">Rina  Fong</span>, <span class="hlFld-ContribAuthor ">Jose  Juarez</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">Mari  Manuia</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Mason</span>, <span class="hlFld-ContribAuthor ">Perry  Gordon</span>, <span class="hlFld-ContribAuthor ">Todd  Groessl</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Yong  Jia</span>, <span class="hlFld-ContribAuthor ">Shailaja  Kasibhatla</span>, <span class="hlFld-ContribAuthor ">Chun  Li</span>, <span class="hlFld-ContribAuthor ">John  Isbell</span>, <span class="hlFld-ContribAuthor ">Glen  Spraggon</span>, <span class="hlFld-ContribAuthor ">Steven  Bender</span>, and <span class="hlFld-ContribAuthor ">Pierre-Yves  Michellys</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6671-6689. <a href="https://doi.org/10.1021/acs.jmedchem.5b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%25252CE%252529-N-%2525287-Chloro-1-%2525281-%25255B4-%252528dimethylamino%252529but-2-enoyl%25255Dazepan-3-yl%252529-1H-benzo%25255Bd%25255Dimidazol-2-yl%252529-2-methylisonicotinamide%252B%252528EGF816%252529%25252C%252Ba%252BNovel%25252C%252BPotent%25252C%252Band%252BWT%252BSparing%252BCovalent%252BInhibitor%252Bof%252BOncogenic%252B%252528L858R%25252C%252Bex19del%252529%252Band%252BResistant%252B%252528T790M%252529%252BEGFR%252BMutants%252Bfor%252Bthe%252BTreatment%252Bof%252BEGFR%252BMutant%252BNon-Small-Cell%252BLung%252BCancers%26aulast%3DLelais%26aufirst%3DG%25C3%25A9rald%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D22122015%26date%3D19072016%26date%3D28072016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dora  Toledo Warshaviak</span>, <span class="hlFld-ContribAuthor ">Gali  Golan</span>, <span class="hlFld-ContribAuthor ">Kenneth W.  Borrelli</span>, <span class="hlFld-ContribAuthor ">Kai  Zhu</span>, and <span class="hlFld-ContribAuthor ">Ori  Kalid</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (7)
                                     , 1941-1950. <a href="https://doi.org/10.1021/ci500175r" title="DOI URL">https://doi.org/10.1021/ci500175r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500175r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500175r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructure-Based%252BVirtual%252BScreening%252BApproach%252Bfor%252BDiscovery%252Bof%252BCovalently%252BBound%252BLigands%26aulast%3DToledo%2BWarshaviak%26aufirst%3DDora%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18032014%26date%3D26062014%26date%3D28072014%26date%3D16062014%26volume%3D54%26issue%3D7%26spage%3D1941%26epage%3D1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tushar  Apsunde</span> and <span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyridin-2-one Synthesis Using Ester Enolates and Aryl Aminoaldehydes and Ketones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2014,</strong> <em>79 </em>
                                    (7)
                                     , 3260-3266. <a href="https://doi.org/10.1021/jo500284n" title="DOI URL">https://doi.org/10.1021/jo500284n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo500284n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo500284n%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPyridin-2-one%252BSynthesis%252BUsing%252BEster%252BEnolates%252Band%252BAryl%252BAminoaldehydes%252Band%252BKetones%26aulast%3DApsunde%26aufirst%3DTushar%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D05022014%26date%3D24032014%26date%3D04042014%26date%3D17032014%26volume%3D79%26issue%3D7%26spage%3D3260%26epage%3D3266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (21)
                                     , 8803-8813. <a href="https://doi.org/10.1021/jm4012388" title="DOI URL">https://doi.org/10.1021/jm4012388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4012388%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidinyl%252BDerivatives%252Bas%252BNew%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252Bwith%252BImproved%252BPharmacokinetic%252BProperties%26aulast%3DXu%26aufirst%3DShilin%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D09082013%26date%3D31102013%26date%3D14112013%26date%3D14102013%26volume%3D56%26issue%3D21%26spage%3D8803%26epage%3D8813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Ku</span>, <span class="hlFld-ContribAuthor ">Fang  Bai</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (20)
                                     , 7821-7837. <a href="https://doi.org/10.1021/jm401045n" title="DOI URL">https://doi.org/10.1021/jm401045n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401045n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPteridin-7%2525288H%252529-one-Based%252BIrreversible%252BInhibitors%252BTargeting%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BKinase%252BT790M%25252FL858R%252BMutant%26aulast%3DZhou%26aufirst%3DWei%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D03042013%26date%3D09102013%26date%3D24102013%26date%3D22092013%26volume%3D56%26issue%3D20%26spage%3D7821%26epage%3D7837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Mark J.  Anderton</span>, <span class="hlFld-ContribAuthor ">Susan  Ashton</span>, <span class="hlFld-ContribAuthor ">Paul A.  Bethel</span>, <span class="hlFld-ContribAuthor ">Matthew  Box</span>, <span class="hlFld-ContribAuthor ">Sam  Butterworth</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Christopher G.  Chorley</span>, <span class="hlFld-ContribAuthor ">Claudio  Chuaqui</span>, <span class="hlFld-ContribAuthor ">Darren A. E.  Cross</span>, <span class="hlFld-ContribAuthor ">Les A.  Dakin</span>, <span class="hlFld-ContribAuthor ">Judit É.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Cath  Eberlein</span>, <span class="hlFld-ContribAuthor ">M. Raymond V.  Finlay</span>, <span class="hlFld-ContribAuthor ">George B.  Hill</span>, <span class="hlFld-ContribAuthor ">Matthew  Grist</span>, <span class="hlFld-ContribAuthor ">Teresa C. M.  Klinowska</span>, <span class="hlFld-ContribAuthor ">Clare  Lane</span>, <span class="hlFld-ContribAuthor ">Scott  Martin</span>, <span class="hlFld-ContribAuthor ">Jonathon P.  Orme</span>, <span class="hlFld-ContribAuthor ">Peter  Smith</span>, <span class="hlFld-ContribAuthor ">Fengjiang  Wang</span>, and <span class="hlFld-ContribAuthor ">Michael J.  Waring</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (17)
                                     , 7025-7048. <a href="https://doi.org/10.1021/jm400822z" title="DOI URL">https://doi.org/10.1021/jm400822z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400822z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-%252Band%252BReactivity-Based%252BDevelopment%252Bof%252BCovalent%252BInhibitors%252Bof%252Bthe%252BActivating%252Band%252BGatekeeper%252BMutant%252BForms%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D03062013%26date%3D30082013%26date%3D12092013%26date%3D09082013%26volume%3D56%26issue%3D17%26spage%3D7025%26epage%3D7048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Chao  Zheng</span>, <span class="hlFld-ContribAuthor ">Ledong  Wan</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Hongbin  Ji</span>, <span class="hlFld-ContribAuthor ">Jide  Tian</span>, and <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4738-4748. <a href="https://doi.org/10.1021/jm400463q" title="DOI URL">https://doi.org/10.1021/jm400463q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400463q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400463q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BHybrids%252Bof%252B%252528Phenylsulfonyl%252529furoxan%252Band%252BAnilinopyrimidine%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252Bfor%252BIntervention%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DHan%26aufirst%3DChun%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D29032013%26date%3D24052013%26date%3D13062013%26date%3D13052013%26volume%3D56%26issue%3D11%26spage%3D4738%26epage%3D4748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Pan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Donghai  Wen</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yubing  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Leng</span>, <span class="hlFld-ContribAuthor ">Xingfen  Lang</span>, <span class="hlFld-ContribAuthor ">Yang  Bai</span>, <span class="hlFld-ContribAuthor ">Miaoqin  She</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Jingxuan  Pan</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (3)
                                     , 879-894. <a href="https://doi.org/10.1021/jm301581y" title="DOI URL">https://doi.org/10.1021/jm301581y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301581y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BGZD824%252Bas%252Ban%252BOrally%252BBioavailable%252BInhibitor%252BThat%252BTargets%252BPhosphorylated%252Band%252BNonphosphorylated%252BBreakpoint%252BCluster%252BRegion%2525E2%252580%252593Abelson%252B%252528Bcr-Abl%252529%252BKinase%252Band%252BOvercomes%252BClinically%252BAcquired%252BMutation-Induced%252BResistance%252Bagainst%252BImatinib%26aulast%3DRen%26aufirst%3DXiaomei%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D17092012%26date%3D28012013%26date%3D14022013%26date%3D09012013%26volume%3D56%26issue%3D3%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bryan K.  Chan</span>, <span class="hlFld-ContribAuthor ">Anthony A.  Estrada</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>, <span class="hlFld-ContribAuthor ">John  Atherall</span>, <span class="hlFld-ContribAuthor ">Charles  Baker-Glenn</span>, <span class="hlFld-ContribAuthor ">Alan  Beresford</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Burdick</span>, <span class="hlFld-ContribAuthor ">Mark  Chambers</span>, <span class="hlFld-ContribAuthor ">Sara L.  Dominguez</span>, <span class="hlFld-ContribAuthor ">Jason  Drummond</span>, <span class="hlFld-ContribAuthor ">Andrew  Gill</span>, <span class="hlFld-ContribAuthor ">Tracy  Kleinheinz</span>, <span class="hlFld-ContribAuthor ">Claire E.  Le Pichon</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Medhurst</span>, <span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">John G.  Moffat</span>, <span class="hlFld-ContribAuthor ">Kevin  Nash</span>, <span class="hlFld-ContribAuthor ">Kimberly  Scearce-Levie</span>, <span class="hlFld-ContribAuthor ">Zejuan  Sheng</span>, <span class="hlFld-ContribAuthor ">Daniel G.  Shore</span>, <span class="hlFld-ContribAuthor ">Hervé  Van de Poël</span>, <span class="hlFld-ContribAuthor ">Shuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Haitao  Zhu</span>, and <span class="hlFld-ContribAuthor ">Zachary K.  Sweeney</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (1)
                                     , 85-90. <a href="https://doi.org/10.1021/ml3003007" title="DOI URL">https://doi.org/10.1021/ml3003007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml3003007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml3003007%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BHighly%252BSelective%25252C%252BBrain-Penetrant%252BAminopyrazole%252BLRRK2%252BInhibitor%26aulast%3DChan%26aufirst%3DBryan%2BK.%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D24092012%26date%3D23112012%26date%3D29112012%26date%3D10012013%26date%3D23112012%26volume%3D4%26issue%3D1%26spage%3D85%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Li-Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Jing-Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Ren-Lin  Zheng</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Pan  Ji</span>, <span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen-Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Xing-Dong  Lin</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (23)
                                     , 10685-10699. <a href="https://doi.org/10.1021/jm301365e" title="DOI URL">https://doi.org/10.1021/jm301365e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301365e%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BOptimization%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BN2-%2525284-%2525284-Methylpiperazin-1-yl%252529phenyl%252529-N8-phenyl-9H-purine-2%25252C8-diamine%252BDerivatives%25252C%252Ba%252BNew%252BClass%252Bof%252BReversible%252BKinase%252BInhibitors%252BTargeting%252Bboth%252BEGFR-Activating%252Band%252BResistance%252BMutations%26aulast%3DYang%26aufirst%3DJiao%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D21092012%26date%3D16112012%26date%3D13122012%26date%3D01112012%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Mengjie  Shen</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Pan</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Donghai  Wen</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Leng</span>, <span class="hlFld-ContribAuthor ">Yingjun  Li</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine315→Isoleucine315 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (22)
                                     , 10033-10046. <a href="https://doi.org/10.1021/jm301188x" title="DOI URL">https://doi.org/10.1021/jm301188x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301188x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301188x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B3-%2525281H-1%25252C2%25252C3-Triazol-1-yl%252529benzamide%252BDerivatives%252Bas%252BPotent%252BPan%252BBcr-Abl%252BInhibitors%252BIncluding%252Bthe%252BThreonine315%2525E2%252586%252592Isoleucine315%252BMutant%26aulast%3DLi%26aufirst%3DYupeng%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D12082012%26date%3D01112012%26date%3D26112012%26date%3D22102012%26volume%3D55%26issue%3D22%26spage%3D10033%26epage%3D10046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Velma Ganga  Reddy</span>, <span class="hlFld-ContribAuthor ">Sonal  Bhandari</span>, <span class="hlFld-ContribAuthor ">T. Srinivasa  Reddy</span>, <span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Akash P.  Sakla</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Bhargava</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112457. <a href="https://doi.org/10.1016/j.ejmech.2020.112457" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112457%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploration%252Bof%252Bcarbamide%252Bderived%252Bpyrimidine-thioindole%252Bconjugates%252Bas%252Bpotential%252BVEGFR-2%252Binhibitors%252Bwith%252Banti-angiogenesis%252Beffect%26aulast%3DSana%26aufirst%3DSravani%26date%3D2020%26volume%3D200%26spage%3D112457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long  Mao</span>, <span class="hlFld-ContribAuthor ">Wei  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Zhang</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Yile  Chen</span>, <span class="hlFld-ContribAuthor ">Yuning  Hua</span>, <span class="hlFld-ContribAuthor ">Bojie  Weng</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Mo</span>, <span class="hlFld-ContribAuthor ">Yimei  Bao</span>, <span class="hlFld-ContribAuthor ">Li  Teng</span>, <span class="hlFld-ContribAuthor ">Lijun  Xu</span>, <span class="hlFld-ContribAuthor ">Yuren  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Wu</span>, <span class="hlFld-ContribAuthor ">Guanglin  Zhou</span>, <span class="hlFld-ContribAuthor ">Bin  Liang</span>, <span class="hlFld-ContribAuthor ">Changxu  Xu</span>, <span class="hlFld-ContribAuthor ">Biao  Xi</span>, <span class="hlFld-ContribAuthor ">Li  Zhao</span>, <span class="hlFld-ContribAuthor ">Rongda  Xu</span>, <span class="hlFld-ContribAuthor ">Che  Fang</span>, <span class="hlFld-ContribAuthor ">Wanhong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2020,</strong> <em>6 </em>, 100035. <a href="https://doi.org/10.1016/j.medidd.2020.100035" title="DOI URL">https://doi.org/10.1016/j.medidd.2020.100035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2020.100035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2020.100035%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%25252C%252BSelective%252Band%252BIrreversible%252BInhibitor%252B%252528Abivertinib%252529%252Bof%252BMutated%252BEGFR%252Band%252BT790M-induced%252BResistance%252Bfor%252Bthe%252BTreatment%252Bof%252BNSCLC%26aulast%3DMao%26aufirst%3DLong%26date%3D2020%26volume%3D6%26spage%3D100035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kunshan  Huang</span>, <span class="hlFld-ContribAuthor ">Beibei  Huo</span>, <span class="hlFld-ContribAuthor ">Dongyao  Li</span>, <span class="hlFld-ContribAuthor ">Jinping  Xue</span>, <span class="hlFld-ContribAuthor ">Juanjuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Enhanced Efficacy of Gefitinib in Drug‐Sensitive and Drug‐Resistant Cancer Cell Lines after Arming with a Singlet Oxygen Releasing Moiety. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (9)
                                     , 794-798. <a href="https://doi.org/10.1002/cmdc.202000036" title="DOI URL">https://doi.org/10.1002/cmdc.202000036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000036%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DEnhanced%252BEfficacy%252Bof%252BGefitinib%252Bin%252BDrug%2525E2%252580%252590Sensitive%252Band%252BDrug%2525E2%252580%252590Resistant%252BCancer%252BCell%252BLines%252Bafter%252BArming%252Bwith%252Ba%252BSinglet%252BOxygen%252BReleasing%252BMoiety%26aulast%3DHuang%26aufirst%3DKunshan%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D794%26epage%3D798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Liu</span>, <span class="hlFld-ContribAuthor ">Xu  Zheng</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (2)
                                     , 182-187. <a href="https://doi.org/10.1002/cmdc.201900606" title="DOI URL">https://doi.org/10.1002/cmdc.201900606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900606%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNovel%252BPyrimidines%252Bas%252BMultitarget%252BProtein%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%252B%252528IPF%252529%26aulast%3DSun%26aufirst%3DBo%26date%3D2020%26date%3D2019%26volume%3D15%26issue%3D2%26spage%3D182%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pedro  de Sena M. Pinheiro</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Rodolfo  do Couto Maia</span>, <span class="hlFld-ContribAuthor ">Sreekanth  Thota</span>, <span class="hlFld-ContribAuthor ">Carlos A.M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of Conformational Restriction in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (19)
                                     , 1712-1733. <a href="https://doi.org/10.2174/1568026619666190712205025" title="DOI URL">https://doi.org/10.2174/1568026619666190712205025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190712205025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190712205025%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DThe%252BUse%252Bof%252BConformational%252BRestriction%252Bin%252BMedicinal%252BChemistry%26aulast%3Dde%2BSena%2BM.%2BPinheiro%26aufirst%3DPedro%26date%3D2019%26volume%3D19%26issue%3D19%26spage%3D1712%26epage%3D1733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuiping  Guo</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Chengqian  Zhang</span>, <span class="hlFld-ContribAuthor ">Piliang  Hao</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (6)
                                     , 834-837. <a href="https://doi.org/10.1039/C8CC08685K" title="DOI URL">https://doi.org/10.1039/C8CC08685K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CC08685K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CC08685K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DMinimalist%252Blinkers%252Bsuitable%252Bfor%252Birreversible%252Binhibitors%252Bin%252Bsimultaneous%252Bproteome%252Bprofiling%25252C%252Blive-cell%252Bimaging%252Band%252Bdrug%252Bscreening%26aulast%3DGuo%26aufirst%3DCuiping%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D6%26spage%3D834%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Yi</span>, <span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Zhao</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2018,</strong> <em>92 </em>
                                    (6)
                                     , 1988-1997. <a href="https://doi.org/10.1111/cbdd.13370" title="DOI URL">https://doi.org/10.1111/cbdd.13370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13370%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DStructural%252Boptimization%252Bof%252Bdiphenylpyrimidine%252Bscaffold%252Bas%252Bpotent%252Band%252Bselective%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Bagainst%252BL858R%25252FT790M%252Bresistance%252Bmutation%252Bin%252Bnonsmall%252Bcell%252Blung%252Bcancer%26aulast%3DYi%26aufirst%3DYuanyuan%26date%3D2018%26date%3D2018%26volume%3D92%26issue%3D6%26spage%3D1988%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun  Patel</span>, <span class="hlFld-ContribAuthor ">Azim  Ansari</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Iqrar  Ansari</span>, <span class="hlFld-ContribAuthor ">Harsha  Jadhav</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5-6)
                                     , 393-412. <a href="https://doi.org/10.1080/10799893.2018.1557207" title="DOI URL">https://doi.org/10.1080/10799893.2018.1557207</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2018.1557207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2018.1557207%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252B2%25252C4-disubstituted%252Baminopyrimidines%25253A%252Breversible%252Bnon-covalent%252BT790M%252BEGFR%252Binhibitors%26aulast%3DPatel%26aufirst%3DHarun%26date%3D2018%26date%3D2019%26volume%3D38%26issue%3D5-6%26spage%3D393%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Hu</span>, <span class="hlFld-ContribAuthor ">Huijuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Mengru  Cao</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shuhong  Wu</span>, <span class="hlFld-ContribAuthor ">Bingliang  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (10)
                                     , 2156-2163. <a href="https://doi.org/10.1158/1535-7163.MCT-17-1173" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-1173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-1173%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DAuranofin%252BEnhances%252BIbrutinib%252527s%252BAnticancer%252BActivity%252Bin%252BEGFR-Mutant%252BLung%252BAdenocarcinoma%26aulast%3DHu%26aufirst%3DJing%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D2156%26epage%3D2163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Zou</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Hongcheng  Wei</span>, <span class="hlFld-ContribAuthor ">Liyan  Song</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
              L858R, T790M
              -mutant resistance in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2018,</strong> <em>7 </em>
                                    (4)
                                     , 1430-1439. <a href="https://doi.org/10.1002/cam4.1392" title="DOI URL">https://doi.org/10.1002/cam4.1392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.1392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.1392%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DYL143%25252C%252Ba%252Bnovel%252Bmutant%252Bselective%252Birreversible%252BEGFR%252Binhibitor%25252C%252Bovercomes%252BEGFR%252BL858R%25252C%252BT790M%252B-mutant%252Bresistance%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DZhang%26aufirst%3DZhang%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D4%26spage%3D1430%26epage%3D1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dexiang  Guo</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 244-253. <a href="https://doi.org/10.1039/C7MD00571G" title="DOI URL">https://doi.org/10.1039/C7MD00571G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00571G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DAllenamide%252Bas%252Ba%252Bbioisostere%252Bof%252Bacrylamide%252Bin%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252Btargeted%252Bcovalent%252Binhibitors%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Weitao  Fu</span>, <span class="hlFld-ContribAuthor ">Chen  Feng</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lulu  Zheng</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Yinda  Qiu</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 510-527. <a href="https://doi.org/10.1016/j.ejmech.2017.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B2%25252C4-diaminopyrimidines%252Bas%252BEGFR%252BL858R%25252FT790M%252Bselective%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2017%26volume%3D140%26spage%3D510%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Han</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2017,</strong> <em>14 </em>
                                    (7)
                                     , e1600372. <a href="https://doi.org/10.1002/cbdv.201600372" title="DOI URL">https://doi.org/10.1002/cbdv.201600372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201600372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DRecent%252BDevelopment%252Bof%252Bthe%252BSecond%252Band%252BThird%252BGeneration%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%26aulast%3DHan%26aufirst%3DWeiwei%26date%3D2017%26date%3D2017%26volume%3D14%26issue%3D7%26spage%3De1600372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Yan-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Sai-Sai  Han</span>, <span class="hlFld-ContribAuthor ">Chun-Mei  Gao</span>, <span class="hlFld-ContribAuthor ">Chun-Yan  Tan</span>, <span class="hlFld-ContribAuthor ">Yu-Yang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2017,</strong> <em>28 </em>
                                    (6)
                                     , 1220-1227. <a href="https://doi.org/10.1016/j.cclet.2017.01.003" title="DOI URL">https://doi.org/10.1016/j.cclet.2017.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2017.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2017.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DDiscovery%252Bof%252BErbB%25252FHDAC%252Binhibitors%252Bby%252Bcombining%252Bthe%252Bcore%252Bpharmacophores%252Bof%252BHDAC%252Binhibitor%252Bvorinostat%252Band%252Bkinase%252Binhibitors%252Bvandetanib%25252C%252BBMS-690514%25252C%252Bneratinib%25252C%252Band%252BTAK-285%26aulast%3DDing%26aufirst%3DChao%26date%3D2017%26volume%3D28%26issue%3D6%26spage%3D1220%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Haiqing  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Jiang</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Hunjun  Sun</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>133 </em>, 329-339. <a href="https://doi.org/10.1016/j.ejmech.2017.03.083" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.083%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bmorpholine-substituted%252Bdiphenylpyrimidine%252Bderivatives%252B%252528Mor-DPPYs%252529%252Bas%252Bpotent%252BEGFR%252BT790M%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Btoward%252Bthe%252Bgefitinib-resistant%252Bnon-small%252Bcell%252Blung%252Bcancers%252B%252528NSCLC%252529%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2017%26volume%3D133%26spage%3D329%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Azim  Ansari</span>, <span class="hlFld-ContribAuthor ">Malleshappa  Noolvi</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (10)
                                     , 2713-2723. <a href="https://doi.org/10.1016/j.bmc.2017.03.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.03.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.03.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bquinazolinones%252Bas%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Bresistance%252Bobstacle%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2017%26volume%3D25%26issue%3D10%26spage%3D2713%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Xiao-e  Yan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Caihong  Yun</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 1107-1117. <a href="https://doi.org/10.1016/j.ejmech.2016.12.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bstructure-guided%252Boptimization%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidin-7-ones%252Bas%252Bselective%252Binhibitors%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%26aulast%3DYu%26aufirst%3DLei%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianfei  Sheng</span>, <span class="hlFld-ContribAuthor ">Zhihong  Liu</span>, <span class="hlFld-ContribAuthor ">Ming  Yan</span>, <span class="hlFld-ContribAuthor ">Xuejing  Zhang</span>, <span class="hlFld-ContribAuthor ">Dejian  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>, <span class="hlFld-ContribAuthor ">Ensheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (23)
                                     , 4971-4977. <a href="https://doi.org/10.1039/C7OB00793K" title="DOI URL">https://doi.org/10.1039/C7OB00793K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00793K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00793K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DBiomass-involved%252Bsynthesis%252Bof%252BN-substituted%252Bbenzofuro%25255B2%25252C3-d%25255Dpyrimidine-4-amines%252Band%252Bbiological%252Bevaluation%252Bas%252Bnovel%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSheng%26aufirst%3DJianfei%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D23%26spage%3D4971%26epage%3D4977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sang Min  Lim</span>, <span class="hlFld-ContribAuthor ">Yujeong  Jeong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (8)
                                     , 853-878. <a href="https://doi.org/10.4155/fmc-2016-0019" title="DOI URL">https://doi.org/10.4155/fmc-2016-0019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0019%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DStrategies%252Bto%252Bovercome%252Bacquired%252Bresistances%252Bconferred%252Bby%252Bmutations%252Bin%252Bthe%252Bkinase%252Bdomain%252Bof%252BEGFR%26aulast%3DLim%26aufirst%3DSang%2BMin%26date%3D2016%26volume%3D8%26issue%3D8%26spage%3D853%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changyan  Wang</span>, <span class="hlFld-ContribAuthor ">Yajun  Sun</span>, <span class="hlFld-ContribAuthor ">Xingqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Bin  Wu</span>, <span class="hlFld-ContribAuthor ">Qiao  Wang</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhen</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Quinazoline Derivatives Bearing Various 4-Aniline Moieties as Potent EGFR Inhibitors with Enhanced Activity Against NSCLC Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (4)
                                     , 635-643. <a href="https://doi.org/10.1111/cbdd.12692" title="DOI URL">https://doi.org/10.1111/cbdd.12692</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12692%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DNovel%252BQuinazoline%252BDerivatives%252BBearing%252BVarious%252B4-Aniline%252BMoieties%252Bas%252BPotent%252BEGFR%252BInhibitors%252Bwith%252BEnhanced%252BActivity%252BAgainst%252BNSCLC%252BCell%252BLines%26aulast%3DWang%26aufirst%3DChangyan%26date%3D2016%26date%3D2015%26volume%3D87%26issue%3D4%26spage%3D635%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiqing  Yu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Xu  Han</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhen</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>110 </em>, 195-203. <a href="https://doi.org/10.1016/j.ejmech.2016.01.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.01.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.01.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B4-anilinoquinazoline%252Bderivatives%252Bfeaturing%252Ban%252B1-adamantyl%252Bmoiety%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bwith%252Benhanced%252Bactivity%252Bagainst%252BNSCLC%252Bcell%252Blines%26aulast%3DYu%26aufirst%3DHaiqing%26date%3D2016%26volume%3D110%26spage%3D195%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Guang  Wang</span>, <span class="hlFld-ContribAuthor ">Jin  Yang</span>, <span class="hlFld-ContribAuthor ">Hai-Yan  Wu</span>, <span class="hlFld-ContribAuthor ">Ling-Mei  Kong</span>, <span class="hlFld-ContribAuthor ">Jia  Su</span>, <span class="hlFld-ContribAuthor ">Xiao-Nian  Li</span>, <span class="hlFld-ContribAuthor ">Xue  Du</span>, <span class="hlFld-ContribAuthor ">Rui  Zhan</span>, <span class="hlFld-ContribAuthor ">Min  Zhou</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Jian-Xin  Pu</span>, <span class="hlFld-ContribAuthor ">Han-Dong  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">ent-Kauranoids isolated from Isodon eriocalyx var. laxiflora and their structure activity relationship analyses. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2015,</strong> <em>71 </em>
                                    (48)
                                     , 9161-9171. <a href="https://doi.org/10.1016/j.tet.2015.09.066" title="DOI URL">https://doi.org/10.1016/j.tet.2015.09.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2015.09.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2015.09.066%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3Dent-Kauranoids%252Bisolated%252Bfrom%252BIsodon%252Beriocalyx%252Bvar.%252Blaxiflora%252Band%252Btheir%252Bstructure%252Bactivity%252Brelationship%252Banalyses%26aulast%3DWang%26aufirst%3DWei-Guang%26date%3D2015%26volume%3D71%26issue%3D48%26spage%3D9161%26epage%3D9171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>, <span class="hlFld-ContribAuthor ">Justin  Bailey</span>, <span class="hlFld-ContribAuthor ">Sheldon  Berke</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2015,</strong> <em>20 </em>
                                    (12)
                                     , 22000-22027. <a href="https://doi.org/10.3390/molecules201219816" title="DOI URL">https://doi.org/10.3390/molecules201219816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules201219816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules201219816%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Band%252BApplication%252Bof%252BRadiolabeled%252BKinase%252BInhibitors%252Bfor%252BPET%252BImaging%26aulast%3DBernard-Gauthier%26aufirst%3DVadim%26date%3D2015%26date%3D2015%26volume%3D20%26issue%3D12%26spage%3D22000%26epage%3D22027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su Xin  Xu</span>, <span class="hlFld-ContribAuthor ">Jian Gang  Chen</span>, <span class="hlFld-ContribAuthor ">Lu Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Bi Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Yi Qi  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Sorption Thermodynamic and Kinetic Study of Polylactic Acid Fibers with Disperse Dyes in Non-Aqueous Medium. </span><span class="cited-content_cbyCitation_journal-name">Key Engineering Materials</span><span> <strong>2015,</strong> <em>671 </em>, 121-132. <a href="https://doi.org/10.4028/www.scientific.net/KEM.671.121" title="DOI URL">https://doi.org/10.4028/www.scientific.net/KEM.671.121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4028/www.scientific.net/KEM.671.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4028%2Fwww.scientific.net%2FKEM.671.121%26sid%3Dliteratum%253Aachs%26jtitle%3DKey%2520Engineering%2520Materials%26atitle%3DSorption%252BThermodynamic%252Band%252BKinetic%252BStudy%252Bof%252BPolylactic%252BAcid%252BFibers%252Bwith%252BDisperse%252BDyes%252Bin%252BNon-Aqueous%252BMedium%26aulast%3DXu%26aufirst%3DSu%2BXin%26date%3D2015%26date%3D2015%26volume%3D671%26spage%3D121%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiyan  Cheng</span>, <span class="hlFld-ContribAuthor ">Shijun  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Ni  Qiu</span>, <span class="hlFld-ContribAuthor ">Peng  Peng</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 826-834. <a href="https://doi.org/10.1016/j.ejmech.2014.11.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.11.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.11.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B6-%252528nitroimidazole-1H-alkyloxyl%252529-4-anilinoquinazolines%252Bas%252Befficient%252BEGFR%252Binhibitors%252Bexerting%252Bcytotoxic%252Beffects%252Bboth%252Bunder%252Bnormoxia%252Band%252Bhypoxia%26aulast%3DCheng%26aufirst%3DWeiyan%26date%3D2015%26volume%3D89%26spage%3D826%26epage%3D834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Zhaoru  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR
              T790M
              mutant. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 1693-1697. <a href="https://doi.org/10.1039/C5MD00208G" title="DOI URL">https://doi.org/10.1039/C5MD00208G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5MD00208G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5MD00208G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DC5-substituted%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidin-7-ones%252Bas%252Bhighly%252Bspecific%252Bkinase%252Binhibitors%252Btargeting%252Bthe%252Bclinical%252Bresistance-related%252BEGFR%252BT790M%252Bmutant%26aulast%3DXu%26aufirst%3DTianfeng%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D1693%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiyan  Cheng</span>, <span class="hlFld-ContribAuthor ">Youting  Yuan</span>, <span class="hlFld-ContribAuthor ">Ni  Qiu</span>, <span class="hlFld-ContribAuthor ">Peng  Peng</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (24)
                                     , 6796-6805. <a href="https://doi.org/10.1016/j.bmc.2014.10.038" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.10.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.10.038%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnovel%252B4-anilinoquinazoline%252Bderivatives%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bboth%252Bunder%252Bnormoxia%252Band%252Bhypoxia%26aulast%3DCheng%26aufirst%3DWeiyan%26date%3D2014%26volume%3D22%26issue%3D24%26spage%3D6796%26epage%3D6805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Junko  Tanizaki</span>, <span class="hlFld-ContribAuthor ">Zhifeng  Huang</span>, <span class="hlFld-ContribAuthor ">Amir R.  Aref</span>, <span class="hlFld-ContribAuthor ">Maria  Rusan</span>, <span class="hlFld-ContribAuthor ">Su-Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Yiyun  Zhang</span>, <span class="hlFld-ContribAuthor ">Dalia  Ercan</span>, <span class="hlFld-ContribAuthor ">Rachel G.  Liao</span>, <span class="hlFld-ContribAuthor ">Marzia  Capelletti</span>, <span class="hlFld-ContribAuthor ">Wenjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Wooyoung  Hur</span>, <span class="hlFld-ContribAuthor ">NamDoo  Kim</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Suzanne  Gaudet</span>, <span class="hlFld-ContribAuthor ">David A.  Barbie</span>, <span class="hlFld-ContribAuthor ">Jing-Ruey Joanna  Yeh</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Peter S.  Hammerman</span>, <span class="hlFld-ContribAuthor ">Moosa  Mohammadi</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2014,</strong> <em>111 </em>
                                    (45)
                                     , E4869-E4877. <a href="https://doi.org/10.1073/pnas.1403438111" title="DOI URL">https://doi.org/10.1073/pnas.1403438111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DDevelopment%252Bof%252Bcovalent%252Binhibitors%252Bthat%252Bcan%252Bovercome%252Bresistance%252Bto%252Bfirst-generation%252BFGFR%252Bkinase%252Binhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2014%26date%3D2014%26volume%3D111%26issue%3D45%26spage%3DE4869%26epage%3DE4877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen  Gao</span>, <span class="hlFld-ContribAuthor ">Michael  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Haibo  Lu</span>, <span class="hlFld-ContribAuthor ">Shuhong  Wu</span>, <span class="hlFld-ContribAuthor ">Bingbing  Dai</span>, <span class="hlFld-ContribAuthor ">Zhishuo  Ou</span>, <span class="hlFld-ContribAuthor ">Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">John V.  Heymach</span>, <span class="hlFld-ContribAuthor ">Kathryn A.  Gold</span>, <span class="hlFld-ContribAuthor ">John  Minna</span>, <span class="hlFld-ContribAuthor ">Jack A.  Roth</span>, <span class="hlFld-ContribAuthor ">Wayne L.  Hofstetter</span>, <span class="hlFld-ContribAuthor ">Stephen G.  Swisher</span>, <span class="hlFld-ContribAuthor ">Bingliang  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">JNCI: Journal of the National Cancer Institute</span><span> <strong>2014,</strong> <em>106 </em>
                                    (9)
                                     <a href="https://doi.org/10.1093/jnci/dju204" title="DOI URL">https://doi.org/10.1093/jnci/dju204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jnci/dju204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjnci%2Fdju204%26sid%3Dliteratum%253Aachs%26jtitle%3DJNCI%253A%2520Journal%2520of%2520the%2520National%2520Cancer%2520Institute%26atitle%3DSelective%252BAntitumor%252BActivity%252Bof%252BIbrutinib%252Bin%252BEGFR-Mutant%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%252BCells%26aulast%3DGao%26aufirst%3DWen%26date%3D2014%26date%3D2014%26volume%3D106%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Ledong  Wan</span>, <span class="hlFld-ContribAuthor ">Hongbin  Ji</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Yisheng  Lai</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>77 </em>, 75-83. <a href="https://doi.org/10.1016/j.ejmech.2014.02.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.02.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.02.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B2-anilinopyrimidines%252Bbearing%252B3-aminopropamides%252Bas%252Bpotential%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%26aulast%3DHan%26aufirst%3DChun%26date%3D2014%26volume%3D77%26spage%3D75%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Mah</span>, <span class="hlFld-ContribAuthor ">Jason R.  Thomas</span>, <span class="hlFld-ContribAuthor ">Cynthia M.  Shafer</span>. </span><span class="cited-content_cbyCitation_article-title">Drug discovery considerations in the development of covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (1)
                                     , 33-39. <a href="https://doi.org/10.1016/j.bmcl.2013.10.003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDrug%252Bdiscovery%252Bconsiderations%252Bin%252Bthe%252Bdevelopment%252Bof%252Bcovalent%252Binhibitors%26aulast%3DMah%26aufirst%3DRobert%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D33%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Chao-Yie  Yang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Fang  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Li</span>, <span class="hlFld-ContribAuthor ">Duanqing  Pei</span>, <span class="hlFld-ContribAuthor ">Qian  Cai</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Shaomeng  Wang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimido[4,5-
              d
              ]pyrimidin-4(1
              H
              )-one Derivatives as Selective Inhibitors of EGFR Threonine
              790
              to Methionine
              790
              (T790M) Mutants. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2013,</strong> <em>125 </em>
                                    (32)
                                     , 8545-8548. <a href="https://doi.org/10.1002/ange.201302313" title="DOI URL">https://doi.org/10.1002/ange.201302313</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201302313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201302313%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DPyrimido%25255B4%25252C5-%252Bd%252B%25255Dpyrimidin-4%2525281%252BH%252B%252529-one%252BDerivatives%252Bas%252BSelective%252BInhibitors%252Bof%252BEGFR%252BThreonine%252B790%252Bto%252BMethionine%252B790%252B%252528T790M%252529%252BMutants%26aulast%3DXu%26aufirst%3DTianfeng%26date%3D2013%26date%3D2013%26volume%3D125%26issue%3D32%26spage%3D8545%26epage%3D8548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Chao-Yie  Yang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Fang  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Li</span>, <span class="hlFld-ContribAuthor ">Duanqing  Pei</span>, <span class="hlFld-ContribAuthor ">Qian  Cai</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Shaomeng  Wang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimido[4,5-
              d
              ]pyrimidin-4(1
              H
              )-one Derivatives as Selective Inhibitors of EGFR Threonine
              790
              to Methionine
              790
              (T790M) Mutants. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2013,</strong> <em>52 </em>
                                    (32)
                                     , 8387-8390. <a href="https://doi.org/10.1002/anie.201302313" title="DOI URL">https://doi.org/10.1002/anie.201302313</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201302313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201302313%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DPyrimido%25255B4%25252C5-%252Bd%252B%25255Dpyrimidin-4%2525281%252BH%252B%252529-one%252BDerivatives%252Bas%252BSelective%252BInhibitors%252Bof%252BEGFR%252BThreonine%252B790%252Bto%252BMethionine%252B790%252B%252528T790M%252529%252BMutants%26aulast%3DXu%26aufirst%3DTianfeng%26date%3D2013%26date%3D2013%26volume%3D52%26issue%3D32%26spage%3D8387%26epage%3D8390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Chao  Zheng</span>, <span class="hlFld-ContribAuthor ">Ledong  Wan</span>, <span class="hlFld-ContribAuthor ">Yisheng  Lai</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Hongbin  Ji</span>, <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>66 </em>, 82-90. <a href="https://doi.org/10.1016/j.ejmech.2013.05.026" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.05.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.05.026%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNitric%252Boxide%252Bdonating%252Banilinopyrimidines%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%252Bas%252BEGFR%252Binhibitors%26aulast%3DHan%26aufirst%3DChun%26date%3D2013%26volume%3D66%26spage%3D82%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuchang  Ouyang</span>, <span class="hlFld-ContribAuthor ">Shuo  Zhou</span>, <span class="hlFld-ContribAuthor ">Chinh Tran To  Su</span>, <span class="hlFld-ContribAuthor ">Zemei  Ge</span>, <span class="hlFld-ContribAuthor ">Runtao  Li</span>, <span class="hlFld-ContribAuthor ">Chee Keong  Kwoh</span>. </span><span class="cited-content_cbyCitation_article-title">CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Chemistry</span><span> <strong>2013,</strong> <em>34 </em>
                                    (4)
                                     , 326-336. <a href="https://doi.org/10.1002/jcc.23136" title="DOI URL">https://doi.org/10.1002/jcc.23136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcc.23136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcc.23136%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Chemistry%26atitle%3DCovalentDock%25253A%252BAutomated%252Bcovalent%252Bdocking%252Bwith%252Bparameterized%252Bcovalent%252Blinkage%252Benergy%252Bestimation%252Band%252Bmolecular%252Bgeometry%252Bconstraints%26aulast%3DOuyang%26aufirst%3DXuchang%26date%3D2013%26date%3D2012%26volume%3D34%26issue%3D4%26spage%3D326%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Galvani</span>, <span class="hlFld-ContribAuthor ">Elisa  Giovannetti</span>, <span class="hlFld-ContribAuthor ">Francesca  Saccani</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Leticia G.  Leon</span>, <span class="hlFld-ContribAuthor ">Henk  Dekker</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>, <span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Godefridus J.  Peters</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2013,</strong> <em>15 </em>
                                    (1)
                                     , 61-IN18. <a href="https://doi.org/10.1593/neo.121434" title="DOI URL">https://doi.org/10.1593/neo.121434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1593/neo.121434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1593%2Fneo.121434%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DMolecular%252BMechanisms%252BUnderlying%252Bthe%252BAntitumor%252BActivity%252Bof%252B3-Aminopropanamide%252BIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DGalvani%26aufirst%3DElena%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D61%26epage%3DIN18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2012,</strong> <em>84 </em>
                                    (11)
                                     , 1388-1399. <a href="https://doi.org/10.1016/j.bcp.2012.07.031" title="DOI URL">https://doi.org/10.1016/j.bcp.2012.07.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2012.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2012.07.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DClinical%252Bperspectives%252Bfor%252Birreversible%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Bcancer%26aulast%3DCarmi%26aufirst%3DCaterina%26date%3D2012%26volume%3D84%26issue%3D11%26spage%3D1388%26epage%3D1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saulo L.  Capim</span>, <span class="hlFld-ContribAuthor ">Paulo H.P.  Carneiro</span>, <span class="hlFld-ContribAuthor ">Paloma C.  Castro</span>, <span class="hlFld-ContribAuthor ">Maithê R.M.  Barros</span>, <span class="hlFld-ContribAuthor ">Bruno G.  Marinho</span>, <span class="hlFld-ContribAuthor ">Mário L.A.A.  Vasconcellos</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Prins-cyclization reaction promoting diastereoselective synthesis of 10 new tetrahydropyran derivatives and in vivo antinociceptive evaluations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>58 </em>, 1-11. <a href="https://doi.org/10.1016/j.ejmech.2012.09.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2012.09.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2012.09.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2012.09.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BPrins-cyclization%252Breaction%252Bpromoting%252Bdiastereoselective%252Bsynthesis%252Bof%252B10%252Bnew%252Btetrahydropyran%252Bderivatives%252Band%252Bin%2525C2%2525A0vivo%252Bantinociceptive%252Bevaluations%26aulast%3DCapim%26aufirst%3DSaulo%2BL.%26date%3D2012%26volume%3D58%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaohua  Chang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhang  zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2012,</strong> <em>3 </em>
                                    (9)
                                     , 1155. <a href="https://doi.org/10.1039/c2md20078c" title="DOI URL">https://doi.org/10.1039/c2md20078c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2md20078c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2md20078c%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Bmolecules%252Binhibiting%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bthreonine790%2525E2%252586%252592%252Bmethionine790%252Bmutant%26aulast%3DXu%26aufirst%3DShilin%26date%3D2012%26volume%3D3%26issue%3D9%26spage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of conformation-constrained derivatives of <b>1</b> as new EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Conformation-Constrained Compounds <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last">Reagent and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), dimethylformamide (DMF), 60 °C, overnight, 97%; (b) lithium aluminum hydride (LAH, 2.0 equiv), THF, −40 °C to r.t., 57%; (c) MnO<sub>2</sub>, dichloromethane, r.t., overnight, 85%; (d) R<sup>2</sup>NH<sub>2</sub>, AcOH, NaBH<sub>4</sub>, MeOH, 0 °C to r.t., overnight; (e) triphosgene (0.34 equiv), Et<sub>3</sub>N (4.0 equiv), 0 °C to r.t., 2.0 h; (f) 3-chloroperbenzoic acid (<i>m</i>-CPBA, 3.0 equiv), dichloromethane, r.t., 3.0 h; (g) R<sup>1</sup>NH<sub>2</sub> (1.0 equiv), trifluoroacetic acid (1.0 equiv), 2-BuOH, 110 °C, sealed tube, 18.0 h, 30–60%; (h) trifluoroacetic acide, dichloromethane, r.t.; (i) acryloyl chloride (1.0 equiv), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 1.0 equiv), 0 °C to r.t.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. KINOMEsacn tree spot maps illustrating the selectivity profiles for compounds <b>2q</b> and <b>2s</b> versus a panel of 451 kinase targets (including 392 wild-type kinases). The size of the red circle is proportional to the percent of DMSO control, where 0% and 35% of control equals 100% and 65% competition, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>2a</b>, <b>2q</b>, and <b>2s</b> inhibit the activation of EGFR and downstream signaling in a dose-dependent manner. (A) Compounds <b>2a</b>, <b>2q</b>, <b>2s</b>, and <b>1</b> inhibit the activation of EGFR and downstream signaling in H1975 NSCLC cells harboring EGFR<sup>L858R/T790M</sup>, while gefitinib has no effects. (B) Compounds <b>2a</b>, <b>2q</b>, <b>2s</b>, <b>1</b>, and gefitinib inhibit the activation of EGFR and downstream signaling in HCC827 NSCLC cells harboring EGFR<sup>del E746-A750</sup>. The results are representative of experiments in triplicate. Gfb: gefitinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/medium/jm-2011-01591k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo antitumor effect of compound <b>2s</b> in a human NSCLC (H1975) xenograft nude mouse model. The H1975 model was resistant to gefitinib. Mice were monitored for signs of morbidity (behavior and body loss), and tumors were measured every other day. Statistical significance (<i>p</i> < 0.05) for antitumor efficacy, based upon tumor growth relative to the vehicle controls. Two animals died at day 10 and 12 in the vehicle control group, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201591k&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0lhr84dZUTuEnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ciaardiello., F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=18337605" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciaardiello.author=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiaardiello.%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lhr84dZUTuEnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+erlotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0li6WbeE65_Bbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makhson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Braud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loos, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koralewski, P.</span><span> </span><span class="NLM_article-title">Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">671</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1200%2FJCO.2008.20.8397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=19114683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsVCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=663-671&author=C.+Bokemeyerauthor=I.+Bondarenkoauthor=A.+Makhsonauthor=J.+T.+Hartmannauthor=J.+Aparicioauthor=F.+de+Braudauthor=S.+Doneaauthor=H.+Ludwigauthor=G.+Schuchauthor=C.+Strohauthor=A.+H.+Loosauthor=A.+Zubelauthor=P.+Koralewski&title=Fluorouracil%2C+leucovorin%2C+and+oxaliplatin+with+and+without+cetuximab+in+the+first-line+treatment+of+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</span></div><div class="casAuthors">Bokemeyer, Carsten; Bondarenko, Igor; Makhson, Anatoly; Hartmann, Joerg T.; Aparicio, Jorge; de Braud, Filippo; Donea, Serban; Ludwig, Heinz; Schuch, Gunter; Stroh, Christopher; Loos, Anja H.; Zubel, Angela; Koralewski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-671</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer.  The influence of KRAS mutation status was investigated.  Patients received cetuximab (400 mg/m2 initial dose followed by 250 mg/m2/wk thereafter) plus FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, plus leucovorin 200 mg/m2 and fluorouracil as a 400 mg/m2 bolus followed by a 600 mg/m2 infusion during 22 h on days 1 and 2; n = 169) or FOLFOX-4 alone (n = 168).  Treatment was continued until disease progression or unacceptable toxicity.  KRAS mutation status was assessed in the subset of patients with assessable tumor samples (n = 233).  The confirmed ORR for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone (46% v 36%).  A statistically significant increase in the odds for a response with the addn. of cetuximab to FOLFOX-4 could not be established (odds ratio = 1.52; P = .064).  In patients with KRAS wild-type tumors, the addn. of cetuximab to FOLFOX-4 was assocd. with a clin. significant increased chance of response (ORR = 61% v 37%; odds ratio = 2.54; P = .011) and a lower risk of disease progression (hazard ratio = 0.57; P = .0163) compared with FOLFOX-4 alone.  Cetuximab plus FOLFOX-4 was generally well tolerated.  KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addn. of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRjIYcrL-IG7Vg90H21EOLACvtfcHk0li6WbeE65_Bbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsVCjsrk%253D&md5=d7ca7c68ee0a4c8e55e11a0fbfa0ada8</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.8397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.8397%26sid%3Dliteratum%253Aachs%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DMakhson%26aufirst%3DA.%26aulast%3DHartmann%26aufirst%3DJ.%2BT.%26aulast%3DAparicio%26aufirst%3DJ.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DDonea%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DH.%26aulast%3DSchuch%26aufirst%3DG.%26aulast%3DStroh%26aufirst%3DC.%26aulast%3DLoos%26aufirst%3DA.%2BH.%26aulast%3DZubel%26aufirst%3DA.%26aulast%3DKoralewski%26aufirst%3DP.%26atitle%3DFluorouracil%252C%2520leucovorin%252C%2520and%2520oxaliplatin%2520with%2520and%2520without%2520cetuximab%2520in%2520the%2520first-line%2520treatment%2520of%2520metastatic%2520colorectal%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D663%26epage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köhne, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaluski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makhson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Haens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintér, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodoky, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roh, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folprecht, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejpar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nippgen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rougier, P.</span><span> </span><span class="NLM_article-title">Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">360</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1056%2FNEJMoa0805019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=19339720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFGjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=1408-1417&author=E.+Van+Cutsemauthor=C.+H.+K%C3%B6hneauthor=E.+Hitreauthor=J.+Zaluskiauthor=C.+C.+R.+Changauthor=A.+Makhsonauthor=G.+D%E2%80%99Haensauthor=T.+Pint%C3%A9rauthor=R.+Limauthor=G.+Bodokyauthor=J.+K.+Rohauthor=G.+Folprechtauthor=P.+Ruffauthor=C.+Strohauthor=S.+Tejparauthor=M.+Schlichtingauthor=J.+Nippgenauthor=P.+Rougier&title=Cetuximab+and+chemotherapy+as+initial+treatment+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</span></div><div class="casAuthors">Van Cutsem, Eric; Kohne, Claus-Henning; Hitre, Erika; Zaluski, Jerzy; Chien, Chung-Rong Chang; Makhson, Anatoly; D'Haens, Geert; Pinter, Tamas; Lim, Robert; Bodoky, Gyorgy; Roh, Jae Kyung; Folprecht, Gunnar; Ruff, Paul; Stroh, Christopher; Tejpar, Sabine; Schlichting, Michael; Nippgen, Johannes; Rougier, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1408-1417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought assocns. between the mutation status of the KRAS gene in tumors and clin. response to cetuximab.  We randomly assigned patients with epidermal growth factor receptor-pos. colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.  The primary end point was progression-free survival.  A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone.  The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048).  There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31).  There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P = 0.44).  The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94); in favor of the cetuximab-FOLFIRI group.  The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P < 0.001), infusion-related reactions (in 2.5% vs. 0%, P < 0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008).  First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer.  The benefit of cetuximab was limited to patients with KRAS wild-type tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl8xKwg-xTfrVg90H21EOLACvtfcHk0lixNmIB04Ef2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFGjt7g%253D&md5=74bb78d1779d6b571930b10d632d273f</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0805019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0805019%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DK%25C3%25B6hne%26aufirst%3DC.%2BH.%26aulast%3DHitre%26aufirst%3DE.%26aulast%3DZaluski%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%2BR.%26aulast%3DMakhson%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DPint%25C3%25A9r%26aufirst%3DT.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DBodoky%26aufirst%3DG.%26aulast%3DRoh%26aufirst%3DJ.%2BK.%26aulast%3DFolprecht%26aufirst%3DG.%26aulast%3DRuff%26aufirst%3DP.%26aulast%3DStroh%26aufirst%3DC.%26aulast%3DTejpar%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DM.%26aulast%3DNippgen%26aufirst%3DJ.%26aulast%3DRougier%26aufirst%3DP.%26atitle%3DCetuximab%2520and%2520chemotherapy%2520as%2520initial%2520treatment%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D1408%26epage%3D1417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Giusti, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shastri, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA drug approval summary: panitumumab (Vectibix)</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=577-583&author=R.+M.+Giustiauthor=K.+A.+Shastriauthor=M.+H.+Cohenauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+panitumumab+%28Vectibix%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiusti%26aufirst%3DR.%2BM.%26aulast%3DShastri%26aufirst%3DK.%2BA.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520panitumumab%2520%2528Vectibix%2529%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D577%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pallis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briasoulis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitriiou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bafaloukos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, S.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1628</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.2174%2F092986711795471383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21428885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1613-1628&author=A.+Pallisauthor=E.+Briasoulisauthor=H.+Linardouauthor=C.+Papadimitriiouauthor=D.+Bafaloukosauthor=P.+Kosmidisauthor=S.+Murray&title=Mechanisms+of+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+patients+with+advanced+non-small-cell+lung+cancer%3A+clinical+and+molecular+considerations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations</span></div><div class="casAuthors">Pallis, A.; Briasoulis, E.; Linardou, H.; Papadimitriou, C.; Bafaloukos, D.; Kosmidis, P.; Murray, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1613-1628</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth factor receptor (EGFR) is anticipated to respond to small-mol. tyrosine kinase inhibitors (TKIs) of the EGFR tyrosine kinase.  There are, however, patients with EGFR mutated tumors who do not demonstrate tumor response.  The most widely accepted mechanism of "de novo" (inherent) resistance to these TKIs involves mutations of the KRAS gene.  KRAS is a downstream mediator of EGFR-induced cell signaling, such mutations appear to be mutually exclusive from EGFR mutations in lung cancer.  The first mol. modifier of resistance identified in patients who developed resistance (termed "acquired resistance") to TK inhibition was a new acquired somatic EGFR mutation (T790M).  Today there is an ever-growing series of mol. events that have recently come to the forefront to explain other instances of TKI resistance not attributable to T790M or KRAS.  These include a no. of mols. that interact with EGFR or form part of its downstream signaling pathway such as HER-2, IGFR-1, MET and B-RAF.  Considering that the majority of studies carried out to date with respect to the identification of resistant clones have not used highly sensitive techniques (e.g. allelic discrimination to identify somatic mutations), coupled with the relatively low no. of studies examg. multiple mol. markers and the accepted mol. heterogeneity of NSCLC raise question as to the existence of "acquired" vs. "de-novo" resistance.  By examg. the current knowledge base with respect to mechanisms of resistance to EGFR TKIs in NSCLC, we explore whether "acquired" resistance is "de-novo" resistance in disguise, and discuss the promises and limitations of mol. stratification with respect to strategies incorporating TKIs in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmcf_n5Pd9F7Vg90H21EOLACvtfcHk0lixNmIB04Ef2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOiurw%253D&md5=5583d328dd5182c2b14ea1f921ec1f64</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.2174%2F092986711795471383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795471383%26sid%3Dliteratum%253Aachs%26aulast%3DPallis%26aufirst%3DA.%26aulast%3DBriasoulis%26aufirst%3DE.%26aulast%3DLinardou%26aufirst%3DH.%26aulast%3DPapadimitriiou%26aufirst%3DC.%26aulast%3DBafaloukos%26aufirst%3DD.%26aulast%3DKosmidis%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DS.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520clinical%2520and%2520molecular%2520considerations%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D1613%26epage%3D1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemieleck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5530</span><span class="NLM_x">–</span> <span class="NLM_lpage">5537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F1078-0432.CCR-10-2571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21775534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5530-5537&author=G.+R.+Oxnardauthor=M.+E.+Arcilaauthor=J.+Chemieleckauthor=M.+Ladanyauthor=V.+A.+Millerauthor=W.+Pao&title=New+strategies+in+overcoming+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Arcila, Maria E.; Chmielecki, Juliann; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5530-5537</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The management of non-small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal growth factor receptor (EGFR) are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKI).  In these patients, acquired resistance to EGFR-TKI develops after a median of 10 to 14 mo, at which time the current std. practice is to switch to conventional cytotoxic chemotherapy.  Several possible mechanisms for acquired resistance have been identified, the most common being the development of an EGFR T790M gatekeeper mutation in more than 50% of cases.  In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies.  Clin Cancer Res; 17(17); 5530-7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqYmPYYBThNLVg90H21EOLACvtfcHk0lit-qwvQw75dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN&md5=209a41173563ee3776e020c0dacdd465</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2571%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChemieleck%26aufirst%3DJ.%26aulast%3DLadany%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNew%2520strategies%2520in%2520overcoming%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5530%26epage%3D5537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pao, W</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi1, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=1-11&author=W+Paoauthor=V.+A.+Millerauthor=K.+A.+Politi1author=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti1%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0liGVK5cppEEkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke Ding, K.</span><span> </span><span class="NLM_article-title">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2146</span><span class="NLM_x">–</span> <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.2174%2F092986711795656135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21517764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2146-2157&author=X.+Luauthor=Q.+Caiauthor=K.+Ke+Ding&title=Recent+developments+in+the+third+generation+inhibitors+of+Bcr-Abl+for+overriding+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span></div><div class="casAuthors">Lu, X. Y.; Cai, Q.; Ding, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2146-2157</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by disrupting important contact interactions between the inhibitors and the enzyme.  To overcome this particular resistance, several different strategies have been explored and many mols. have been investigated as capable of potently inhibiting Bcr-Abl T315I.  Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the "hybrid-design" strategy for creating type-II class ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoM774pVEqrVg90H21EOLACvtfcHk0liGVK5cppEEkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D&md5=23109d1eb81a48f93cdf9ffbb4728c7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F092986711795656135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795656135%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DKe%2BDing%26aufirst%3DK.%26atitle%3DRecent%2520developments%2520in%2520the%2520third%2520generation%2520inhibitors%2520of%2520Bcr-Abl%2520for%2520overriding%2520T315I%2520mutation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2146%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liTqmRUm-i5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">Recent examples see: </p></div><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno[2,3-<i>d</i>]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.-H.+Wuauthor=M.+S.+Coumarauthor=C.-Y.+Chuauthor=W.-H.+Linauthor=Y.-R.+Chenauthor=C.-T.+Chenauthor=H.-Y.+Shiaoauthor=S.+Rafiauthor=S.-Y.+Wangauthor=H.+Hsuauthor=C.-H.+Chenauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=T.-W.+Lienauthor=M.-Y.+Fangauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=J.+T.-A+Hsuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+The+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DY.-R.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520The%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monica, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2038</span><span class="NLM_x">–</span> <span class="NLM_lpage">2050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901558p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2038-2050&author=C.+Carmiauthor=A.+Cavazzoniauthor=S.+Vezzosiauthor=F.+Bordiauthor=F.+Vacondioauthor=C.+Silvaauthor=S.+Rivaraauthor=A.+Lodolaauthor=R.+R.+Alfieriauthor=S.+L.+Monicaauthor=M.+Galettiauthor=A.+Ardizzoniauthor=P.+G.+Petroniniauthor=M.+Mor&title=Novel+irreversible+epidermal+growth+factor+receptor+inhibitors+by+chemical+modulation+of+the+cysteine-trap+portion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DVezzosi%26aufirst%3DS.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DMonica%26aufirst%3DS.%2BL.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DNovel%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520chemical%2520modulation%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2038%26epage%3D2050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0liTqmRUm-i5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of A novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901146p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+A+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Fjm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520A%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6880%26epage%3D6888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leou, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.-T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=Y.-H.+Pengauthor=J.-S.+Leouauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.-K.+Chittimallaauthor=J.-S.+Songauthor=J.-T.+A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+Aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0liB1aPEv7dnsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.-T.%2BA.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520Aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors%3A+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+Wangauthor=L.+M.+Greenbergerauthor=H.+Tsou&title=Synthesis+and+structure%E2%80%93activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles%3A+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles%253A%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">31192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-31192&author=J.+A.+Engelmanauthor=F.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+Pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DF.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520Pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D31192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+Application+to+the+design+of+selective+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lhaGWJPMkYACA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520Application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: An orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+An+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lhaGWJPMkYACA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520An%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+Results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0ljtPeuPFqHD1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520Results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">7596</span><div class="note"><p class="first last"> (suppl; abstr)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=7596&author=A.+Campbellauthor=K.+L.+Reckampauthor=D.+R.+Camidgeauthor=G.+Giacconeauthor=S.+M.+Gadgeelauthor=F.+R.+Khuriauthor=J.+A.+Engelmanauthor=L.+J.+Denisauthor=J.+P.+O%E2%80%99Connellauthor=P.+A.+Janne&title=PF-00299804+%28PF299%29+patient+%28pt%29-reported+outcomes+%28PROs%29+and+efficacy+in+adenocarcinoma+%28adeno%29+and+nonadeno+non-small+cell+lung+cancer+%28NSCLC%29%3A+A+phase+%28P%29+II+trial+in+advanced+NSCLC+after+failure+of+chemotherapy+%28CT%29+and+erlotinib+%28E%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BP.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPF-00299804%2520%2528PF299%2529%2520patient%2520%2528pt%2529-reported%2520outcomes%2520%2528PROs%2529%2520and%2520efficacy%2520in%2520adenocarcinoma%2520%2528adeno%2529%2520and%2520nonadeno%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520A%2520phase%2520%2528P%2529%2520II%2520trial%2520in%2520advanced%2520NSCLC%2520after%2520failure%2520of%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520%2528E%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D7596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberdick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span> </span><span class="NLM_article-title">Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1–2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">LBA1</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=LBA1&author=C.+Yangauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+Chenauthor=K.+Parkauthor=S.+Kimauthor=T.+Chaoauthor=M.+Oberdickauthor=M+Shahidiauthor=V.+Miller&title=Phase+IIb%2FIII+double-blind+randomized+trial+of+BIBW+2992%2C+an+irreversible%2C+dual+inhibitor+of+EGFR+and+HER2+plus+best+supportive+care+%28BSC%29+versus+placebo+plus+BSC+in+patients+with+NSCLC+failing+1%E2%80%932+lines+of+chemotherapy+%28CT%29+and+erlotinib+or+gefitinib+%28LUX-+Lung1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChao%26aufirst%3DT.%26aulast%3DOberdick%26aufirst%3DM.%26aulast%3DShahidi%26aufirst%3DM%26aulast%3DMiller%26aufirst%3DV.%26atitle%3DPhase%2520IIb%252FIII%2520double-blind%2520randomized%2520trial%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%252C%2520dual%2520inhibitor%2520of%2520EGFR%2520and%2520HER2%2520plus%2520best%2520supportive%2520care%2520%2528BSC%2529%2520versus%2520placebo%2520plus%2520BSC%2520in%2520patients%2520with%2520NSCLC%2520failing%25201%25E2%2580%25932%2520lines%2520of%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520or%2520gefitinib%2520%2528LUX-%2520Lung1%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26spage%3DLBA1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">7525</span><div class="note"><p class="first last"> (suppl; abstr)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=7525&author=Y.+Y.+Janjigianauthor=H.+J.+Groenauthor=L.+Hornauthor=E.+F.+Smitauthor=Y.+Fuauthor=F.+Wangauthor=M.+Shahidiauthor=L.+J.+Denisauthor=W.+Paoauthor=V.+A.+Miller&title=Activity+and+tolerability+of+afatinib+%28BIBW+2992%29+and+cetuximab+in+NSCLC+patients+with+acquired+resistance+to+erlotinib+or+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DGroen%26aufirst%3DH.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DActivity%2520and%2520tolerability%2520of%2520afatinib%2520%2528BIBW%25202992%2529%2520and%2520cetuximab%2520in%2520NSCLC%2520patients%2520with%2520acquired%2520resistance%2520to%2520erlotinib%2520or%2520gefitinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D7525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yuanauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Lacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lj0QUVipdv1TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DLacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+Janneauthor=N.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lj0QUVipdv1TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jare-Erijma, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jov, T. M.</span><span> </span><span class="NLM_article-title">FRET imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jare-Erijmaauthor=T.+M.+Jov&title=FRET+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJare-Erijma%26aufirst%3DE.%2BA.%26aulast%3DJov%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">The assay was performed based on the manufacturer’s instructions (Invitrogen).</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+assay+was+performed+based+on+the+manufacturer%E2%80%99s+instructions+%28Invitrogen%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Steiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joynes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadari, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span> </span><span class="NLM_article-title">Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1540</span><span class="NLM_x">–</span> <span class="NLM_lpage">1551</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F1078-0432.CCR-06-1887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=17332300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1540-1551&author=P.+Steinerauthor=C.+Joynesauthor=R.+Bassiauthor=S.+Wangauthor=J.+R.+Tonraauthor=Y.+R.+Hadariauthor=D.+J.+Hicklin&title=Tumor+growth+inhibition+with+cetuximab+and+chemotherapy+in+non-small+cell+lung+cancer+xenografts+expressing+wild-type+and+mutated+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor</span></div><div class="casAuthors">Steiner, Philipp; Joynes, Christopher; Bassi, Rajiv; Wang, Su; Tonra, James R.; Hadari, Yaron R.; Hicklin, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1540-1551</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor (EGFR) is a validated approach to treat cancer.  In non-small cell lung cancer (NSCLC), EGFR contains somatic mutations in 10% of patients, which correlates with increased response rates to small mol. inhibitors of EGFR.  We analyzed the effects of the monoclonal IgG1 antibody Erbitux (cetuximab) in NSCLC xenografts with wild-type (wt) or mutated EGFR.  NSCLC cell lines were grown s.c. in nude mice.  Dose-dependent efficacy was established for cetuximab.  To det. whether combination therapy produces tumor regressions, cetuximab was dosed at half-maximal efficacy with chemotherapy used at max. tolerated dose.  Cetuximab showed antitumor activity in wt (A549, NCI-H358, NCI-H292) and mutated [HCC-827 (delE746-A750), NCI-H1975 (L858R, T790M)] EGFR-expressing xenografts.  In the H292 model, cetuximab and docetaxel combination therapy was more potent to inhibit tumor growth than cetuximab or docetaxel alone.  Cisplatin augmented efficacy of cetuximab to produce 6 of 10 regressions, whereas 1 of 10 regressions was found with cetuximab and no regression was found with cisplatin.  Using H1975 xenografts, gemcitabine increased efficacy of cetuximab resulting in 12 of 12 regressions.  Docetaxel with cetuximab was more efficacious with seven of nine regressions compared with single treatments.  Cetuximab inhibited autophosphorylation of EGFR in both H292 and H1975 tumor lysates.  Exploring the underlying mechanism for combination effects in the H1975 xenograft model, docetaxel in combination with cetuximab added to the antiproliferative effects of cetuximab but was the main component in this drug combination to induce apoptosis.  Cetuximab showed antitumor activity in NSCLC models expressing wt and mutated EGFR.  Combination treatments increased the efficacy of cetuximab, which may be important for the management of patients with chemorefractory NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzO5QyA9_4rVg90H21EOLACvtfcHk0lgFQbrQ_aE67w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLw%253D&md5=8a39b5dd9916f184996fdeed9b381bb1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1887%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DP.%26aulast%3DJoynes%26aufirst%3DC.%26aulast%3DBassi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTonra%26aufirst%3DJ.%2BR.%26aulast%3DHadari%26aufirst%3DY.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DTumor%2520growth%2520inhibition%2520with%2520cetuximab%2520and%2520chemotherapy%2520in%2520non-small%2520cell%2520lung%2520cancer%2520xenografts%2520expressing%2520wild-type%2520and%2520mutated%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1540%26epage%3D1551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Libermann, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nusbaum, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lax, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soreq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Amplification, enhanced expression and possible rearrangement of egf receptor gene in primary human-brain tumors of glial origin</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=144-147&author=T.+A.+Libermannauthor=H.+R.+Nusbaumauthor=N.+Razonauthor=R.+Krisauthor=I.+Laxauthor=H.+Soreqauthor=N.+Whittleauthor=M.+D.+Waterfieldauthor=A.+Ullrichauthor=J.+Schlessinger&title=Amplification%2C+enhanced+expression+and+possible+rearrangement+of+egf+receptor+gene+in+primary+human-brain+tumors+of+glial+origin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLibermann%26aufirst%3DT.%2BA.%26aulast%3DNusbaum%26aufirst%3DH.%2BR.%26aulast%3DRazon%26aufirst%3DN.%26aulast%3DKris%26aufirst%3DR.%26aulast%3DLax%26aufirst%3DI.%26aulast%3DSoreq%26aufirst%3DH.%26aulast%3DWhittle%26aufirst%3DN.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DAmplification%252C%2520enhanced%2520expression%2520and%2520possible%2520rearrangement%2520of%2520egf%2520receptor%2520gene%2520in%2520primary%2520human-brain%2520tumors%2520of%2520glial%2520origin%26jtitle%3DNature%26date%3D1985%26volume%3D313%26spage%3D144%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchihashi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1185</span><span class="NLM_x">–</span> <span class="NLM_lpage">1194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1093%2Fjnci%2Fdji238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16106023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=1185-1194&author=T.+Mukoharaauthor=J.+A.+Engelmanauthor=N.+H.+Hannaauthor=B.+Y.+Yeapauthor=S.+Kobayashiauthor=N.+Lindemanauthor=B.+Halmosauthor=J.+Pearlbergauthor=Z.+Tsuchihashiauthor=L.+C.+Cantleyauthor=D.+G.+Tenenauthor=B.+E.+Johnsonauthor=P.+A.+Janne&title=Differential+effects+of+gefitinib+and+cetuximab+on+non-small-cell+lung+cancers+bearing+epidermal+growth+factor+receptor+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Effects of Gefitinib and Cetuximab on Non-small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations</span></div><div class="casAuthors">Mukohara, Toru; Engelman, Jeffrey A.; Hanna, Nasser H.; Yeap, Beow Y.; Kobayashi, Susumu; Lindeman, Neal; Halmos, Balazs; Pearlberg, Joseph; Tsuchihashi, Zenta; Cantley, Lewis C.; Tenen, Daniel G.; Johnson, Bruce E.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1185-1194</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Many patients with non-small-cell lung cancer (NSCLC) who achieve radiog. responses to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib have somatic mutations in the EGFR tyrosine kinase domain.  However, little is known about the efficacy of cetuximab, an antibody against the EGFR extracellular domain, in EGFR mutant NSCLC.  Methods: NSCLC cell lines carrying wild-type EGFR (A549, H441, and H1666) or mutant EGFR (H3255, DFCILU-011, PC-9, and HCC827) were treated with various dilns. of gefitinib or cetuximab relative to maximal achievable serum concn.  Cell growth was analyzed by the MTS assay, with differences between dose-response curves analyzed nonparametrically.  Apoptosis was analyzed by propidium iodide staining and immunoblotting for PARP.  Phosphorylation of EGFR and the downstream signaling components ERK1/2 and Akt were analyzed by immunoblotting.  Statistical tests were two-sided.  Results: Growth of NSCLC lines with wild-type EGFR was slightly (A549 and H441) or moderately (H1666) inhibited by gefitinib and cetuximab, and the effects of the two agents were similar.  Both agents also induced no (H441) or moderate (H1666) apoptosis in NSCLC cells with wild-type EGFR.  By contrast, gefitinib was statistically significantly more effective than cetuximab at inhibiting growth of EGFR mutant cells (H3255: P = .003, DFCILU-011: P = .011, and PC-9: P = .003), and gefitinib-treated EGFR mutant cells had higher levels of apoptosis than cetuximab-treated cells (mean fold increase in apoptosis by 1 μM of gefitinib and 10 μg/mL of cetuximab relative to control, H3255: 8.3 [95% confidence interval {CI} = 4.8 to 11.8] and 2.1 [95% CI = 2.0 to 2.2], resp., P = .025; DFCILU-011: 5.7 [95% CI = 5.1 to 6.3] and. 0.9 [95% CI = 0.3 to 1.5], resp., P < .001).  Gefitinib treatment decreased EGFR, ERK1/2, and Akt phosphorylation in EGFR mutant cell lines whereas cetuximab had relatively little effect.  Both gefitinib and cetuximab inhibited the growth of HCC827 cells, but gefitinib inhibited growth to a greater extent (P = .003).  Conclusions: EGFR mutations in NSCLC cells are assocd. with sensitivity to gefitinib but not to cetuximab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfmCDcRLe60rVg90H21EOLACvtfcHk0lgFQbrQ_aE67w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVaks7Y%253D&md5=60c96e3587183397139243b4dd3bdc84</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdji238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdji238%26sid%3Dliteratum%253Aachs%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DPearlberg%26aufirst%3DJ.%26aulast%3DTsuchihashi%26aufirst%3DZ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DDifferential%2520effects%2520of%2520gefitinib%2520and%2520cetuximab%2520on%2520non-small-cell%2520lung%2520cancers%2520bearing%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2005%26volume%3D97%26spage%3D1185%26epage%3D1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wei, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span> </span><span class="NLM_article-title">SeO2 induces apoptosis with down-regulation of Bcl-2 and up-regulation of P53 expression in both immortal human hepatic cell line and hepatoma cell line</span> <span class="citation_source-journal">Mutat. Res.: Genet. Toxicol. Environ. Mutagen</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">490</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2001&pages=113-121&author=Y.+M.+Weiauthor=X.+Z.+Caoauthor=Y.+X.+Ouauthor=J.+H.+Luauthor=C.+P.+Xingauthor=R.+L.+Zheng&title=SeO2+induces+apoptosis+with+down-regulation+of+Bcl-2+and+up-regulation+of+P53+expression+in+both+immortal+human+hepatic+cell+line+and+hepatoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DY.%2BM.%26aulast%3DCao%26aufirst%3DX.%2BZ.%26aulast%3DOu%26aufirst%3DY.%2BX.%26aulast%3DLu%26aufirst%3DJ.%2BH.%26aulast%3DXing%26aufirst%3DC.%2BP.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26atitle%3DSeO2%2520induces%2520apoptosis%2520with%2520down-regulation%2520of%2520Bcl-2%2520and%2520up-regulation%2520of%2520P53%2520expression%2520in%2520both%2520immortal%2520human%2520hepatic%2520cell%2520line%2520and%2520hepatoma%2520cell%2520line%26jtitle%3DMutat.%2520Res.%253A%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen%26date%3D2001%26volume%3D490%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Breul, K. H. B. S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hance, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, M. P R</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, R G.</span><span> </span><span class="NLM_article-title">Control of collagen production by human diploid lung fibroblasts</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">255</span><span class="NLM_x">, </span> <span class="NLM_fpage">5250</span><span class="NLM_x">–</span> <span class="NLM_lpage">5260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=7372635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADyaL3cXksVans7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1980&pages=5250-5260&author=K.+H.+B.+S.+D.+Breulauthor=A.+J.+Hanceauthor=M.+P+R+Schaferauthor=A+Bergauthor=R+G.+Crystal&title=Control+of+collagen+production+by+human+diploid+lung+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Control of collagen production by human diploid lung fibroblasts</span></div><div class="casAuthors">Breul, Sally D.; Bradley, Kathryn H.; Hance, Allan J.; Schafer, Millie P.; Berg, Richard A.; Crystal, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5250-60</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">To evaluate the control soft tissue fibroblasts have over collagen prodn., HFL-1, a diploid human lung cell strain, was studied during periods of rapid cell growth and relatively slow growth over 25 population doublings.  To minimize environmental influences, the extracellular milieu of the cells was kept const. throughout the study period.  Rates of collagen prodn. per cell unit time were quantitated by labeling HFL-1 with [14C]proline and measuring the prodn. of [14C]hydroxyproline after taking into consideration the sp. activity of [14C]proline within the free intracellular proline pool and the percent hydroxylation of proline residues in newly synthesized collagen.  Although the sp. activity of intracellular free proline and the percent hydroxylation of proline in collagen varied considerably depending on the growth rates of the cells, collagen prodn. by HFL-1 was const., even during periods of rapid cell growth.  Thus, under conditions of a stable environment, populations of soft tissue fibroblasts rigidly control their collagen prodn.  In cultures that maintained a const. doubling time, this stability was maintained over ≥25 population doublings, suggesting that on the av., collagen prodn. appears to be tightly controlled and dissocd. from the events and sequelae of cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyK2bRXCUwSrVg90H21EOLACvtfcHk0lj7J09-3gZFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXksVans7s%253D&md5=73ba43348807e2bdd8fe59b18af080ea</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBreul%26aufirst%3DK.%2BH.%2BB.%2BS.%2BD.%26aulast%3DHance%26aufirst%3DA.%2BJ.%26aulast%3DSchafer%26aufirst%3DM.%2BP%2BR%26aulast%3DBerg%26aufirst%3DA%26aulast%3DCrystal%26aufirst%3DR%2BG.%26atitle%3DControl%2520of%2520collagen%2520production%2520by%2520human%2520diploid%2520lung%2520fibroblasts%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1980%26volume%3D255%26spage%3D5250%26epage%3D5260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Toulany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodemann, H. P.</span><span> </span><span class="NLM_article-title">Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway</span> <span class="citation_source-journal">Radiother. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1016%2Fj.radonc.2005.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16024124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslChsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2005&pages=143-150&author=M.+Toulanyauthor=K.+Dittmannauthor=M.+Krugerauthor=M.+Baumannauthor=H.+P.+Rodemann&title=Radioresistance+of+K-Ras+mutated+human+tumor+cells+is+mediated+through+EGFR-dependent+activation+of+PI3K-AKT+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway</span></div><div class="casAuthors">Toulany, Mahmoud; Dittmann, Klaus; Krueger, Maren; Baumann, Michael; Rodemann, H. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-150</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the context of EGFR-targeting strategies we investigated autocrine/paracrine factors leading to in vitro radioresistance of K-Ras mutated tumor cells through activation of EGFR mediated signal transduction.  Ras mutated (Rasmt) and normal Ras (Raswt) presenting human tumor cell lines were used to analyze the potential of conditioned media (CM) of both cell types to mediate radioresistance and to activate EGFR-signaling cascades.  Therefore, clonogenic assays as well as SDS-PAGE combined with immunoblotting was performed.  Addnl., Ras-mutated cells were transfected with K-Ras-siRNA to investigate, how downregulation of mutated K-Ras affects secretion of EGFR-ligands, stimulation of EGFR-signaling and modulation of radiation response.  TGFα, Amphiregulin (ARG) and CM from Rasmt cells (Rasmt-CM) resulted in an increased clonogenic survival of irradiated Raswt cells.  Both, EGFR ligands as well as Rasmt-CM led to a strong phosphorylation of EGFR and activation of downstream pathways, i.e. PI3K-AKT.  However, neutralization of TGFα or ARG in Rasmt-CM led to a marked redn. of P-AKT.  Furthermore, Rasmt-CM from K-Ras-siRNA transfected Rasmt-cells markedly inhibited phosphorylation of AKT in Raswt cells and enhanced radiation sensitivity of A549 cells transfected with the siRNA.  The data suggest that constitutively upregulated autocrine/paracrine secretion of EGF receptor ligands, esp. ARG from K-Ras mutated cells, mediates radioresistance in Rasmt-cells through stimulation of EGFR-PI3K-AKT pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHKxuufeqS7Vg90H21EOLACvtfcHk0lj7J09-3gZFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslChsb4%253D&md5=5ddcac2c06906c05f1d3e265cdece924</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2005.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2005.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DDittmann%26aufirst%3DK.%26aulast%3DKruger%26aufirst%3DM.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DRodemann%26aufirst%3DH.%2BP.%26atitle%3DRadioresistance%2520of%2520K-Ras%2520mutated%2520human%2520tumor%2520cells%2520is%2520mediated%2520through%2520EGFR-dependent%2520activation%2520of%2520PI3K-AKT%2520pathway%26jtitle%3DRadiother.%2520Oncol.%26date%3D2005%26volume%3D76%26spage%3D143%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun., F</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&author=H.+G.+Choiauthor=P.+Renauthor=F+Adrianauthor=F+Sun.author=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF%26aulast%3DSun.%26aufirst%3DF%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5439%26epage%3D5448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Paulsen, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K. S.</span><span> </span><span class="NLM_article-title">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1038%2Fnchembio.736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=57-64&author=C.+E.+Paulsenauthor=T.+H.+Truongauthor=F.+J.+Garciaauthor=A.+Homannauthor=V.+Guptaauthor=S%2C+E.+Leonardauthor=K.+S.+Carroll&title=Peroxide-dependent+sulfenylation+of+the+EGFR+catalytic+site+enhances+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span></div><div class="casAuthors">Paulsen, Candice E.; Truong, Thu H.; Garcia, Francisco J.; Homann, Arne; Gupta, Vinayak; Leonard, Stephen E.; Carroll, Kate S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein sulfenylation is a post-translational modification of emerging importance in higher eukaryotes.  However, investigation of its diverse roles remains challenging, particularly within a native cellular environment.  Herein we report the development and application of DYn-2, a new chemoselective probe for detecting sulfenylated proteins in human cells.  These studies show that epidermal growth factor receptor (EGFR)-mediated signaling results in H2O2 prodn. and oxidn. of downstream proteins.  In addn., we demonstrate that DYn-2 has the ability to detect differences in sulfenylation rates within the cell, which are assocd. with differences in target protein localization.  We also show that the direct modification of epidermal growth factor receptor by H2O2 at a crit. active site cysteine (Cys797) enhances its tyrosine kinase activity.  Collectively, our findings reveal sulfenylation as a global signaling mechanism that is akin to phosphorylation and has regulatory implications for other receptor tyrosine kinases and irreversible inhibitors that target oxidant-sensitive cysteines in proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp30snMrGIfzLVg90H21EOLACvtfcHk0lhGikiSfy3x2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E&md5=44011c82266cf6a47922b1ba1038cc30</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.736%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DC.%2BE.%26aulast%3DTruong%26aufirst%3DT.%2BH.%26aulast%3DGarcia%26aufirst%3DF.%2BJ.%26aulast%3DHomann%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLeonard%26aufirst%3DS%252C%2BE.%26aulast%3DCarroll%26aufirst%3DK.%2BS.%26atitle%3DPeroxide-dependent%2520sulfenylation%2520of%2520the%2520EGFR%2520catalytic%2520site%2520enhances%2520kinase%2520activity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D57%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, Erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm201591k&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm201591k&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm201591k&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+Erlotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0lhGikiSfy3x2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520Erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i49"><a href="/doi/suppl/10.1021/jm201591k">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_41177"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR spectrum and purity determination for compounds <b>2a</b>–<b>x</b>, apoptosis, cell cycle arrest, and colony formation inhibition induced by compounds <b>2q</b> and <b>2s</b>, Western blot analysis on A549 and A431 cells, growth inhibition on HLF-1 cells. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201591k/suppl_file/jm201591k_si_001.pdf">jm201591k_si_001.pdf (3.63 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201591k&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm201591k%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201591k" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6a4e0d1c3d3c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
